IL-1 O
induces O
a O
rapid O
, O
protein O
synthesis-independent O
appearance O
of O
IL-2R B
alpha I
mRNA I
that O
is O
blocked O
by O
inhibitors O
of O
NF-kappa O
B O
activation O
. O

It O
also O
primes O
cells O
to O
become O
IL-2 O
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL-2 O
induces O
a O
100-fold O
further O
increase O
in O
IL-2R B
alpha I
transcripts I
. O

In O
addition O
, O
when O
used O
together O
IL-2 O
and O
IL-12 O
synergized O
in O
the O
induction O
of O
IFN-gamma O
and O
GM-CSF O
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN-gamma B
and I
GM-CSF I
mRNAs I
. O

The O
results O
suggest O
that O
activation O
of O
protein O
kinase O
C O
, O
but O
not O
new O
protein O
synthesis O
, O
is O
required O
for O
IL-2 O
induction O
of O
IFN-gamma B
and I
GM-CSF I
cytoplasmic I
mRNA I
. O

In O
contrast O
, O
IL-12 O
induction O
of O
IFN-gamma B
cytoplasmic I
mRNA I
appears O
to O
only O
partially O
depend O
on O
activation O
of O
protein O
kinase O
C O
. O

Priming O
by O
IFN-gamma O
was O
primarily O
manifested O
at O
the O
level O
of O
TNF B
mRNA I
accumulation O
. O

Primed O
monocytes O
transcribed O
TNF B
mRNA I
at O
a O
higher O
rate O
than O
freshly O
isolated O
monocytes O
upon O
activation O
with O
LPS O
. O

An O
additional O
significant O
finding O
was O
than O
TNF B
mRNA I
induced O
in O
primed O
cells O
was O
much O
more O
stable O
than O
in O
unprimed O
cells O
( O
T1/2 O
increased O
6-8-fold O
) O
. O

Consistent O
with O
the O
increased O
mRNA B
stability O
, O
the O
duration O
of O
mRNA B
accumulation O
was O
longer O
following O
LPS O
stimulation O
in O
primed O
monocytes O
, O
in O
addition O
to O
being O
of O
greater O
magnitude O
. O

H-89 O
substantially O
suppressed O
LPS-induced O
TNF B
mRNA I
accumulation O
in O
unprimed O
cells O
, O
but O
had O
no O
effect O
on O
primed O
monocytes O
following O
LPS O
stimulation O
. O

Epo O
elicited O
a O
rapid O
, O
dose-related O
increase O
in O
TAL1 B
mRNA I
by O
increasing O
transcription O
of O
the O
gene O
and O
stabilizing O
one O
of O
its O
mRNAs B
. O

An O
Epo O
-inducible O
TAL1 O
DNA O
binding O
activity O
was O
identified O
in O
FVA O
cell O
nuclear O
extracts O
that O
subsequently O
decayed O
despite O
accumulating O
mRNA B
and O
protein O
. O

We O
describe O
a O
method O
for O
relative O
quantification O
of O
specific O
mRNA B
using O
a O
nonradioactive O
assay O
based O
on O
DNA O
strand O
competition O
between O
identical O
sequences O
of O
biotin- O
and O
fluorescein-labeled O
amplicon O
( O
probe O
) O
and O
unlabeled O
amplicon O
( O
target O
) O
during O
hybridization O
. O

We O
observed O
that O
TPA O
treatment O
was O
associated O
with O
an O
increase O
in O
specific O
binding O
of O
[ O
3H O
] O
dexamethasone O
and O
up-regulation O
of O
GR B
mRNA I
while O
no O
enhanced O
GR O
expression O
was O
perceived O
with O
RA/VD O
treatment O
. O

By O
increasing O
GATA-1 O
levels O
via O
co-transfection O
, O
we O
were O
able O
to O
transactivate O
the O
hEpoR O
promoter O
in O
K562 O
cells O
and O
non-erythroid O
cells O
, O
but O
not O
in O
the O
highly O
active O
OCIM1 O
cells O
, O
although O
GATA-1 B
mRNA I
levels O
were O
comparable O
in O
OCIM1 O
and O
K562 O
. O

DR-nm23 B
mRNA I
is O
preferentially O
expressed O
at O
early O
stages O
of O
myeloid O
differentiation O
of O
highly O
purified O
CD34+ O
cells O
. O

CIITA B
mRNA I
is O
normally O
inducible O
by O
IFN-gamma O
in O
class O
II O
non-inducible O
, O
RB-defective O
lines O
, O
and O
in O
one O
line O
, O
re-expression O
of O
RB O
has O
no O
effect O
on O
CIITA B
mRNA I
induction O
levels O
. O

In O
addition O
, O
integrin O
ligation O
leads O
to O
nuclear O
translocation O
of O
the O
p50 O
and O
p65 O
subunits O
of O
the O
NF-kappa O
B O
transcription O
factor O
, O
to O
activation O
of O
a O
reporter O
gene O
driven O
by O
a O
promoter O
containing O
NF-kappa O
B O
sites O
, O
and O
to O
increased O
levels O
of O
mRNAs B
for O
immediate-early O
genes O
, O
including O
the O
cytokine O
interleukin O
( O
IL O
) O
-1 O
beta O
. O

The O
mRNA B
for O
the O
Duffy O
blood O
group O
antigen O
, O
the O
erythrocyte O
receptor O
for O
the O
Plasmodium O
vivax O
malaria O
parasite O
, O
has O
recently O
been O
cloned O
and O
shown O
to O
encode O
a O
widely O
expressed O
chemokine O
receptor O
. O

Aspirin O
appeared O
to O
prevent O
VCAM-1 O
transcription O
, O
since O
it O
dose-dependently O
inhibited O
induction O
of O
VCAM-1 B
mRNA I
by O
TNF O
. O

Northern O
blot O
analysis O
showed O
that O
TCDD O
treatment O
decreased O
steady O
state O
levels O
of O
CD19 B
mRNA I
by O
67 O
% O
in O
the O
IM-9 O
cell O
line O
. O

1. O
Administration O
of O
danazol O
for O
over O
one O
month O
reduced O
the O
levels O
of O
estrogen O
receptor O
( O
ER O
) O
and O
its O
mRNA B
to O
approximately O
50 O
and O
20 O
% O
, O
respectively O
in O
monocytes O
. O

2. O
Danazol O
did O
not O
alter O
the O
degradation O
rate O
of O
ER B
mRNA I
in O
monocytes O
. O

4. O
Danazol O
may O
release O
estrogen O
predominance O
via O
the O
reduction O
of O
transcription O
for O
ER O
gene O
, O
which O
leads O
to O
the O
reduction O
of O
ER B
mRNA I
and O
ER O
expressions O
in O
monocytes O
. O

These O
compounds O
also O
inhibited O
beta-galactosidase B
mRNA I
levels O
. O

We O
examined O
mRNA B
levels O
of O
various O
V-ATPase O
subunits O
during O
differentiation O
of O
both O
native O
monocytes O
and O
the O
cell O
line O
THP-1 O
, O
and O
found O
that O
transcriptional O
and O
post-transcriptional O
mechanisms O
could O
account O
for O
increases O
in O
cell O
V-ATPase O
content O
. O

Analysis O
of O
AP-1 O
activity O
using O
gel O
mobility O
shift O
assays O
confirms O
that O
the O
requirements O
for O
synergy O
in O
c-fos B
mRNA I
induction O
are O
paralleled O
by O
requirements O
for O
synergy O
in O
induction O
of O
AP-1 O
activity O
. O

Signaling O
in O
B O
cells O
due O
to O
anti-Ig O
stimulation O
involves O
both O
kinase O
C O
activation O
and O
release O
of O
intracellular O
calcium O
, O
and O
results O
in O
c-fos B
mRNA I
induction O
. O

The O
PAF O
-induced O
up-regulation O
of O
HB-EGF B
mRNA I
was O
accompanied O
by O
an O
increase O
in O
kappa O
B O
binding O
activity O
. O

These O
functions O
of O
PAF O
appeared O
to O
be O
mediated O
through O
the O
cell O
surface O
PAF O
receptors O
, O
as O
two O
PAF O
receptor O
antagonists O
, O
WEB O
2086 O
and O
L-659 O
, O
989 O
, O
blocked O
both O
the O
up-regulation O
of O
HB-EGF B
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF O
. O

The O
antagonists O
, O
however O
, O
had O
no O
effect O
on O
phorbol O
ester-induced O
up-regulation O
of O
HB-EGF B
mRNA I
and O
kappa O
B O
binding O
activity O
. O

Pyrrolidine O
dithiocarbamate O
, O
an O
inhibitor O
for O
NF-kappa O
B O
activation O
, O
markedly O
reduced O
PAF O
-stimulated O
kappa O
B O
binding O
activity O
as O
well O
as O
up-regulation O
of O
HB-EGF B
mRNA I
. O

Germ B
line I
C I
transcripts I
can O
be O
induced O
by O
IL-4 O
in O
the O
human O
B O
cell O
line O
, O
BL-2 O
. O

Erythroid-specific B
mRNAs I
encoding O
gamma-globin O
and O
erythroid O
delta-aminolevulinate O
synthase O
were O
found O
to O
be O
expressed O
in O
blasts O
from O
most O
of O
these O
cases O
, O
indicating O
that O
majorities O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

We O
also O
found O
that O
mRNAs B
encoding O
GATA-1 O
and O
GATA-2 O
are O
expressed O
in O
all O
these O
cases O
. O

We O
have O
previously O
found O
a O
high O
expression O
of O
human B
Ah I
receptor I
( I
TCDD I
receptor I
) I
mRNA I
in O
peripheral O
blood O
cells O
of O
individuals O
. O

Then O
the O
expression O
levels O
of O
AhR B
mRNA I
in O
various O
hematopoietic O
cell O
lines O
were O
examined O
together O
with O
those O
of O
Arnt O
and O
P450IA1 O
. O

HL60 O
cells O
were O
induced O
to O
differentiate O
toward O
monocytes-macrophages O
by O
incubation O
with O
phorbol O
ester O
, O
showing O
a O
5- O
to O
2-fold O
increase O
of O
AhR B
mRNA I
. O

The O
incubation O
with O
transforming O
growth O
factor O
beta O
1 O
and O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
resulted O
in O
a O
5- O
to O
7-fold O
increase O
of O
AhR B
mRNA I
. O

The O
HEL O
cells O
also O
exhibited O
a O
similar O
elevation O
of O
AhR B
mRNA I
level O
, O
when O
they O
had O
differentiated O
toward O
monocyte-macrophage O
cells O
by O
these O
combined O
inducers O
, O
but O
little O
change O
in O
the O
mRNA O
level O
was O
observed O
when O
the O
cells O
were O
induced O
to O
differentiate O
into O
other O
cell O
types O
. O

These O
results O
indicated O
that O
expression O
of O
AhR B
mRNA I
was O
significantly O
induced O
during O
monocytic O
differentiation O
and O
that O
the O
differentiated O
cells O
were O
responsive O
to O
xenobiotics O
. O

Here O
, O
we O
report O
that O
PU.1 B
mRNA I
is O
upregulated O
during O
myeloid O
differentiation O
of O
human O
purified O
CD34+ O
cells O
and O
murine O
multipotential O
FDCP-mix O
A4 O
cells O
, O
suggesting O
that O
PU.1 O
is O
upregulated O
as O
an O
early O
event O
during O
differentiation O
of O
multipotential O
progenitor O
cells O
. O

In O
contrast O
to O
PU.1 O
, O
significant O
levels O
of O
Spi-B B
mRNA I
and O
protein O
are O
found O
only O
in O
some O
B-cell O
lines O
and O
spleen O
but O
are O
not O
found O
in O
myeloid O
cell O
lines O
, O
neutrophils O
, O
or O
macrophages O
. O

When O
sequences O
from O
-417 O
to O
-207 O
5 O
' O
to O
the O
zeta-globin B
mRNA I
cap I
site I
were O
deleted O
, O
up O
to O
95 O
% O
of O
the O
zeta-globin O
promoter O
activity O
was O
lost O
in O
K562 O
cells O
. O

Large O
amounts O
of O
viral B
RNA I
and O
particles O
were O
synthesized O
in O
infections O
established O
using O
the O
tat O
mutants O
that O
contain O
modified O
LTRs O
. O

Thus O
, O
despite O
its O
essential O
role O
for O
releasing O
an O
elongation O
block O
, O
Tat O
is O
not O
otherwise O
absolutely O
required O
for O
synthesis O
of O
full-length B
HIV I
transcripts I
and O
assembly O
of O
virus O
particles O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV-encoded O
nuclear O
antigens O
( O
EBNA1 O
, O
2 O
, O
3A O
, O
3B O
, O
3C O
, O
-LP O
) O
, O
three O
latent O
membrane O
proteins O
( O
LMP1 O
, O
2A O
, O
2B O
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
EBV-positive O
cases O
of O
Hodgkin O
's O
disease O
, O
the O
EBERs B
, O
EBNA1 O
, O
and O
the O
LMPs O
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
's O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 O
have O
been O
detected O
( O
latency O
I O
) O
. O

IL-4 O
, O
another O
cytokine O
that O
inhibits O
cytokine B
mRNA I
accumulation O
in O
monocytes O
, O
shows O
little O
inhibitory O
effect O
on O
LPS-induced O
NF O
kappa O
B O
activation O
. O

Further O
examination O
reveals O
that O
, O
unlike O
IL-10 O
, O
IL-4 O
enhances O
mRNA B
degradation O
and O
does O
not O
suppress O
cytokine O
gene O
transcription O
. O

Detection O
of O
the O
chromosome B
16 I
CBF I
beta-MYH11 I
fusion I
transcript I
in O
myelomonocytic O
leukemias O
. O

Characterization O
of O
the O
two O
genes O
involved O
in O
the O
inv O
( O
16 O
) O
( O
p13q22 O
) O
, O
CBF O
beta O
and O
MYH11 O
, O
has O
allowed O
the O
detection O
of O
fusion B
transcripts I
by O
reverse-transcriptase O
polymerase O
chain O
reaction O
( O
RT-PCR O
) O
. O

We O
have O
analyzed O
CBF B
beta-MYH11 I
fusion I
transcripts I
by O
RT-PCR O
in O
myelomonocytic O
leukemias O
, O
with O
or O
without O
eosinophilia O
, O
to O
determine O
whether O
their O
presence O
correlates O
with O
morphology O
. O

These O
data O
show O
that O
CBF B
beta-MYH11 I
fusion I
transcripts I
occur O
not O
only O
in O
the O
vast O
majority O
of O
typical O
AML O
M4Eo O
, O
but O
also O
in O
approximately O
10 O
% O
of O
AML O
M4 O
without O
eosinophilic O
abnormalities O
, O
a O
much O
higher O
incidence O
than O
the O
sporadic O
reports O
of O
chromosome O
16 O
abnormalities O
in O
AML O
M4 O
would O
suggest O
. O

Taken O
together O
with O
the O
detection O
of O
CBF O
beta O
- O
MYH11 B
transcripts I
in O
the O
absence O
of O
apparent O
chromosome O
16 O
abnormalities O
by O
classical O
banding O
techniques O
, O
these O
data O
show O
that O
additional O
screening O
by O
either O
RT-PCR O
or O
FISH O
should O
be O
performed O
in O
all O
AML O
M4 O
, O
regardless O
of O
morphologic O
features O
, O
to O
allow O
accurate O
evaluation O
of O
the O
prognostic O
importance O
of O
this O
fusion B
transcript I
. O

Maximal O
induction O
of O
TNF B
alpha I
mRNA I
can O
be O
induced O
by O
treatment O
of O
T O
cells O
with O
calcium O
ionophores O
alone O
, O
via O
a O
calcineurin O
-dependent O
process O
that O
is O
blocked O
by O
cyclosporin O
A O
. O

As O
we O
reported O
previously O
, O
MNDA B
mRNA I
level O
in O
adherent O
monocytes O
is O
elevated O
by O
IFN-alpha O
; O
in O
this O
study O
, O
we O
further O
assessed O
MNDA O
expression O
in O
in O
vitro O
monocyte-derived O
macrophages O
. O

The O
results O
also O
reveal O
a O
discordance O
in O
certain O
MNDA O
positive O
cells O
between O
steady-state O
levels O
or O
changes O
in O
levels O
of O
protein O
and O
mRNA B
indicating O
that O
the O
regulation O
of O
MNDA O
expression O
occurs O
at O
more O
than O
one O
point O
. O

Enhanced O
Ig O
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig O
genes O
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig O
heavy O
chain O
. O

Hemoglobin O
concentration O
and O
gamma-globin O
and O
erythroid B
delta-aminolevulinate I
synthase I
mRNA I
levels O
were O
significantly O
higher O
in O
M-TAT/EPO O
cells O
than O
in O
M-TAT/GM-CSF O
cells O
. O

When O
the O
supplemented O
cytokine O
was O
switched O
from O
GM-CSF O
to O
EPO O
, O
hemoglobin O
synthesis O
in O
M-TAT/GM-CSF O
cells O
increased O
rapidly O
( O
within O
5 O
h O
) O
, O
and O
the O
level O
of O
GATA-1 B
mRNA I
increased O
. O

The O
role O
of O
cellular O
transcription O
factor O
E2F O
in O
the O
regulation O
of O
cdc2 B
mRNA I
expression O
and O
cell O
cycle O
control O
of O
human O
hematopoietic O
cells O
. O

cdc2 B
mRNA I
transcripts I
were O
detected O
in O
immature O
bone O
marrow O
cells O
and O
became O
undetectable O
along O
with O
differentiation O
. O

Peripheral O
blood O
resting O
cells O
did O
not O
express O
cdc2 B
mRNA I
, O
but O
it O
was O
induced O
in O
T-lymphocytes O
when O
the O
cells O
reentered O
the O
cell O
cycle O
in O
response O
to O
specific O
mitogens O
. O

In O
contrast O
, O
cdc2 B
mRNA I
could O
not O
be O
induced O
in O
granulocytes O
and O
monocytes O
even O
after O
the O
culture O
with O
the O
appropriate O
stimulants O
. O

In O
order O
to O
investigate O
the O
mechanism O
of O
the O
regulation O
of O
cdc2 B
mRNA I
expression O
in O
hematopoietic O
cells O
, O
we O
isolated O
the O
5'-flanking O
sequence O
of O
the O
cdc2 O
gene O
and O
found O
the O
putative O
E2F O
binding O
site O
at O
the O
position O
of O
nucleotides O
-124 O
to O
-117 O
. O

The O
binding O
of O
E2F O
at O
this O
region O
was O
detected O
by O
a O
gel-retardation O
assay O
and O
DNaseI O
footprinting O
in O
phytohemagglutinin-stimulated O
T-lymphocytes O
, O
which O
was O
coincident O
with O
the O
expression O
of O
cdc2 B
mRNA I
. O

E2F-1 B
and I
DP-1 I
mRNAs I
were O
not O
detectable O
in O
granulocytes O
, O
monocytes O
and O
resting O
T-lymphocytes O
but O
were O
induced O
after O
the O
mitogenic O
stimulation O
of O
T-lymphocytes O
. O

The O
induction O
of O
E2F O
activity O
preceded O
the O
appearance O
of O
cdc2 B
mRNA I
, O
which O
is O
consistent O
with O
the O
role O
of O
E2F O
in O
the O
regulation O
of O
cdc2 O
mRNA O
expression O
. O

These O
results O
suggest O
that O
cdc2 B
mRNA I
expression O
is O
related O
to O
the O
cell O
cycling O
of O
normal O
human O
hematopoietic O
cells O
and O
that O
E2F O
plays O
some O
roles O
in O
the O
regulation O
of O
its O
expression O
. O

Transcription-independent O
turnover O
of O
I O
kappa O
B O
alpha O
during O
monocyte O
adherence O
: O
implications O
for O
a O
translational O
component O
regulating O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
levels O
. O

The O
demonstration O
that O
NF-kappa O
B O
can O
regulate O
I O
kappa O
B O
alpha/MAD-3 O
gene O
transcription O
in O
other O
cell O
types O
suggested O
that O
the O
rapid O
increase O
in O
steady-state O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
levels O
we O
observed O
within O
30 O
min O
of O
monocyte O
adherence O
would O
result O
from O
NF-kappa O
B O
-dependent O
transcriptional O
stimulation O
of O
the O
I O
kappa O
B O
alpha/MAD-3 O
gene O
. O

The O
adherence-dependent O
increase O
in O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
levels O
was O
also O
not O
a O
consequence O
of O
mRNA B
stabilization O
events O
. O

Interestingly O
, O
while O
increases O
in O
both O
IL-1 O
beta O
and O
I O
kappa O
B O
alpha/MAD-3 O
mRNA O
levels O
were O
detected O
in O
nuclei O
of O
adherent O
monocytes O
, O
cytoplasmic O
levels O
of O
IL-1 B
beta I
mRNA I
increased O
during O
adherence O
whereas O
those O
of O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
did O
not O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
two O
interactive O
mechanisms O
regulate O
monocytic B
I I
kappa I
B I
alpha/MAD-3 I
mRNA I
levels O
. O

We O
propose O
that O
adherent O
monocytes O
regulate O
nuclear O
processing O
( O
or O
decay O
) O
of O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
, O
thereby O
increasing O
mRNA O
levels O
without O
stimulating O
I O
kappa O
B O
alpha/MAD-3 O
gene O
transcription O
. O

Moreover O
, O
since O
inhibition O
of O
protein O
synthesis O
leads O
to O
accumulation O
of O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
without O
stimulating O
I O
kappa O
B O
alpha/MAD-3 O
gene O
transcription O
, O
we O
suggest O
that O
low O
cytoplasmic O
levels O
of O
I B
kappa I
B I
alpha/MAD-3 I
mRNA I
are O
maintained O
by O
a O
translation-dependent O
degradation O
mechanism O
. O

Although O
we O
detected O
no O
IL-2 B
mRNA I
in O
ALD-treated O
cells O
, O
the O
nuclei O
of O
these O
cells O
contain O
proteins O
capable O
of O
binding O
to O
three O
regulatory O
sequences O
in O
the O
IL-2 O
promoter O
region O
: O
NFAT O
, O
NF O
kappa O
B O
, O
and O
AP-1 O
. O

Isolation O
of O
differentially O
expressed O
sequence O
tags O
from O
steroid-responsive O
cells O
using O
mRNA B
differential O
display O
. O

In O
this O
paper O
we O
describe O
results O
using O
mRNA B
differential O
display O
reverse O
transcriptase O
PCR O
( O
DDPCR O
) O
to O
identify O
and O
isolate O
short O
cDNA O
sequence O
tags O
from O
thymocyte O
and O
prostate O
cells O
under O
various O
hormone O
conditions O
. O

We O
also O
used O
DDPCR O
to O
isolate O
DESTs O
from O
androgen-modulated O
rat O
ventral O
prostate O
tissue O
, O
one O
of O
which O
we O
characterized O
and O
found O
to O
correspond O
to O
the O
3 B
' I
end I
of O
prostatic B
spermine I
binding I
protein I
mRNA I
, O
a O
known O
androgen-regulated O
gene O
. O

Consistent O
with O
the O
activity O
of O
B95-8 O
, O
EBNA-2 B
transcripts I
were O
identified O
within O
infected O
thymocyte O
populations O
. O

In O
peripheral O
lymphocytes O
, O
GR B
mRNA I
levels O
were O
significantly O
down-regulated O
. O

MTIIa B
mRNA I
levels O
increased O
significantly O
. O

Activation O
also O
induced O
c-rel O
and O
p105/p50 O
mRNA O
synthesis O
, O
but O
not O
p65 B
mRNA I
whose O
expression O
was O
constitutive O
. O

TNF-alpha O
, O
therefore O
, O
emerges O
as O
the O
main O
factor O
responsible O
for O
a O
second O
phase O
of O
NF-kappa O
B O
regulation O
, O
controlling O
both O
translocation O
of O
p65 O
and O
c-rel O
, O
and O
new O
mRNA B
synthesis O
for O
c-rel O
and O
p105/p50 O
. O

However O
, O
TG O
induced O
increases O
in O
IL-2R O
alpha O
protein O
as O
well O
as O
IL-2R B
alpha I
mRNA I
in O
Jurkat O
T O
cells O
in O
a O
dose-dependent O
manner O
. O

Within O
this O
region O
we O
have O
identified O
a O
gene O
coding O
for O
a O
1.3-kb B
transcript I
, O
expressed O
only O
in O
restricted O
subsets O
of O
cells O
within O
the O
lymphoid O
lineage O
and O
expressed O
at O
high O
levels O
in O
leukemic O
cells O
carrying O
a O
t O
( O
14 O
; O
14 O
) O
( O
q11 O
; O
q32 O
) O
chromosome O
translocation O
or O
a O
inv O
( O
14 O
) O
( O
q11 O
; O
q32 O
) O
chromosome O
inversion O
. O

In O
contrast O
to O
parental O
U937 O
cells O
, O
PKC-zeta O
cells O
constitutively O
expressed O
mRNA B
transcripts I
for O
c-jun O
and O
a O
low O
mobility O
AP-1 O
binding O
activity O
. O

The O
OBF-1 B
mRNA I
is O
expressed O
in O
a O
highly O
cell-specific O
manner O
, O
being O
most O
abundant O
in O
B O
cells O
and O
essentially O
absent O
in O
most O
of O
the O
other O
cells O
or O
tissues O
tested O
. O

We O
have O
measured O
the O
level O
of O
junB B
mRNA I
in O
the O
B O
hybridoma O
cell O
line O
7TD1 O
, O
under O
interleukin-6 O
( O
IL-6 O
) O
stimulation O
. O

IL-6 O
increases O
junB B
mRNA I
in O
a O
biphasic O
fashion O
. O

The O
first O
early-induced O
peak O
was O
transient O
and O
likely O
corresponds O
to O
the O
well O
documented O
typical O
junB B
mRNA I
, O
stimulated O
in O
response O
to O
numerous O
growth O
factors O
, O
including O
IL-6 O
. O

As O
a O
consequence O
of O
its O
effect O
on O
junB B
mRNA I
, O
IL-6 O
stimulated O
, O
in O
a O
biphasic O
fashion O
, O
the O
nuclear O
accumulation O
of O
the O
JunB O
protein O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
IL-6 O
regulation O
occurred O
exclusively O
at O
the O
transcriptional O
level O
and O
that O
the O
bimodal O
increase O
of O
junB B
mRNA I
and O
JunB O
protein O
can O
be O
accounted O
for O
by O
a O
biphasic O
stimulation O
of O
junB O
transcription O
. O

Second O
, O
tyrphostin O
, O
a O
tyrosine O
kinase O
inhibitor O
, O
impaired O
the O
expression O
of O
the O
first O
but O
not O
the O
second O
junB B
mRNA I
peak O
. O

Conversely O
, O
genistein O
, O
another O
tyrosine O
kinase O
inhibitor O
, O
totally O
abolished O
the O
expression O
of O
the O
second O
peak O
of O
junB B
mRNA I
whereas O
it O
did O
not O
affect O
the O
expression O
of O
the O
first O
peak O
. O

Untreated O
NS-Meg O
cells O
expressed O
mRNA B
for O
the O
Epo O
receptor O
( O
EpoR O
) O
, O
for O
GATA-1 O
, O
and O
for O
alpha O
1 O
, O
alpha O
2 O
and O
gamma O
globin O
genes O
. O

In O
this O
paper O
, O
we O
report O
that O
cross-linking O
of O
CD28 O
( O
but O
not O
CD2 O
, O
CD5 O
, O
LFA-1 O
, O
or O
CD7 O
) O
leads O
to O
an O
elevation O
of O
c-jun B
mRNA I
, O
with O
only O
minimal O
activation O
of O
c-fos O
expression O
. O

Furthermore O
, O
CD28 O
-dependent O
elevation O
of O
c-jun B
mRNA I
does O
not O
appear O
to O
be O
mediated O
at O
the O
level O
of O
mRNA O
stability O
. O

The O
constitutive O
NF-kappa O
B O
appears O
to O
be O
functionally O
active O
, O
since O
a O
low O
level O
of O
tumour B
necrosis I
factor I
( I
TNF I
) I
transcript I
is O
detectable O
in O
monocytes O
, O
and O
this O
level O
can O
be O
increased O
by O
blocking O
transcript O
degradation O
using O
cycloheximide O
. O

In O
contrast O
, O
SCL B
mRNA I
levels O
did O
not O
decrease O
significantly O
between O
day O
7 O
and O
day O
14 O
cells O
, O
suggesting O
that O
posttranscriptional O
mechanisms O
are O
largely O
responsible O
for O
the O
decrease O
in O
SCL O
protein O
observed O
. O

SCL B
mRNA I
levels O
assessed O
by O
Northern O
blot O
in O
day O
7 O
cells O
did O
not O
increase O
significantly O
in O
response O
to O
Steel O
factor O
stimulation O
, O
suggesting O
that O
posttranscriptional O
mechanisms O
may O
also O
be O
important O
in O
the O
increase O
in O
SCL O
protein O
observed O
in O
response O
to O
Steel O
. O

Induction O
of O
TaxI O
in O
a O
human O
T-cell O
line O
Jurkat O
carrying O
the O
TaxI O
gene O
under O
the O
metallothionein O
promoter O
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM-I O
. O

ICAM-I B
mRNA I
was O
quite O
low O
in O
MT-I O
, O
but O
no O
genomic O
changes O
were O
found O
. O

Three O
other O
ATL O
cell O
lines O
( O
TL-OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA-I O
beta O
chain O
( O
CD18 O
) O
. O

H582 O
and O
HuT102 O
were O
also O
negative O
for O
the O
LFA-I B
alpha I
chain I
( I
CDIIa I
) I
mRNA I
. O

In O
addition O
we O
assayed O
the O
level O
of O
mRNA B
encoding O
c-Fos O
, O
a O
common O
component O
of O
AP-1 O
and O
observed O
that O
it O
was O
indeed O
up-regulated O
in O
infected O
cells O
. O

The O
mechanism O
of O
transactivation O
by O
BMLF1 O
proteins O
has O
been O
controversial O
but O
SM O
was O
shown O
to O
transactivate O
gene O
expression O
from O
a O
CAT O
reporter O
construct O
by O
increasing O
the O
amount O
of O
cytoplasmic B
CAT I
mRNA I
. O

The O
human O
platelet-activating O
factor O
receptor O
( O
PAFR O
) O
gene O
is O
transcribed O
by O
two O
distinct O
promoters O
( O
promoter O
1 O
and O
promoter O
2 O
) O
to O
generate O
two O
transcripts O
( O
designated O
as O
PAFR B
transcript I
1 I
and O
PAFR B
transcript I
2 I
) O
, O
though O
their O
open O
reading O
frames O
are O
identical O
. O

By O
primer O
extension O
analysis O
to O
discriminate O
two O
transcripts O
, O
we O
found O
that O
the O
levels O
of O
PAFR B
transcript I
1 I
( O
leukocyte-type O
) O
, O
but O
not O
PAFR B
transcript I
2 I
( O
tissue-type O
) O
, O
are O
upregulated O
by O
PAF O
as O
well O
as O
by O
12-O-tetradecanoylphorbol-13-acetate O
( O
TPA O
) O
in O
the O
human O
stomach O
cancer O
cell O
line O
( O
JR-St O
cells O
) O
which O
expresses O
both O
functional O
PAFR B
transcript I
1 I
and O
PAFR B
transcript I
2 I
endogenously O
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen O
La/SS-B O
from O
a O
cDNA O
library O
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

Thereby O
an O
alternative O
type O
of O
La B
mRNA I
was O
identified O
that O
differed O
from O
the O
known O
La B
mRNA I
due O
to O
an O
exchange O
of O
the O
exon O
1 O
. O

In O
consequence O
, O
the O
alternative B
La I
mRNA I
is O
the O
result O
of O
a O
promoter O
switching O
combined O
with O
an O
alternative O
splicing O
mechanism O
. O

Both O
TPCK O
and O
TLCK O
inhibited O
LPS O
induction O
of O
TF O
protein O
, O
TF B
mRNA I
and O
TF O
promoter O
activity O
in O
a O
dose-dependent O
manner O
. O

Androgen B
receptor I
mRNA I
was O
translated O
in O
vitro O
, O
and O
androgen- O
and O
antiandrogen-bound O
receptor O
complexes O
were O
studied O
using O
limited O
proteolytic O
digestion O
by O
trypsin O
. O

In O
order O
to O
elucidate O
the O
role O
of O
c-myb O
gene O
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin O
( O
Hm O
) O
and O
erythropoietin O
( O
Epo O
) O
, O
we O
constructed O
recombinant O
plasmid O
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

During O
treatment O
with O
Hm O
, O
K562 O
cells O
constitutively O
expressed O
c-myb B
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin O
( O
Hb O
) O
. O

Expression O
of O
antisense B
myb I
RNA I
reduced O
the O
amount O
of O
c-myb B
mRNA I
, O
and O
the O
percentage O
of O
Hb-synthesizing O
cells O
was O
decreased O
to O
20 O
% O
. O

In O
the O
presence O
of O
Epo O
, O
c-myb B
mRNA I
declined O
and O
20 O
% O
of O
K562 O
cells O
synthesized O
Hb O
regardless O
of O
antisense B
myb I
RNA I
expression O
. O

It O
is O
suggested O
that O
constitutive O
expression O
of O
c-myb B
mRNA I
is O
necessary O
for O
Hm O
-induced O
differentiation O
, O
and O
that O
a O
decrease O
in O
the O
amount O
of O
c-myb B
mRNA I
induced O
by O
antisense B
myb I
RNA I
expression O
suppresses O
Hm O
-induced O
differentiation O
. O

The O
amount O
of O
c-myb B
mRNA I
in O
K562 O
cells O
was O
reduced O
during O
the O
differentiation O
induced O
by O
Epo O
. O

Expression O
of O
GATA-1 B
mRNA I
was O
almost O
constant O
during O
Hm O
-induced O
differentiation O
, O
but O
increased O
during O
Epo O
treatment O
. O

The O
AP-1 O
complex O
consists O
of O
distinct O
protein O
heterodimers O
encoded O
by O
the O
proto-oncogene O
c-fos O
and O
c-jun B
mRNA I
whose O
gene O
expression O
can O
be O
induced O
by O
TPA O
, O
cyclic O
AMP O
and O
growth O
factors O
. O

Recent O
findings O
suggest O
an O
involvement O
of O
reactive O
oxygen O
species O
in O
the O
pathway O
of O
TPA O
and O
protein O
kinase O
C O
leading O
to O
expression O
of O
c-fos B
and I
c-jun I
mRNA I
. O

To O
investigate O
the O
role O
of O
reactive O
oxygen O
species O
we O
studied O
the O
effects O
of O
alpha-lipoic O
acid O
and O
dihydrolipoic O
acid O
( O
natural O
thiol O
antioxidants O
) O
on O
the O
expression O
of O
c-fos B
mRNA I
in O
human O
Jurkat O
T O
cells O
. O

When O
cells O
were O
preincubated O
with O
dihydrolipoic O
acid O
( O
0.2 O
mM O
) O
the O
expression O
of O
c-fos B
mRNA I
was O
suppressed O
at O
30 O
min O
after O
stimulation O
of O
TPA O
( O
0.5 O
microM O
) O
whereas O
in O
the O
case O
of O
preincubation O
of O
alpha-lipoic O
acid O
( O
0.2 O
microM O
) O
, O
the O
expression O
was O
enhanced O
at O
30 O
min O
. O

These O
studies O
support O
the O
idea O
that O
superoxide O
anion O
radical O
plays O
a O
role O
in O
the O
expression O
of O
c-fos B
mRNA I
. O

The O
inhibition O
correlated O
with O
a O
decrease O
in O
steady O
state O
levels O
of O
E-selectin B
mRNA I
and O
cell O
surface O
expression O
of O
E-selectin O
which O
is O
consistent O
with O
the O
ability O
of O
a O
monoclonal O
antibody O
to O
E-selectin O
to O
inhibit O
monocytic O
cell O
adhesion O
in O
this O
system O
. O

Translational O
initiation O
of O
encephalomyocarditis B
virus I
( I
EMCV I
) I
mRNA I
occurs O
by O
ribosomal O
entry O
into O
the O
5 O
' O
nontranslated O
region O
of O
the O
EMCV B
mRNA I
, O
rather O
than O
by O
ribosomal O
scanning O
. O

IRES O
elements O
have O
been O
proposed O
to O
be O
involved O
in O
the O
translation O
of O
picornavirus B
mRNAs I
and O
some O
cellular B
mRNAs I
. O

Internal O
ribosome O
binding O
likely O
requires O
the O
interaction O
of O
trans-acting O
factors O
that O
recognize O
both O
the O
mRNA B
and O
the O
ribosomal O
complex O
. O

RA O
also O
enhanced O
lyn B
mRNA I
production O
rapidly O
in O
HL-60 O
, O
indicating O
that O
the O
activation O
of O
lyn O
gene O
expression O
is O
common O
in O
monocytic O
and O
granulocytic O
maturation O
of O
myeloid O
leukemia O
cells O
. O

These O
events O
are O
accompanied O
by O
marked O
increases O
in O
the O
expression O
of O
RAG-1 B
and I
RAG-2 I
RNAs I
. O

Northern O
blot O
analysis O
of O
poly B
( I
A I
) I
RNA I
purified O
from O
the O
human O
B O
cell O
line O
RPMI O
8226 O
and O
from O
activated O
T O
cells O
revealed O
a O
major B
mRNA I
transcript I
of O
2.2 O
kilobases O
. O

Similar O
analysis O
of O
poly B
( I
A I
) I
RNA I
from O
a O
variety O
of O
adult O
tissues O
demonstrated O
HB9 O
transcripts O
in O
pancreas O
, O
small O
intestine O
, O
and O
colon O
. O

Reverse O
transcriptase-polymerase O
chain O
reaction O
was O
used O
to O
examine O
HB9 B
RNA I
transcripts I
in O
hematopoietic O
cell O
lines O
. O

HB9 B
RNA I
transcripts I
were O
most O
prevalent O
in O
several O
human O
B O
cell O
lines O
and O
K562 O
cells O
. O

Analysis O
of O
mRNA B
suggested O
that O
Tat O
exerts O
its O
effect O
on O
IL-2 O
primarily O
at O
the O
transcriptional O
level O
. O

Alternative O
splicing O
of O
RNA B
transcripts I
encoded O
by O
the O
murine O
p105 O
NF-kappa O
B O
gene O
generates O
I O
kappa O
B O
gamma O
isoforms O
with O
different O
inhibitory O
activities O
. O

A O
transcription O
start O
site O
is O
located O
approximately O
4 O
kilobases O
5 O
' O
to O
the O
translation O
initiation O
codon O
, O
and O
an O
RNA O
splice O
of O
3863 O
bases O
occurs O
in O
the O
5'-untranslated O
region O
to O
generate O
mature B
HeLa I
cell I
mRNA I
. O

Antioxidant-mediated O
inhibition O
of O
cytokine O
production O
was O
correlated O
with O
low O
levels O
of O
the O
corresponding O
messenger B
RNAs I
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF O
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA O
binding O
protein O
nuclear O
factor O
( O
NF O
) O
-kB O
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines O
were O
analyzed O
. O

LIF O
increased O
steady-state O
levels O
of O
HIV B
mRNA I
at O
2.0 O
, O
4.3 O
, O
and O
9.2 O
kB O
. O

L227 O
induced O
an O
increase O
in O
intracellular O
free O
Ca2+ O
concentration O
( O
[ O
Ca2+ O
] O
i O
) O
from O
the O
intracellular O
pool O
and O
little O
or O
no O
protein O
tyrosine O
phosphorylation O
, O
phosphatidyl O
inositol O
turnover O
, O
or O
expression O
of O
Egr-1 B
mRNA I
, O
whereas O
2.06 O
plus O
GAM O
induced O
an O
increase O
in O
[ O
Ca2+ O
] O
i O
from O
both O
the O
intracellular O
and O
, O
in O
particular O
, O
the O
extracellular O
pools O
. O

Although O
resting O
tonsillar O
B O
cells O
did O
not O
express O
VDR B
mRNA I
, O
activation O
of O
these O
cells O
with O
interleukin-4 O
induced O
VDR O
in O
the O
absence O
of O
exogenously O
supplemented O
1 O
alpha O
, O
25- O
( O
OH O
) O
2D3 O
. O

Furthermore O
, O
1 O
alpha O
, O
25- O
( O
OH O
) O
2D3 O
induced O
24-hydroxylase O
mRNA O
expression O
and O
metabolic O
activity O
in O
both O
U937 O
cells O
and O
lectin-activated O
T O
cells O
, O
yet O
failed O
to O
induce O
24-hydroxylase B
mRNA I
or O
its O
metabolic O
activity O
in O
B O
cells O
. O

These O
findings O
suggest O
that O
although O
human O
B O
lymphocytes O
can O
express O
VDR B
mRNA I
and O
protein O
, O
they O
exhibit O
a O
functional O
block O
for O
vitamin O
D-dependent O
gene O
regulation O
. O

Priming O
with O
10 O
nM O
RA O
, O
or O
subsequent O
treatment O
with O
D3 O
( O
5 O
nM O
) O
, O
did O
not O
alter O
expression O
of O
mRNAs B
encoding O
receptors O
for O
D3 O
( O
VDR O
) O
, O
RA O
( O
RAR O
alpha O
) O
or O
9-CIS O
RA O
( O
RXR O
alpha O
, O
beta O
, O
gamma O
) O
. O

Production O
of O
IL-8 O
by O
hypoxic O
ECs O
occurred O
concomitantly O
with O
both O
increased O
levels O
of O
IL-8 B
mRNA I
, O
based O
on O
polymerase O
chain O
reaction O
analysis O
, O
and O
increased O
IL-8 O
transcription O
, O
based O
on O
nuclear O
run-on O
assays O
. O

Northern O
analysis O
of O
mRNA O
from O
hypoxic O
ECs O
also O
demonstrated O
increased O
levels O
of O
mRNA B
for O
macrophage O
chemotactic O
protein-1 O
, O
another O
member O
of O
the O
chemokine O
superfamily O
of O
proinflammatory O
cytokines O
. O

The O
magnitude O
of O
the O
thrombin O
response O
in O
the O
different O
cell O
types O
paralleled O
the O
expression O
of O
the O
thrombin B
receptor I
mRNA I
. O

We O
found O
that O
activation O
of O
Jurkat O
T O
cells O
by O
a O
combination O
of O
phytohemagglutinin O
and O
phorbol O
12-myristate O
13-acetate O
led O
to O
a O
dramatic O
inhibition O
of O
thrombin B
receptor I
mRNA I
expression O
and O
to O
a O
concomitant O
loss O
of O
the O
thrombin O
response O
. O

However O
, O
all O
20 O
cases O
lacked O
the O
t O
( O
15 O
; O
17 O
) O
and O
17 O
cases O
tested O
lacked O
the O
promyelocytic/retinoic B
acid I
receptor I
alpha I
( I
RAR I
alpha I
) I
fusion I
transcript I
in O
RT-PCR O
assays O
; O
12 O
cases O
had O
46 O
, O
XX O
or O
46 O
, O
XY O
karyotypes O
, O
whereas O
2 O
cases O
had O
abnormalities O
of O
chromosome O
17q O
: O
1 O
with O
del O
( O
17 O
) O
( O
q25 O
) O
and O
the O
other O
with O
t O
( O
11 O
; O
17 O
) O
( O
q23 O
; O
q21 O
) O
and O
the O
promyelocytic B
leukemia I
zinc I
finger/RAR I
alpha I
fusion I
transcript I
. O

The O
induced O
expression O
of O
IL-1 B
beta I
and I
TNF I
alpha I
mRNA I
in O
the O
monocytic O
THP-1 O
cell O
line O
increased O
as O
quickly O
as O
in O
primary O
cells O
. O

In O
THP-1 O
cells O
c-jun B
mRNA I
expression O
increased O
after O
incubation O
with O
MDHM O
while O
positive O
c-fos O
expression O
remained O
unaffected O
. O

In O
the O
primary O
cells O
MDHM-induced O
elevation O
of O
cytokine B
mRNA I
levels O
was O
preceded O
by O
a O
downregulation O
of O
c-fos O
expression O
while O
positive O
c-jun O
expression O
was O
not O
modulated O
. O

c-myc B
mRNA I
expression O
, O
constitutively O
high O
in O
THP-1 O
cells O
, O
was O
induced O
in O
MDHM-stimulated O
PBMo O
. O

In O
conclusion O
, O
MDHM-stimulated O
induction O
of O
cytokine B
mRNA I
expression O
was O
accompanied O
by O
different O
proto-oncogene O
responses O
in O
PBMo O
and O
THP-1 O
cells O
. O

This O
increase O
in O
p50 O
homodimers O
coincides O
with O
an O
increase O
in O
p105 B
mRNA I
, O
suggestive O
of O
a O
transcriptional O
up-regulation O
of O
p50 O
. O

We O
then O
analyzed O
the O
expression O
of O
the O
master O
GATA1 O
gene O
, O
which O
encodes O
a O
finger O
transcription O
factor O
required O
for O
normal O
erythroid O
development O
; O
addition O
of O
RA O
to O
HPC O
stimulated O
into O
unilineage O
erythropoietic O
differentiation O
in O
liquid O
culture O
caused O
a O
virtually O
complete O
inhibition O
of O
GATA1 B
mRNA I
induction O
. O

Induction O
of O
phosphatidylinositol O
turnover O
and O
EGR-1 B
mRNA I
expression O
by O
crosslinking O
of O
surface O
IgM O
and O
IgD O
in O
the O
human O
B O
cell O
line O
B104 O
. O

Both O
sIgM- O
and O
sIgD-crosslinking O
with O
antibodies O
induced O
elevation O
of O
cAMP O
levels O
, O
phosphatidylinositol O
turnover O
, O
PKC O
activation O
and O
expression O
of O
Egr-1 B
and I
c-fos I
mRNA I
, O
although O
sIgM O
-crosslinking O
was O
more O
effective O
than O
sIgD O
-crosslinking O
, O
presumably O
due O
to O
the O
higher O
expression O
of O
sIgM O
than O
of O
sIgD O
. O

Egr-1 B
mRNA I
expression O
induced O
by O
sIgM- O
and O
sIgD-crosslinking O
was O
inhibited O
by O
H7 O
, O
erbstatin O
and O
genistein O
, O
but O
not O
by O
HA1004 O
. O

Erbstatin O
and O
genistein O
inhibited O
the O
sIg-crosslinking-induced O
Egr-1 B
mRNA I
expression O
in O
a O
dose-dependent O
manner O
parallel O
to O
that O
observed O
in O
the O
inhibition O
of O
sIg-crosslinking-induced O
protein O
tyrosine O
phosphorylation O
. O

Phorbol O
myristate O
acetate O
induced O
Egr-1 B
mRNA I
expression O
but O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
did O
not O
. O

These O
findings O
suggest O
that O
the O
Egr-1 B
mRNA I
activating O
signals O
through O
sIgM O
and O
sIgD O
are O
protein O
tyrosine O
kinase- O
and O
PKC-dependent O
, O
but O
protein O
kinase O
A O
-independent O
. O

Cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
rescued O
B104 O
cells O
from O
death O
induced O
by O
anti-IgM O
Ab O
, O
but O
did O
not O
affect O
the O
expression O
of O
Egr-1 O
and O
c-fos B
mRNA I
, O
showing O
that O
CsA O
and O
FK506 O
affect O
signal O
transducers O
differently O
from O
or O
downstream O
to O
these O
molecules O
. O

Furthermore O
, O
loss O
of O
CD5 O
surface O
expression O
correlated O
with O
the O
absence O
of O
specific O
mRNA B
. O

Both O
drugs O
dose-dependently O
inhibited O
LPS-induced O
TF O
and O
TNF-alpha O
synthesis O
at O
the O
mRNA B
and O
the O
protein O
level O
, O
and O
reduced O
PGE2 O
production O
. O

Similarly O
, O
interferons O
could O
act O
on O
APL O
cells O
, O
alone O
or O
in O
combination O
with O
all-trans O
retinoic O
acid O
( O
RA O
) O
, O
especially O
if O
the O
PML/RAR B
alpha I
fusion I
transcript I
that O
results O
from O
the O
t O
( O
15 O
; O
17 O
) O
is O
induced O
by O
interferon O
. O

G O
( O
Anh O
) O
MTetra O
was O
found O
to O
strongly O
induce O
interleukin O
( O
IL O
) O
-1 O
beta O
and O
IL-6 B
mRNA I
expression O
after O
2 O
h O
and O
IL-1 O
beta O
and O
IL-6 O
protein O
secretion O
after O
48 O
h O
of O
activation O
. O

Experiments O
using O
inhibitors O
of O
protein O
kinase O
C O
, O
protein O
kinase O
A O
, O
and O
tyrosine O
kinase-dependent O
pathways O
revealed O
that O
G O
( O
Anh O
) O
MTetra-induced O
IL-1 O
beta O
and O
IL-6 B
mRNA I
expression O
involves O
activation O
of O
an O
H7-inhibitable O
pathway O
. O

By O
using O
the O
protein O
synthesis O
inhibitor O
cycloheximide O
, O
it O
was O
shown O
that O
G O
( O
Anh O
) O
MTetra-induced O
IL-6 B
mRNA I
expression O
depends O
on O
the O
synthesis O
of O
new O
protein O
, O
whereas O
G O
( O
Anh O
) O
MTetra-induced O
IL-1 O
beta O
mRNA O
accumulation O
does O
not O
. O

Furthermore O
, O
maximal O
G O
( O
Anh O
) O
MTetra-induced O
IL-1 O
beta O
and O
IL-6 B
mRNA I
expression O
could O
be O
enhanced O
by O
co-stimulation O
with O
LPS O
or O
MDP O
, O
suggesting O
that O
different O
receptors O
and/or O
transduction O
pathways O
were O
involved O
. O

Tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
stimulated O
the O
terminal O
differentiation O
of O
the O
DC O
by O
downregulating O
the O
expression O
of O
the O
M-CSF O
receptor O
, O
cfms B
mRNA I
, O
and O
aborting O
the O
potential O
to O
convert O
to O
macrophages O
. O

The O
restricted O
pattern O
of O
SCL O
protein O
synthesis O
is O
consistent O
with O
the O
restricted O
expression O
of O
SCL B
mRNA I
documented O
previously O
. O

Pervanadate O
also O
stimulated O
transcription O
of O
the O
c-fos O
gene O
and O
accumulation O
of O
its O
mRNA B
as O
well O
as O
several O
other O
hallmarks O
of O
T-lymphocyte O
activation O
such O
as O
surface O
expression O
of O
the O
CD69 O
antigen O
and O
the O
interleukin O
2 O
receptor O
alpha-chain O
( O
CD25 O
) O
. O

TSC2 B
messenger I
RNA I
was O
widely O
expressed O
in O
various O
cell O
types O
throughout O
the O
body O
, O
including O
epithelia O
, O
lymphocytes O
, O
and O
cells O
with O
endocrine O
functions O
, O
e.g. O
, O
adrenal O
cortex O
and O
anterior O
pituitary O
. O

In O
this O
investigation O
an O
enhanced O
and O
prolonged O
IL-2 O
and O
IL-2 B
mRNA I
response O
was O
also O
detected O
in O
both O
stimulated O
( O
T O
cell O
mitogens O
or O
alloantigens O
) O
murine O
splenocytes O
and O
in O
the O
stimulated O
murine O
T O
cell O
line O
EL-4 O
in O
the O
presence O
of O
ciprofloxacin O
( O
5-80 O
micrograms/ml O
) O
as O
compared O
to O
control O
cells O
without O
antibiotics O
. O

However O
, O
in O
contrast O
to O
human O
lymphocytes O
, O
IFN-gamma O
production O
was O
inhibited O
and O
IFN-gamma B
mRNA I
levels O
were O
unaffected O
at O
24 O
h O
and O
only O
slightly O
upregulated O
at O
48 O
and O
72 O
h O
of O
culture O
in O
murine O
splenocytes O
incubated O
with O
cipro O
( O
20 O
micrograms/ml O
) O
. O

CD40 O
induced O
not O
only O
nuclear O
translocation O
but O
also O
de O
novo O
synthesis O
of O
RelB B
RNA I
and O
protein O
. O

High O
levels O
of O
Sp140 B
mRNA I
were O
detected O
in O
human O
spleen O
and O
peripheral O
blood O
leukocytes O
, O
but O
not O
other O
human O
tissues O
. O

The O
level O
of O
SP140 B
mRNA I
in O
myeloid O
precursor O
cell O
lines O
HL60 O
and O
NB4 O
markedly O
increased O
in O
response O
to O
chemically O
induced O
cellular O
differentiation O
. O

Inhibition O
of O
nuclear B
factor I
kappa I
B I
subunit I
p65 I
mRNA I
accumulation O
in O
lipopolysaccharide-stimulated O
human O
monocytic O
cells O
treated O
with O
sodium O
salicylate O
. O

To O
examine O
the O
mechanisms O
by O
which O
salicylates O
affect O
cytokine O
gene O
transcription O
, O
the O
amount O
of O
active O
and O
inactive O
NF-kappa O
B O
and O
NF-kappa B
B I
mRNA I
, O
in O
Porphyromonas O
gingivalis O
lipopolysaccharide-stimulated O
human O
monocytic O
cells O
was O
assessed O
. O

High O
doses O
of O
sodium O
salicylate O
suppressed O
NF-kappa O
B O
p65 B
mRNA I
accumulation O
, O
resulting O
in O
suppression O
of O
total O
NF-kappa O
B O
, O
p50 O
on O
tissue O
oligonucleotide O
had O
no O
effects O
on O
lipopolysaccharide-induced O
NF-kappa O
B O
activation O
. O

We O
observed O
that O
dexamethasone O
dramatically O
inhibited O
RANTES B
mRNA I
expression O
dose O
dependently O
in O
anti-CD3 O
activated O
Hut-78 O
T O
cells O
and O
human O
PBMCs O
. O

Although O
, O
the O
level O
of O
MNDA B
mRNA I
in O
primary O
monocytes O
is O
very O
low O
it O
was O
up-regulated O
at O
6 O
h O
following O
the O
addition O
of O
interferon O
alpha O
. O

The O
effect O
of O
interferon O
alpha O
on O
the O
MNDA B
mRNA I
is O
also O
observed O
in O
the O
cell O
lines O
HL-60 O
, O
U937 O
, O
and O
THP-1 O
. O

The O
MNDA B
mRNA I
level O
in O
primary O
granulocytes O
was O
unaffected O
by O
addition O
of O
interferon O
alpha O
and O
other O
agents O
including O
interferon O
gamma O
, O
endotoxin O
, O
poly O
( O
I O
) O
.poly O
( O
C O
) O
, O
and O
FMLP O
. O

The O
MNDA B
mRNA I
level O
in O
the O
myeloid O
cell O
lines O
was O
also O
unaffected O
by O
the O
latter O
four O
agents O
. O

Induction O
of O
differentiation O
in O
the O
myeloid O
cell O
lines O
with O
phorbol O
ester O
induces O
monocyte O
differentiation O
which O
was O
accompanied O
by O
a O
decrease O
in O
MNDA B
mRNA I
level O
. O

This O
reduced O
level O
of O
mRNA B
could O
then O
be O
elevated O
with O
subsequent O
interferon O
alpha O
treatment O
. O

The O
effects O
of O
phorbol O
ester O
on O
MNDA B
mRNA I
appeared O
to O
be O
associated O
with O
induced O
differentiation O
since O
inhibiting O
cell O
proliferation O
did O
not O
alter O
the O
level O
of O
MNDA B
mRNA I
and O
cell O
cycle O
variation O
in O
MNDA B
mRNA I
levels O
were O
not O
observed O
. O

The O
ability O
of O
interferon O
alpha O
to O
up-regulate O
MNDA B
mRNA I
in O
phorbol O
ester O
treated O
myeloid O
cell O
lines O
is O
consistent O
with O
the O
observations O
made O
in O
primary O
monocytes O
. O

Freshly O
isolated O
cells O
show O
high O
levels O
of O
FOSB/G0S3 B
and I
FOS/G0S7 I
mRNAs I
, O
which O
decline O
rapidly O
during O
incubation O
in O
culture O
medium O
. O

In O
cells O
preincubated O
for O
a O
day O
, O
levels O
of O
FOS B
mRNA I
reach O
a O
maximum O
20 O
min O
after O
the O
addition O
of O
lectin O
and O
decline O
to O
control O
levels O
over O
the O
next O
3 O
hr O
. O

Levels O
of O
FOSB B
mRNA I
reach O
a O
maximum O
40 O
min O
after O
the O
addition O
of O
lectin O
and O
decline O
to O
control O
levels O
over O
the O
next O
6 O
hr O
. O

In O
freshly O
isolated O
cells O
, O
both O
FOS B
and I
FOSB I
mRNAs I
increase O
dramatically O
in O
response O
to O
the O
protein O
synthesis O
inhibitor O
cycloheximide O
. O

ISH O
for O
EBV-encoded B
small I
non-polyadenylated I
RNAs I
showed O
that O
all O
cases O
, O
whether O
NK O
or O
T O
, O
harboured O
EBV O
in O
virtually O
all O
tumour O
cells O
. O

RT-PCR O
demonstrated O
that O
NL O
of O
both O
subtypes O
expressed O
EBNAI O
of O
the O
QUK O
splice O
pattern O
, O
the O
latent O
membrane O
proteins O
, O
LMP1 O
and O
2 O
and O
the O
BamHI B
A I
rightward I
transcripts I
in O
the O
absence O
of O
EBNA2 B
mRNAs I
, O
compatible O
with O
the O
latency O
type O
II O
pattern O
. O

We O
show O
that O
PML/RAR B
alpha I
mRNA I
was O
still O
detectable O
despite O
clinical O
remission O
following O
ATRA O
treatment O
, O
but O
undetectable O
following O
consolidation O
with O
chemotherapy O
. O

The O
data O
indicate O
that O
10 O
( O
-6 O
) O
M O
DM O
increased O
T O
cell O
p50 O
NF-kappa B
B I
mRNA I
levels O
by O
four-fold O
compared O
to O
the O
levels O
obtained O
in O
the O
absence O
of O
DM O
. O

Interestingly O
, O
the O
expression O
level O
of O
p27Kip1 B
mRNA I
was O
maximal O
in O
resting O
Go O
T-cells O
and O
rapidly O
declined O
following O
anti-CD3 O
activation O
. O

Subsequent O
studies O
have O
revealed O
that O
( O
i O
) O
cytoplasmic O
RelA O
is O
stably O
associated O
not O
only O
with O
I O
kappa O
B O
alpha O
but O
also O
with O
other O
ankyrin O
motif-rich O
proteins O
including O
the O
products O
of O
the O
NF-kappa O
B2 O
( O
p100 O
) O
and O
NF-kappa O
B1 O
( O
p105 O
) O
genes O
; O
( O
ii O
) O
in O
contrast O
to O
RelA O
-I O
kappa O
B O
alpha O
, O
RelA-p100 O
cytoplasmic O
complexes O
are O
not O
dissociated O
following O
tumor O
necrosis O
factor O
alpha O
activation O
; O
( O
iii O
) O
p100 O
functions O
as O
a O
potent O
inhibitor O
of O
RelA O
-mediated O
transcription O
in O
vivo O
; O
( O
iv O
) O
the O
interaction O
of O
RelA O
and O
p100 O
involves O
the O
conserved O
Rel O
homology O
domain O
of O
both O
proteins O
but O
not O
the O
nuclear O
localization O
signal O
of O
RelA O
, O
which O
is O
required O
for O
I O
kappa O
B O
alpha O
binding O
; O
( O
v O
) O
p100 O
inhibition O
of O
RelA O
function O
requires O
the O
C-terminal O
ankyrin O
motif O
domain O
, O
which O
mediates O
cytoplasmic O
retention O
of O
RelA O
; O
and O
( O
vi O
) O
as O
observed O
with O
I O
kappa O
B O
alpha O
, O
nuclear O
RelA O
stimulates O
p100 B
mRNA I
and O
protein O
expression O
. O

Bcd B
mRNA I
transcripts I
of O
< O
or O
= O
2.6 O
kb O
were O
selectively O
expressed O
in O
PBL O
and O
testis O
of O
healthy O
individuals O
. O

These O
blast O
cells O
express O
lineage-specific O
transcription O
factors O
such O
as O
GATA-1 O
common O
to O
these O
lineages O
and O
frequently O
express O
erythroid-specific B
mRNAs I
such O
as O
gamma-globin O
and O
erythroid O
delta-aminolevulinate O
synthase O
( O
ALAS-E O
) O
, O
indicating O
that O
most O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

We O
find O
that O
in O
the O
absence O
of O
EKLF O
, O
while O
human O
beta-globin O
expression O
is O
dramatically O
reduced O
, O
gamma-globin B
transcripts I
are O
elevated O
approximately O
5-fold O
. O

Here O
, O
we O
show O
that O
zinc O
addition O
in O
a O
serum- O
and O
lipopolysaccharide-free O
cell O
culture O
system O
leads O
to O
significantly O
enhanced O
levels O
of O
interleukin O
1 O
beta O
( O
IL-1 O
beta O
) O
and O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
and O
to O
expression O
of O
the O
corresponding O
mRNA B
in O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
. O

They O
fail O
to O
induce O
mRNA B
of O
TNF-alpha O
after O
3 O
h O
of O
culture O
. O

Moreover O
, O
mRNA B
for O
IL-2 O
and O
IFN-gamma O
could O
not O
be O
detected O
. O

All O
cells O
tested O
express O
TAFII105 B
mRNA I
, O
but O
only O
B O
cells O
contain O
significant O
levels O
of O
protein O
associated O
with O
TFIID O
. O

Levels O
of O
bcl-2 B
mRNA I
and O
protein O
increase O
with O
cross-linking O
of O
surface O
immunoglobulin O
. O

Northern O
analysis O
using O
a O
probe O
encompassing O
a O
common O
region O
of O
both O
isoforms O
showed O
two O
mRNA B
species I
of O
2.7 B
and I
4.5 I
kilobase I
pairs I
, O
while O
an O
NFATc.beta-specific O
probe O
detected O
only O
the O
4.5-kilobase B
pair I
mRNA I
which O
was O
preferentially O
expressed O
in O
the O
spleen O
. O

IFN-gamma B
mRNA I
and O
protein O
are O
expressed O
predominantly O
by O
T O
cells O
and O
large O
granular O
lymphocytes O
. O

The O
IFN-gamma B
mRNA I
is O
induced/inhibited O
in O
these O
cell O
types O
by O
a O
wide O
variety O
of O
extracellular O
signals O
, O
thus O
implicating O
a O
number O
of O
diverse O
, O
yet O
convergent O
signal O
transduction O
pathways O
in O
its O
transcriptional O
control O
. O

Reverse O
transcription-PCR O
analysis O
showed O
that O
all O
seven O
EBV-positive O
tumour O
tissues O
constitutively O
expressed O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
1 I
mRNA I
, O
but O
not O
EBNA2 B
mRNA I
. O

The O
EBNA O
transcription O
was O
initiated O
from O
one O
of O
three O
EBNA O
promoters O
, O
Qp O
: O
by O
contrast O
, O
both O
Cp O
and O
Wp O
were O
silent O
, O
thus O
resulting O
in O
the O
lack O
of O
EBNA2 B
mRNA I
. O

Latent B
membrane I
protein I
( I
LMP I
) I
2A I
mRNA I
was O
detected O
in O
three O
of O
seven O
cases O
; O
however O
, O
neither B
LMP1 I
nor I
LMP2B I
mRNA I
was O
detected O
in O
any O
of O
the O
tumours O
tested O
. O

BZLF1 B
mRNA I
and O
the O
product O
, O
an O
immediate-early O
gene O
for O
EBV O
replication O
, O
was O
not O
expressed O
in O
any O
of O
them O
, O
thereby O
suggesting O
that O
the O
tumour O
cells O
carried O
EBV O
genomes O
in O
a O
tightly O
latent O
form O
. O

Constitutive O
expression O
of O
IFN-alpha5 O
and O
IFN-beta O
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse O
transcriptase O
-polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified O
product O
. O

Northern O
analysis O
revealed O
expression O
of O
a O
minor O
1.1 B
kb I
Id-3L I
transcript I
together O
with O
the O
predominant O
0.95 B
kb I
Id-3 I
transcript I
in O
the O
majority O
of O
adult O
human O
tissues O
analysed O
. O

In O
situ O
hybridizations O
of O
adult O
murine O
tissues O
demonstrate O
Spi-B B
mRNA I
in O
the O
medulla O
of O
the O
thymus O
, O
the O
white O
pulp O
of O
the O
spleen O
, O
and O
the O
germinal O
centers O
of O
lymph O
nodes O
. O

Spi-B O
expression O
is O
very O
abundant O
in O
B O
cells O
and O
both O
Spi-B B
mRNA I
and O
protein O
are O
detected O
in O
some O
T O
cells O
. O

The O
primary B
RNA I
transcript I
of O
the O
gene O
is O
subject O
to O
alternative O
splicing O
to O
yield O
different O
variants O
which O
can O
either O
activate O
or O
repress O
gene O
expression O
. O

In O
addition O
, O
inhibition O
of O
mRNA B
synthesis O
with O
actinomycin O
D O
indicated O
that O
DOX O
induced O
an O
increased O
stability O
of O
PBGD B
and I
GATA-1 I
mRNAs I
, O
whereas O
ACLA O
did O
not O
affect O
the O
half-lives O
of O
these O
mRNAs B
. O

Because O
the O
increase O
in O
erythroid B
mRNA I
steady-state O
level O
in O
anthracycline-treated O
cells O
was O
inhibited O
by O
cycloheximide O
, O
this O
suggests O
that O
transcriptional O
activation O
in O
ACLA-treated O
cells O
and O
mRNA O
stabilization O
in O
DOX-treated O
cells O
were O
dependent O
on O
de O
novo O
protein O
synthesis O
. O

We O
have O
studied O
the O
proliferation O
and O
CD40 O
antigen O
expression O
of O
lymphocytes O
, O
and O
the O
cytotoxicity O
to O
monocytes O
, O
of O
antisense O
phosphorothioate O
oligodeoxynucleotides O
complementary O
to O
the O
SP O
II O
promoter O
of O
HBV B
mRNA I
( O
sequence O
I O
) O
and O
the O
X O
gene O
( O
sequence O
II O
) O
in O
patients O
with O
chronic O
hepatitis O
B O
. O

Using O
reverse-transcription O
PCR O
differential O
display O
, O
we O
isolated O
an O
mRNA B
species I
expressed O
in O
IL-2 O
-but O
not O
IL-12-stimulated O
NK O
cells O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription O
factor O
egr-1 O
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL-2 O
, O
but O
not O
IL-12 O
, O
stimulation O
. O

Analysis O
of O
the O
expression O
of O
genes O
reported O
to O
regulate O
cytokine O
-induced O
proliferation O
demonstrated O
that O
both O
IL-2 O
and O
IL-12 O
induce O
c-myc B
mRNA I
accumulation O
in O
NK O
and O
T O
cells O
, O
whereas O
only O
IL-2 O
induces O
bcl-2 O
expression O
. O

This O
was O
unambiguously O
demonstrated O
by O
the O
fact O
that O
plasmacytoma O
x O
B O
cell O
hybrids O
carrying O
an O
AIR-1 O
locus O
derived O
from O
CIITA-expressing O
cells O
do O
not O
express O
CIITA-specific B
transcripts I
. O

Reverse O
transcription-PCR O
and O
Western O
blot O
analysis O
demonstrated O
that O
10 O
microM O
of O
C-JUN O
AS O
oligonucleotides O
reduced O
c-jun O
expression O
at O
both O
the O
mRNA B
and O
protein O
levels O
. O

We O
showed O
that O
both O
IL-10 O
and O
IL-4 O
inhibit O
LPS-induced B
IL-6 I
mRNA I
and O
protein O
expression O
by O
inhibiting O
the O
transcription O
rate O
of O
the O
IL-6 O
gene O
. O

Downregulation O
of O
LPS-induced O
AP-1 O
was O
accompanied O
, O
and O
thus O
possibly O
explained O
, O
by O
a O
reduced O
expression O
at O
mRNA B
level O
of O
the O
two O
major O
components O
of O
the O
AP-1 O
complex O
, O
namely O
c-fos O
and O
c-jun O
as O
determined O
by O
Northern O
experiments O
. O

NF-IL6 B
mRNA I
levels O
were O
not O
affected O
by O
IL-10 O
or O
IL-4 O
, O
suggesting O
that O
IL-4 O
affects O
binding O
activity O
of O
preexisting O
NF-IL6 O
. O

Furthermore O
, O
neither O
IL-10 O
nor O
IL-4 O
showed O
any O
effect O
on O
I-kappa B
B I
mRNA I
expression O
as O
determined O
by O
Northern O
experiments O
. O

The O
present O
results O
show O
that O
Jurkat O
T O
cells O
acutely O
exposed O
to O
micromolar O
concentrations O
of O
H2O2 O
exhibit O
substantial O
increases O
in O
AP-1 O
binding O
activity O
and O
the O
expression O
of O
c-jun O
but O
not O
c-fos B
mRNA I
. O

The O
preferential O
induction O
of O
c-jun O
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA/PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c-jun O
promoter O
via O
the O
proximal O
jun1 O
tumor O
promoter-responsive O
element O
( O
TRE O
) O
-like O
promoter O
element O
. O

However O
, O
PHA/PMA O
but O
not O
oxidative O
signals O
induced O
the O
coordinate O
activation O
of O
reporter O
constructs O
containing O
the O
AP-1-TRE O
, O
NF-AT O
, O
and O
IL-2 O
promoter O
regions O
along O
with O
IL-2 B
mRNA I
expression O
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF-AT O
and O
IL-2 O
reporters O
as O
well O
as O
the O
expression O
of O
IL-2 B
mRNA I
in O
cells O
stimulated O
with O
PHA/PMA O
. O

Transcriptional O
induction O
of O
the O
RAR B
( I
alpha I
) I
and I
PML-RAR I
mRNAs I
is O
rapid O
and O
it O
is O
parallelled O
by O
an O
increase O
in O
the O
corresponding O
proteins O
. O

Up-regulation O
of O
RAR O
( O
alpha O
) O
and O
PML-RAR O
gene O
expression O
by O
IFN O
( O
alpha O
) O
is O
accompanied O
by O
a O
strong O
potentiation O
in O
the O
induction O
of O
2 O
retinoid-dependent O
granulocytic O
markers O
, O
i.e. O
, O
granulocyte-colony-stimulating B
factor I
receptor I
mRNA I
and O
leukocyte O
alkaline O
phosphatase O
. O

We O
demonstrated O
that O
CMV O
infection O
increased O
both O
IL-6 O
protein O
and O
mRNA B
in O
peripheral O
blood O
mononuclear O
cells O
. O

The O
Rex O
protein O
of O
human O
T-cell O
leukemia O
virus O
type O
1 O
is O
required O
for O
the O
nuclear O
export O
of O
unspliced B
viral I
mRNA I
and O
, O
therefore O
, O
for O
virus O
replication O
. O

U1 O
lines O
overexpressing O
C/EBP O
activator O
NF-IL-6 O
produced O
more O
viral B
mRNA I
and O
virus O
particles O
following O
cellular O
activation O
than O
control O
lines O
, O
demonstrating O
that O
C/EBP O
proteins O
are O
limiting O
for O
virus O
transcription O
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post-transcriptional O
regulation O
of O
IL-6 O
gene O
expression O
by O
IL-4 O
and O
IL-10 O
, O
we O
studied O
IL-6 O
production O
, O
expression O
level O
of O
IL-6 B
mRNA I
, O
IL-6 O
promoter O
activity O
, O
transcriptional O
activity O
of O
NF-kappaB O
and O
NF-IL-6 O
, O
and O
IL-6 B
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP-1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL-4 O
or O
IL-10 O
. O

Both O
IL-4 O
and O
IL-10 O
were O
seen O
to O
inhibit O
IL-6 O
production O
and O
the O
expression O
of O
IL-6 B
mRNA I
in O
both O
monocytic O
cell O
lines O
studied O
. O

On O
the O
other O
hand O
, O
IL-10 O
enhanced O
the O
degradation O
of O
IL-6 B
mRNA I
in O
a O
mRNA O
stability O
assay O
. O

These O
results O
suggest O
that O
IL-4 O
may O
inhibit O
the O
transcription O
of O
the O
IL-6 O
gene O
by O
affecting O
NF-kappaB O
binding O
activity O
, O
while O
IL-10 O
may O
inhibit O
the O
IL-6 B
mRNA I
levels O
post-transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

TNF-alpha B
mRNA I
and O
release O
was O
inhibited O
even O
if O
IL-10 O
was O
added O
up O
to O
8 O
h O
after O
cryptococcal O
stimulation O
. O

In O
contrast O
, O
inhibition O
of O
IL-1 B
beta I
mRNA I
was O
of O
lesser O
magnitude O
and O
occurred O
only O
when O
IL-10 O
was O
added O
within O
2 O
h O
of O
cryptococcal O
stimulation O
. O

After O
20 O
h O
of O
stimulation O
with O
8-bromo-cAMP O
, O
AR B
mRNA I
was O
upregulated O
in O
LNCaP O
but O
not O
in O
either O
PC-3 O
or O
DU-145 O
cell O
lines O
. O

Finally O
, O
GM3 O
greatly O
reduced O
the O
concentration O
of O
endogenous O
GM-CSF B
mRNA I
induced O
by O
different O
stimuli O
in O
Jurkat O
T O
cells O
but O
did O
not O
affect O
interleukin B
3 I
mRNA I
levels O
in O
the O
same O
cells O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM-CSF O
resulted O
in O
the O
accumulation O
of O
steady-state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV O
long O
terminal O
repeat O
-driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular O
transcription O
factor O
nuclear O
factor-kappa O
B O
, O
was O
noted O
. O

Abundant O
expression O
of O
erythroid B
transcription I
factor I
P45 I
NF-E2 I
mRNA I
in O
human O
peripheral O
granurocytes O
. O

While O
p45 O
expression O
was O
shown O
to O
be O
restricted O
to O
erythroid O
cells O
, O
megakaryocytes O
and O
mast O
cells O
in O
hematopoietic O
lineage O
, O
we O
found O
in O
this O
study O
that O
p45 B
mRNA I
is O
abundantly O
transcribed O
in O
the O
granulocyte O
fraction O
of O
human O
peripheral O
blood O
cells O
. O

p45 B
mRNA I
is O
also O
expressed O
in O
HL-60 O
promyelocytes O
, O
albeit O
the O
expression O
level O
is O
much O
lower O
than O
that O
of O
the O
granulocyte O
fraction O
. O

HL-60 O
cells O
were O
found O
to O
express O
mafK B
mRNA I
, O
indicating O
the O
presence O
of O
genuine O
NF-E2 O
complex O
in O
the O
cells O
. O

Although O
p45 B
mRNA I
is O
transcribed O
from O
two O
different O
promoters O
, O
aNF-E2 O
promoter O
and O
fNF-E2 O
promoter O
, O
in O
erythroid O
and O
megakaryocytic O
lineage O
cells O
, O
p45 B
mRNA I
is O
transcribed O
only O
from O
aNF-E2 O
promoter O
. O

The O
expression O
of O
p45 O
megakaryocytic O
lineage O
cells O
, O
p45 B
mRNA I
is O
transcribed O
only O
from O
aNF-E2 O
promoter O
. O

The O
expression O
of O
p45 B
mRNA I
in O
the O
neutrophils O
declined O
rapidly O
after O
transfer O
of O
the O
cells O
to O
in O
vitro O
culture O
and O
G-CSF O
could O
not O
sustain O
the O
expression O
from O
the O
down-regulation O
, O
suggesting O
the O
E2 O
may O
also O
participate O
in O
the O
regulation O
of O
neutrophil-specific O
gene O
expression O
. O

CNI-1493 O
blocked O
neither O
the O
lipopolysaccharide O
( O
LPS O
) O
-induced O
increases O
in O
the O
expression O
of O
TNF B
mRNA I
nor O
the O
translocation O
of O
nuclear O
factor O
NF-kappa O
B O
to O
the O
nucleus O
in O
macrophages O
activated O
by O
15 O
min O
of O
LPS O
stimulation O
, O
indicating O
that O
CNI-1493 O
does O
not O
interfere O
with O
early O
NF-kappa O
B O
-mediated O
transcriptional O
regulation O
of O
TNF O
. O

Alternative O
splicing O
generates O
type B
A I
and I
B I
transcripts I
that O
potentially O
encode O
two O
entirely O
distinct O
proteins O
; O
type O
A B
transcripts I
code O
for O
a O
small O
mitochondrial O
protein O
, O
p8MTCP1 O
, O
and O
type B
B I
transcripts I
, O
containing O
an O
additional O
open O
reading O
frame O
, O
may O
code O
for O
107 O
amino-acid O
protein O
, O
p13MTCP1 O
. O

Priming O
of O
human O
monocytes O
with O
IFN-gamma O
resulted O
in O
the O
down O
regulation O
of O
c-fos B
and I
c-jun I
mRNA I
in O
response O
to O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
compared O
to O
the O
effects O
of O
LPS O
alone O
. O

LPS-stimulated O
monocytes O
showed O
an O
increased O
expression O
of O
p105 B
mRNA I
, O
the O
precursor O
of O
the O
p50 O
subunit O
of O
the O
transcription O
factor O
nuclear O
factor-kappa O
B O
( O
NF-kappa O
B O
) O
, O
while O
no O
effect O
was O
noticed O
on O
the O
expression O
of O
p65 B
mRNA I
. O

In O
contrast O
, O
IFN-gamma O
priming O
did O
not O
affect O
the O
expression O
of O
p105 B
transcripts I
but O
enhanced O
the O
expression O
of O
p65 B
mRNA I
( O
two-fold O
) O
. O

Priming O
with O
IFN-gamma O
followed O
by O
LPS O
stimulation O
resulted O
in O
a O
further O
increase O
in O
the O
expression O
of O
p65 B
mRNA I
. O

This O
was O
due O
to O
an O
increase O
in O
the O
half-life O
of O
p65 B
mRNA I
( O
75 O
vs O
150 O
minutes O
) O
. O

BCR O
-induced O
increases O
in O
CD44 B
mRNA I
expression O
and O
transcription O
levels O
are O
shown O
to O
occur O
in O
EGR1-expressing O
but O
not O
in O
nonexpressing O
subclones O
of O
the O
B-cell O
line O
WEHI-231 O
. O

Finally O
, O
we O
have O
studied O
the O
progression O
of O
one O
case O
of O
CLL O
into O
Richter O
's O
syndrome O
and O
have O
found O
that O
the O
Richter O
's O
cells O
expressed O
about O
25-fold O
less O
A-myb B
RNA I
than O
the O
CLL O
cells O
from O
the O
same O
patient. O
The O
pattern O
of O
c-myb O
and O
B-myb O
was O
clearly O
distinct O
from O
that O
of O
A-myb O
. O

Similar O
to O
IL-4 O
, O
IL-13 B
mRNA I
expression O
was O
highest O
in O
T-cell O
populations O
enriched O
for O
cells O
that O
had O
previously O
been O
primed O
in O
vivo O
or O
in O
vitro O
, O
indicating O
that O
priming O
increases O
the O
expression O
of O
the O
IL-13 O
and O
IL-4 O
genes O
in O
a O
coordinate O
manner O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte B
alkaline I
phosphatase I
, I
CD11b I
, I
CD33 I
, I
and I
G-CSF I
receptor I
mRNA I
, O
at O
concentrations O
that O
are O
10- O
to O
100-fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

Resting O
B O
and O
T O
lymphocytes O
contain O
high O
levels O
of O
BCL-6 B
mRNA I
. O

Stimulation O
of O
mouse O
B O
cells O
with O
anti-IgM O
or O
IgD O
antibodies O
, O
bacterial O
lipopolysaccharide O
, O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin O
, O
or O
CD40 O
ligand O
led O
to O
a O
five-fold O
to O
35-fold O
decrease O
in O
BCL-6 B
mRNA I
levels O
. O

Similar O
downregulation O
of O
BCL-6 B
mRNA I
was O
seen O
in O
human O
B O
cells O
stimulated O
with O
Staphylococcus O
aureus O
plus O
interleukin-2 O
or O
anti-IgM O
antibodies O
and O
in O
human O
T O
lymphocytes O
stimulated O
with O
phytohemagglutinin O
. O

BCL-6 B
mRNA I
levels O
began O
to O
decrease O
8 O
to O
16 O
hours O
after O
stimulation O
, O
before O
cells O
entered O
S O
phase O
. O

Compared O
to O
normal O
lymphocytes O
, O
MOLT-4 O
and O
CEM O
cells O
exhibited O
an O
altered O
cell O
cycle O
regulation O
of O
thymidine O
kinase O
, O
a O
much O
higher O
intracellular O
activity O
of O
this O
enzyme O
, O
and O
higher O
thymidine B
kinase I
mRNA I
expression O
. O

To O
clarify O
the O
presence O
of O
histamine O
receptor O
and O
its O
transmembrane O
mechanism O
in O
human O
T O
lymphocytes O
, O
we O
investigated O
the O
effects O
of O
agonists O
or O
antagonists O
of O
histamine O
receptor O
subtypes O
and O
bacterial O
toxins O
on O
intracellular O
concentration O
of O
Ca2+ O
[ O
Ca2+ O
] O
i O
) O
, O
[ O
3H O
] O
pyrilamine O
binding O
and O
c-fos B
mRNA I
expression O
in O
Jurkat O
cells O
, O
cloned O
human O
T O
lymphocytes O
. O

Histamine O
induced O
mRNA B
expression O
of O
an O
immediate O
early O
gene O
c-fos O
. O

In O
B O
lymphoid O
cells O
, O
deltaspi-B B
and I
spi-B I
mRNAs I
were O
present O
simultaneously O
in O
a O
ratio O
of O
around O
10 O
% O
. O

Moreover O
, O
in O
the O
presence O
of O
CIITA O
, O
interactions O
between O
class O
II O
promoters O
and O
Bob1 O
are O
independent O
of O
the O
octamer-binding B
site I
. O

The O
aim O
of O
the O
present O
study O
was O
to O
compare O
the O
expression O
of O
mRNA B
for O
glucocorticoid O
receptor O
in O
human O
blood O
monocytes O
obtained O
from O
seven O
unstable O
untreated O
asthmatic O
patients O
who O
were O
subsequently O
treated O
with O
high O
doses O
of O
parenteral O
corticosteroid O
( O
methyl O
prednisolone O
120 O
mg/day O
) O
for O
10 O
days O
. O

mRNA B
expression O
was O
identified O
after O
RNA O
extraction O
using O
RNAzol O
and O
analysed O
after O
reverse O
transcriptase O
, O
by O
polymerase O
chain O
reaction O
using O
a O
semiquantitative O
competitive O
hybridization O
assay O
. O

All O
asthmatic O
patients O
showed O
an O
improvement O
in O
their O
FEV1 O
values O
after O
corticosteroid O
treatment O
( O
per O
cent O
of O
predicted O
value O
68.28 O
+/- O
4.93 O
versus O
95.57 O
+/- O
6.41 O
, O
P O
< O
0.02 O
) O
, O
and O
a O
significant O
decrease O
for O
glucocorticoid O
receptor O
mRNA B
expression O
( O
P O
< O
0.02 O
) O
was O
observed O
in O
their O
monocytes O
. O

This O
is O
the O
first O
report O
of O
an O
ex O
vivo O
down-regulation O
for O
the O
glucocorticoid O
receptor O
mRNA B
expression O
, O
following O
corticosteroid O
treatment O
. O

The O
objective O
of O
this O
study O
was O
to O
develop O
U937 O
transfectants O
expressing O
antisense O
VDR B
mRNA I
, O
and O
to O
use O
these O
to O
examine O
the O
role O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
-VDR O
interaction O
in O
this O
lineage O
. O

We O
previously O
demonstrated O
that O
both O
synthetic O
( O
Exosurf O
) O
and O
modified O
natural O
surfactant O
( O
Survanta O
) O
downregulated O
endotoxin-stimulated O
inflammatory B
c I
ytokine I
mRNA I
levels O
and O
protein O
products O
( O
tumor O
necrosis O
factor-alpha O
[ O
TNF O
] O
, O
interleukin-1-beta O
[ O
IL-1 O
] O
, O
interleukin-6 O
[ O
IL-6 O
] O
) O
in O
human O
alveolar O
macrophages O
. O

In O
this O
study O
, O
we O
report O
that O
both O
Exosurf O
and O
Survanta O
suppress O
TNF B
mRNA I
and O
secretion O
( O
85 O
+/- O
4 O
% O
mean O
percent O
inhibition O
+/- O
SEM O
by O
Exosurf O
; O
71 O
+/- O
6 O
% O
by O
Survanta O
) O
by O
endotoxin-stimulated O
THP-1 O
, O
a O
human O
monocytic O
cell O
line O
. O

IL-11 B
mRNA I
and O
protein O
were O
both O
up-regulated O
during O
the O
course O
of O
this O
inflammatory O
response O
. O

Human B
monocyte I
IL-1 I
receptor I
antagonist I
( I
IL-1ra I
) I
messenger I
ribonucleic I
acid I
( O
mRNA O
) O
expression O
and O
protein O
secretion O
are O
inhibited O
by O
dexamethasone O
. O

We O
found O
that O
cortisol O
incubation O
induced O
a O
decrease O
in O
IL-1ra B
mRNA I
expression O
and O
a O
significant O
inhibition O
of O
IL-1ra O
protein O
secretion O
in O
cell O
cultures O
of O
human O
peripheral O
monocytes O
stimulated O
with O
the O
bacterial O
endotoxin O
lipopolysaccharide O
( O
LPS O
) O
. O

In O
addition O
, O
the O
expression O
of O
mineralocorticoid B
receptor I
mRNA I
in O
human O
monocytes O
was O
observed O
by O
PCR O
of O
reversed B
transcribed I
RNA I
. O

Reactive O
oxygen O
intermediate-release O
of O
fibre-exposed O
monocytes O
increases O
inflammatory O
cytokine-mRNA B
level O
, O
protein O
tyrosine O
kinase O
and O
NF-kappaB O
activity O
in O
co-cultured O
bronchial O
epithelial O
cells O
( O
BEAS-2B O
) O
. O

After O
up O
to O
90 O
min O
exposure O
time O
ELISA O
, O
EMSA O
( O
electromobility O
shift O
assay O
) O
and O
RT-PCR O
were O
used O
to O
measure O
protein O
tyrosine O
kinase O
activity O
, O
protein O
activity O
of O
NF-kappaB O
and O
cytokine O
( O
IL-1beta O
, O
IL-6 O
, O
TNF-alpha O
) O
specific O
mRNA B
levels O
in O
BEAS-2B O
cells O
. O

Consecutive O
IL-1beta- B
, I
IL-6- I
and I
TNF-alpha-mRNA I
were O
elevated O
( O
up O
to O
1.9 O
+/- O
0.58-fold O
) O
. O

Protein O
tyrosine O
kinase O
activity O
, O
NF-kappaB O
activity O
, O
and O
the O
synthesis O
of O
cytokine-specific B
mRNA I
were O
inhibited O
by O
antioxidants O
. O

Inhibition O
studies O
indicate O
that O
specific O
tyrosine O
phosphorylation O
following O
PTK O
activation O
is O
involved O
in O
the O
mobilization O
of O
the O
transcription O
factor O
, O
nuclear O
factor O
kappa O
B O
, O
and O
VCAM-1 B
mRNA I
expression O
. O

We O
report O
that O
both O
natural O
and O
synthetic O
PPARgamma O
agonists O
induce O
time- O
and O
dose-dependent O
increases O
in O
aP2 B
mRNA I
in O
both O
primary O
human O
monocytes O
and O
the O
monocytic O
cell O
line O
, O
THP-1 O
. O

Consistent O
with O
these O
data O
, O
CD40 O
signals O
up-regulate O
c-jun B
but I
not I
c-fos I
mRNA I
and O
alter O
the O
transcription O
factor O
ATF2 O
but O
not O
the O
Raf-1 O
protein O
. O

Expression O
of O
MIP-1alpha-R B
mRNA I
in O
these O
cells O
suggests O
an O
autocrine O
role O
for O
this O
chemokine O
in O
HTLV-I O
infected O
T-cells O
. O

MBP O
stimulated O
2-fold O
increases O
in O
IL-8 B
messenger I
RNA I
( O
mRNA B
) O
after O
1 O
and O
3 O
h O
of O
incubation O
, O
which O
were O
blocked O
by O
pretreatment O
with O
actinomycin O
D O
. O

In O
addition O
, O
stimulation O
with O
MBP O
prolonged O
the O
stability O
of O
IL-8 B
mRNA I
. O

MBP O
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage O
inflammatory O
protein O
( O
MIP O
) O
-1alpha O
and O
MIP-1beta O
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine O
. O

We O
also O
show O
that O
expression O
of O
the O
B1 B
transcript I
from O
a O
second O
gene O
, O
MTCP1 O
, O
occurred O
at O
a O
relatively O
high O
level O
only O
in O
two O
T-PLL O
tumours O
from O
A-T O
patients O
with O
t O
( O
X O
; O
14 O
) O
translocations O
whereas O
the O
MTCP1/A1 B
transcript I
is O
much O
more O
widely O
expressed O
in O
both O
tumour O
and O
non O
tumour O
cells O
of O
A-T O
and O
non-A-T O
individuals O
. O

MCP-1 B
RNA I
level O
was O
also O
increased O
in O
RA-treated O
cells O
. O

Using O
the O
technique O
of O
reverse O
transcription-polymerase O
chain O
reaction O
( O
PCR O
) O
with O
RNA O
isolated O
from O
lymphoid O
cell O
lines O
of O
the O
patient O
and O
of O
controls O
, O
no O
evidence O
was O
found O
that O
IVS1-10TC O
abnormally O
disrupted O
mRNA B
splicing O
or O
caused O
the O
absence O
of O
BRCA1 B
mRNA I
. O

RNA B
was O
extracted O
by O
phenol/chloroform O
and O
c-fos O
expression O
was O
analyzed O
by O
PCR O
assisted O
mRNA O
assay O
. O

Both O
PPAR-alpha B
and I
PPAR-gamma I
mRNAs I
were O
detected O
in O
HAECs O
by O
using O
reverse O
transcription-polymerase O
chain O
reaction O
and O
a O
ribonuclease O
protection O
assay O
; O
however O
, O
we O
have O
yet O
to O
determine O
which O
, O
if O
any O
, O
of O
the O
PPARs O
are O
mediating O
this O
process O
. O

In O
the O
cell O
line O
HT93A O
, O
which O
is O
capable O
of O
differentiating O
towards O
both O
the O
eosinophil O
and O
neutrophil O
lineages O
in O
response O
to O
retinoic O
acid O
( O
RA O
) O
, O
C/EBPalpha B
mRNA I
expression O
decreased O
significantly O
concomitant O
with O
eosinophilic O
and O
neutrophilic O
differentiation O
, O
whereas O
C/EBPbeta O
expression O
was O
markedly O
increased O
. O

We O
have O
isolated O
the O
5 O
' O
region O
of O
the O
ecto-5'-nucleotidase O
( O
low O
K O
( O
m O
) O
5'-NT O
) O
gene O
and O
established O
that O
a O
969-base O
pair O
( O
bp O
) O
fragment O
confers O
cell-specific O
expression O
of O
a O
CAT O
reporter O
gene O
that O
correlates O
with O
the O
expression O
of O
endogenous B
ecto-5'-NT I
mRNA I
and O
enzymatic O
activity O
. O

TNFalpha O
is O
a O
rapid O
activator O
of O
IL-8 O
gene O
expression O
by O
U937 O
, O
producing O
a O
50-fold O
induction O
of O
mRNA B
within O
1 O
hour O
of O
treatment O
. O

mRNA B
levels O
for O
IL-13R O
alpha1 O
, O
but O
not O
IL-4R O
alpha O
, O
were O
markedly O
decreased O
in O
in O
vitro O
monocyte-derived O
macrophages O
( O
MDMac O
) O
, O
and O
with O
increasing O
time O
of O
monocytes O
in O
culture O
correlated O
with O
the O
loss O
of O
IL-13 O
regulation O
of O
lipopolysaccharide-induced O
TNF-alpha O
production O
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum O
inhibitory O
factor O
, O
CIF O
) O
inhibits O
interleukin O
2 O
( O
IL2 O
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

This O
effect O
was O
paralleled O
by O
a O
reduction O
in O
the O
expression O
of O
MSR O
protein O
and O
mRNA B
. O

The O
BCL-6 B
gene I
encoding O
a O
nuclear-located O
Kruppel-type O
zinc O
finger O
protein O
is O
rearranged O
in O
about O
30 O
% O
diffuse O
large O
B-cell O
lymphomas O
and O
is O
expressed O
predominantly O
in O
normal O
germinal O
center O
B O
cells O
and O
related O
lymphomas O
. O

Nuclear O
factor-90 O
of O
activated O
T-cells O
: O
A O
double-stranded B
RNA I
-binding O
protein O
and O
substrate O
for O
the O
double-stranded O
RNA-dependent O
protein O
kinase O
, O
PKR O
. O

The O
subunits O
of O
this O
heterodimer O
have O
been O
cloned O
, O
and O
NF90 O
was O
found O
to O
encode O
a O
protein O
containing O
two O
domains O
that O
are O
predicted O
to O
form O
motifs O
capable O
of O
binding O
to O
double-stranded B
RNA I
. O

Using O
in O
vitro O
translated O
polypeptides O
, O
we O
have O
demonstrated O
that O
NF90 O
specifically O
binds O
to O
double-stranded B
RNA I
. O

Furthermore O
, O
NF90 O
was O
phosphorylated O
in O
a O
double-stranded B
RNA I
-dependent O
manner O
likely O
by O
the O
interferon-induced O
, O
double-stranded O
RNA-dependent O
protein O
kinase O
, O
PKR O
. O

IL-8 O
secretion O
was O
accompanied O
by O
accumulation O
of O
IL-8 B
mRNA I
in O
the O
cytosol O
and O
by O
nuclear O
expression O
of O
a O
kappaB O
DNA O
binding O
activity O
within O
30 O
minutes O
. O

Alternative O
splicing O
of O
the O
GC B
receptor I
( I
GCR I
) I
pre-mRNA I
generates O
a O
second O
GCR O
, O
termed O
GCRbeta O
, O
which O
does O
not O
bind O
GC O
but O
antagonizes O
the O
transactivating O
activity O
of O
the O
classic O
GCR O
. O

HTLV-1-transformed O
T-cell O
lines O
expressed O
higher O
amounts O
of O
STAT1 B
, I
STAT3 I
and I
STAT5 I
RNA I
and O
proteins O
than O
virus-negative O
T O
cells O
. O

The O
expression O
of O
STAT1 B
, I
STAT3 I
and I
STAT5 I
mRNAs I
were O
also O
induced O
by O
a O
T-cell O
mitogen O
in O
normal O
human O
peripheral O
blood O
mononuclear O
cells O
. O

OBJECTIVE O
: O
We O
investigated O
the O
effect O
of O
DEP-PAHs O
on O
the O
release O
and O
mRNA B
expression O
of O
IL-8 O
, O
MCP-1 O
, O
and O
RANTES O
by O
PBMCs O
obtained O
from O
healthy O
subjects O
. O

METHODS O
: O
Protein O
production O
in O
supernatants O
was O
assessed O
by O
ELISA O
, O
and O
mRNA B
expression O
was O
evaluated O
by O
semiquantitative O
RT-PCR O
. O

Messenger B
RNA I
production O
coding O
for O
IL-8 O
, O
RANTES O
, O
and O
MCP-1 O
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent O
proteins O
. O

This O
correlated O
with O
the O
initiation O
of O
signaling O
downstream O
of O
Notch O
, O
as O
evidenced O
by O
increased O
levels O
of O
HES-1 B
transcripts I
in O
co-cultivated O
T O
cells O
and O
of O
CD23 B
transcripts I
in O
co-cultivated O
B O
cells O
. O

To O
evaluate O
the O
effect O
of O
UV O
light O
on O
cytochrome O
P4501A1 O
gene O
expression O
, O
we O
studied O
the O
induction O
of O
CYP1A1 B
mRNA I
by O
UV O
irradiation O
of O
cultured O
human O
keratinocytes O
( O
HaCaT O
cell O
line O
) O
, O
primary O
human O
blood O
lymphocytes O
and O
mouse O
Hepa-1 O
cells O
. O

The O
results O
show O
that O
the O
CYP1A1 B
mRNA I
level O
induced O
by O
UV O
in O
the O
presence O
of O
tryptophan O
was O
higher O
than O
that O
induced O
by O
UV O
alone O
in O
both O
HaCaT O
cells O
and O
lymphocytes O
after O
3 O
h O
of O
incubation O
post-UV O
irradiation O
. O

Furthermore O
, O
Id3 O
impedes O
expression O
of O
recombination O
activating O
genes O
and O
downregulates O
pre-Talpha B
mRNA I
. O

Likewise O
, O
NF-AT1 B
mRNA I
and O
NF-AT4 B
mRNA I
have O
been O
detected O
in O
resting O
eosinophils O
, O
and O
their O
levels O
can O
be O
significantly O
up-regulated O
by O
the O
Th2-associated O
cytokines O
IL-4 O
and O
IL-5 O
. O

We O
found O
that O
overexpression O
of O
IkappaB-alpha O
in O
endothelial O
cells O
using O
a O
recombinant O
adenovirus O
prevented O
tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
-induced O
degradation O
of O
IkappaB-alpha O
and O
suppressed O
the O
upregulation O
of O
vascular O
cell O
adhesion O
molecule-1 O
( O
VCAM-1 O
) O
, O
intercellular O
adhesion O
molecule-1 O
( O
ICAM-1 O
) O
, O
and O
E-selectin B
mRNA I
and O
surface O
protein O
expression O
and O
the O
upregulation O
of O
transcripts O
for O
the O
chemokines O
monocyte O
chemoattractant O
protein O
1 O
( O
MCP-1 O
) O
and O
growth-related O
activity-alpha O
( O
GRO-alpha O
) O
by O
TNF-alpha O
. O

PML B
mRNA I
and O
protein O
, O
while O
barely O
detectable O
in O
quiescent O
HPCs O
, O
are O
consistently O
induced O
by O
growth O
factor O
stimulation O
through O
the O
erythroid O
or O
granulocytic O
lineage O
. O

In O
functional O
studies O
, O
PML O
expression O
was O
inhibited O
by O
addition O
of O
antisense O
oligomers O
targeting O
PML B
mRNA I
( O
alpha-PML O
) O
. O

Furthermore O
, O
PD98059 O
completely O
blocked O
the O
TPA-induced O
differentiation O
of O
ML-1 O
cells O
, O
as O
assessed O
by O
a O
number O
of O
features O
associated O
with O
mononuclear O
differentiation O
including O
changes O
in O
morphology O
, O
nonspecific O
esterase O
activity O
, O
phagocytic O
ability O
, O
NADPH O
oxidase O
activity O
, O
mitochondrial O
respiration O
, O
and O
c-jun B
mRNA I
inducibility O
. O

In O
addition O
, O
only O
a O
subset O
of O
the O
NSAIDs O
induced O
HSP70 B
mRNA I
species I
. O

IL-2 O
secretion O
was O
paralleled O
by O
increased O
expression O
of O
IL-2 B
mRNA I
, O
resulting O
from O
enhanced O
IL-2 B
mRNA I
stability O
. O

CTLA-4 O
ligation O
inhibited O
CD3/ O
CD28 O
-induced O
IL-2 B
mRNA I
accumulation O
by O
inhibiting O
IL-2 O
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF-AT O
accumulation O
in O
the O
nuclei O
. O

However O
, O
CTLA-4 O
ligation O
did O
not O
appear O
to O
affect O
the O
CD28 O
-mediated O
stabilization O
of O
IL-2 B
mRNA I
. O

Inhibition O
of O
NF-kappaB O
activity O
inhibits O
the O
P/I O
mediated O
induction O
of O
FasL B
mRNA I
and O
decreases O
the O
level O
of O
apoptosis O
in O
these O
cultures O
, O
thus O
establishing O
NF-kappaB O
as O
a O
proapoptotic O
factor O
in O
this O
context O
. O

In O
addition O
, O
competitive O
single-cell O
RT-PCR O
was O
used O
to O
assay O
CD34 B
mRNA I
transcripts I
in O
sibling O
CD34 O
( O
+ O
) O
CD38 O
( O
- O
) O
cells O
differentiating O
in O
unilineage O
erythroid O
cultures O
: O
this O
analysis O
allowed O
us O
to O
semiquantitate O
the O
gradual O
downmodulation O
of O
CD34 B
mRNA I
from O
progenitor O
cells O
through O
their O
differentiating O
erythroid O
progeny O
. O

TNF B
mRNA I
expression O
induced O
by O
LPS O
was O
decreased O
when O
the O
pre-treatment O
of O
PBMC O
with O
IL-10 O
was O
performed O
on O
plastic O
, O
whereas O
this O
was O
not O
the O
case O
when O
cells O
were O
pre-cultured O
with O
IL-10 O
on O
Teflon O
. O

Inhibition O
of O
LITAF B
mRNA I
expression O
in O
THP-1 O
cells O
resulted O
in O
a O
reduction O
of O
TNF-alpha O
transcripts O
. O

In O
addition O
, O
high O
level O
of O
expression O
of O
LITAF B
mRNA I
was O
observed O
predominantly O
in O
the O
placenta O
, O
peripheral O
blood O
leukocytes O
, O
lymph O
nodes O
, O
and O
the O
spleen O
. O

This O
effect O
can O
be O
associated O
with O
the O
activation O
of O
specific O
hormone O
receptors O
, O
since O
we O
observed O
the O
expression O
of O
the O
estrogen B
receptor I
alpha I
( I
ER-alpha I
) I
, I
ER-beta I
, I
and I
progesterone I
receptor I
( I
PR I
) I
mRNAs I
; O
the O
ER-alpha O
protein O
expression O
was O
confirmed O
by O
immunocytochemical O
analysis O
. O

Stimulation O
of O
HUVEC O
with O
thrombin O
resulted O
in O
dose- O
and O
time-dependent O
increases O
in O
ICAM-1 B
mRNA I
and O
cell O
surface O
expression O
and O
in O
ICAM-1 O
-dependent O
endothelial O
adhesivity O
toward O
polymorphonuclear O
leukocytes O
. O

In O
vivo O
modulation O
of O
glucocorticoid B
receptor I
mRNA I
by O
inhaled O
fluticasone O
propionate O
in O
bronchial O
mucosa O
and O
blood O
lymphocytes O
in O
subjects O
with O
mild O
asthma O
. O

OBJECTIVE O
: O
We O
sought O
to O
determine O
the O
in O
vivo O
modulation O
of O
GR B
mRNA I
expression O
by O
fluticasone O
propionate O
( O
FP O
) O
in O
subjects O
with O
mild O
asthma O
. O

Before O
and O
after O
treatment O
, O
the O
patients O
underwent O
fiberoptic O
bronchoscopy O
with O
endobronchial O
biopsy O
and O
sampling O
of O
venous O
blood O
for O
measurements O
of O
GR B
mRNA I
levels O
. O

A O
solution O
hybridization O
assay O
was O
used O
for O
quantitative O
analysis O
of O
GR B
mRNA I
. O

RESULTS O
: O
A O
high O
interindividual O
variation O
in O
GR B
mRNA I
expression O
was O
seen O
. O

However O
, O
we O
detected O
a O
significant O
reduction O
of O
the O
GR B
mRNA I
levels O
in O
the O
endobronchial O
biopsy O
specimens O
after O
FP O
treatment O
( O
36.6 O
+/- O
23.1 O
and O
25.0 O
+/- O
10.9 O
amol O
GR B
mRNA I
/microg O
RNA O
, O
respectively O
; O
P O
< O
.01 O
) O
. O

In O
the O
peripheral O
blood O
lymphocytes O
an O
even O
more O
striking O
downregulation O
of O
the O
GR O
by O
its O
cognate O
ligand O
was O
documented O
( O
30.3 O
+/- O
26.5 O
and O
8.8 O
+/- O
5 O
amol O
GR B
mRNA I
/microg O
RNA O
, O
respectively O
; O
P O
< O
.001 O
) O
, O
possibly O
reflecting O
differences O
in O
glucocorticoid O
sensitivity O
between O
tissues O
. O

Spi-C B
RNA I
was O
expressed O
in O
mature O
B O
lymphocytes O
and O
at O
lower O
levels O
in O
macrophages O
. O

In O
the O
absence O
of O
tetracycline O
, O
GR B
mRNA I
and O
protein O
expression O
increased O
2-3-fold O
, O
and O
cells O
expressed O
48 O
, O
000 O
receptors O
, O
a O
level O
nearly O
equivalent O
to O
that O
present O
in O
6TG1.1 O
cells O
after O
18 O
h O
of O
autoinduction O
. O

Inhibition O
of O
p38alpha O
MAPk O
resulted O
in O
a O
transient O
decrease O
in O
TNF-alpha B
mRNA I
accumulation O
but O
persistent O
loss O
of O
TNF-alpha O
synthesis O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte O
chemotactic O
protein-1 O
( O
a O
CC O
chemokine O
) O
and O
the O
activation O
of O
the O
transcriptional O
factor O
( O
FcRFgamma O
) O
bound O
to O
the O
gamma O
response O
region O
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma O
treatment O
in O
PMA O
-or O
RA-differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP-10 B
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma O
. O

Increased O
expression O
of O
IFNgamma O
-induced O
IP-10 B
mRNA I
following O
the O
differentiation O
of O
U937 O
cells O
was O
mediated O
largely O
by O
augmented O
transcriptional O
activity O
of O
the O
gene O
and O
was O
related O
to O
differentiation-dependent O
changes O
of O
the O
proteins O
bound O
to O
IFN O
stimulus O
response O
element O
( O
ISRE O
) O
and O
kB O
sites O
, O
suggesting O
that O
these O
nuclear O
proteins O
may O
determine O
the O
IP-10 B
mRNA I
inducibility O
by O
IFNgamma O
. O

Associated O
with O
these O
findings O
, O
the O
levels O
of O
p21 O
( O
WAF1/CIP1 O
) O
and O
p27 B
( I
KIP1 I
) I
mRNA I
and O
protein O
increased O
in O
these O
cells O
. O

Northern O
blot O
analysis O
showed O
that O
p21 B
( I
WAF1/CIP1 I
) I
and I
p27 I
( I
KIP1 I
) I
mRNA I
and O
protein O
increased O
in O
these O
cells O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E-selectin O
, O
ICAM-1 O
, O
and O
VCAM-1 O
were O
noted O
within O
hours O
. O

We O
found O
that O
they O
reduced O
the O
initial O
interleukin-1beta B
mRNA I
transcription O
rate O
through O
prevention O
of O
degradation O
of O
inhibitor-kappaB O
alpha O
. O

These O
common O
sequence O
variants O
were O
not O
found O
within O
three O
message-destabilizing O
elements O
that O
we O
mapped O
within O
the O
3'-UTR O
of O
the O
vitamin B
D I
receptor I
mRNA I
. O

Reverse O
transcriptase O
polymerase O
chain O
reaction O
and O
Northern O
analyses O
confirmed O
that O
normal O
and O
leukemic O
myeloid O
progenitor O
cells O
expressed O
mRNA B
for O
the O
type O
I O
and O
IV O
isoforms O
of O
17 O
beta-hydroxysteroid O
dehydrogenase O
. O

Detection O
of O
NF-ATc.alpha B
mRNA I
is O
strictly O
dependent O
on O
cell O
activation O
signals O
in O
both O
T O
and O
mast O
cell O
lines O
. O

Here O
, O
we O
report O
that O
expression O
of O
FasL O
protein O
and O
mRNA B
in O
activated O
NK O
cells O
is O
also O
regulated O
by O
redox O
. O

Apart O
from O
clear-cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2-type O
lymphokines O
, O
such O
as O
IL-4 O
, O
IL-5 O
, O
IL-10 O
and O
IL-13 O
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11+/CD4+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr/lpr O
and O
gld/gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas O
and O
FasL O
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE O
and O
Egr O
family O
proteins O
have O
in O
this O
aberrant O
expression O
of O
fasL O
. O

Although O
overexpressed O
Egr-1 O
was O
ineffective O
, O
overexpressed O
Egr-2 O
was O
as O
potent O
as O
Egr-3 O
in O
inducing O
fasL O
promoter-dependent O
reporter O
constructs O
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up-regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

In O
fact O
, O
NF-YA B
mRNA I
is O
present O
at O
the O
same O
level O
at O
all O
days O
of O
monocyte O
cultivation O
, O
whereas O
the O
protein O
is O
absent O
in O
freshly O
isolated O
monocytes O
but O
is O
progressively O
synthesized O
during O
the O
maturation O
process O
. O

Although O
resting O
Jurkat O
cells O
express O
Fas O
, O
Fas B
mRNA I
was O
induced O
approximately O
10-fold O
in O
2 O
h O
upon O
P/I O
stimulation O
. O

Fusion O
of O
anergic O
murine O
T O
cells O
to O
human O
Jurkat O
T O
leukemia O
cells O
and O
formation O
of O
heterokaryons O
failed O
to O
result O
in O
a O
complementation O
of O
this O
signaling O
defect O
and O
restoration O
of O
murine B
IL-2 I
mRNA I
inducibility O
. O

The O
lack O
of O
B29 B
transcripts I
, O
coding O
for O
the O
beta O
subunit O
of O
the O
B-cell O
receptor O
complex O
, O
in O
pro-B O
cells O
from O
EBF O
-deficient O
mice O
suggested O
that O
B29 O
might O
be O
a O
genetic O
target O
for O
EBF O
. O

Induction O
of O
interleukin-12 O
p40 B
transcript I
by O
CD40 O
ligation O
via O
activation O
of O
nuclear O
factor-kappaB O
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 O
or O
by O
transfection O
with O
a O
CD40L O
expression O
vector O
, O
secreted O
p40 O
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

In O
humans O
, O
alternative O
splicing O
of O
the O
GR B
precursor I
mRNA I
gives O
rise O
to O
two O
receptor O
isoforms O
, O
termed O
GRalpha O
and O
GRbeta O
. O

We O
found O
that O
: O
( O
i O
) O
both O
CTCF B
mRNA I
and O
protein O
are O
down-regulated O
during O
terminal O
differentiation O
in O
most O
cell O
lines O
tested O
; O
( O
ii O
) O
CTCF O
down-regulation O
is O
retarded O
and O
less O
pronounced O
than O
that O
of O
c-myc O
; O
( O
iii O
) O
CTCF O
protein O
is O
differentially O
phosphorylated O
and O
the O
phosphorylation O
profiles O
depend O
on O
the O
differentiation O
pathway O
. O

Because O
Egr-1 B
mRNA I
and O
protein O
levels O
were O
observed O
to O
increase O
significantly O
before O
induction O
of O
elk-1 O
expression O
, O
we O
propose O
that O
Egr-1 O
is O
important O
for O
the O
regulation O
of O
elk-1 O
transcription O
in O
differentiating O
monocytes O
. O

Induction O
of O
TF B
mRNA I
expression O
by O
LPS O
tended O
to O
be O
partially O
reduced O
by O
the O
lysophospholipid O
. O

The O
binding O
of O
these O
proteins O
to O
the O
regulatory O
region O
of O
IL-2 O
gene O
in O
vitro O
and O
stimulation O
of O
the O
IL-2mRNA B
synthesis O
in O
splenic O
T-lymphocytes O
culture O
in O
normal O
conditions O
were O
shown O
. O

The O
protective O
effect O
of O
SP O
and O
BP O
on O
the O
IL-2mRNA B
synthesis O
in O
stressful O
conditions O
and O
by O
the O
T-cells O
treatment O
with O
the O
CsA O
was O
demonstrated O
. O

TNF O
increased O
VCAM-1 O
protein O
and O
mRNA B
in O
HUVECs O
that O
was O
blocked O
by O
pyrrolidinedithiocarbamate O
. O

In O
both O
cell O
types O
the O
cellular O
levels O
of O
IkappaBalpha B
mRNA I
and O
protein O
were O
evaluated O
by O
DEX O
treatment O
. O

Over O
the O
next O
week O
, O
this O
cell O
population O
accumulates O
phenotypic O
markers O
of O
osteoclasts O
( O
vitronectin O
receptor O
[ O
VR O
] O
, O
calcitonin O
receptor O
, O
TRAP O
, O
cathepsin O
K O
protein O
, O
and O
mRNA B
) O
with O
increased O
nuclearity O
, O
covering O
the O
entire O
surface O
by O
15 O
days O
. O

The O
endothelial O
expression O
of O
vascular O
cell O
adhesion O
molecule-1 O
( O
VCAM-1 O
) O
, O
E-selectin O
, O
and O
intercellular O
adhesion O
molecule-1 O
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady-state O
levels O
of O
VCAM-1 B
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

Oleate O
also O
produced O
a O
quantitatively O
similar O
reduction O
of O
VCAM-1 B
mRNA I
levels O
on O
Northern O
blot O
analysis O
and O
inhibited O
nuclear O
factor-kappaB O
activation O
on O
electrophoretic O
mobility O
shift O
assays O
. O

Northern O
blot O
analysis O
showed O
that O
C3a O
as O
well O
as O
C3a O
( O
desArg O
) O
enhanced O
LPS O
-induced B
mRNA I
levels O
for O
IL-6 O
. O

Our O
studies O
showed O
that O
levels O
of O
C/EBP B
epsilon I
mRNA I
were O
markedly O
increased O
in O
NB4 O
cells O
( O
promyelocytic O
leukemia O
line O
) O
, O
because O
they O
were O
induced O
by O
9-cis O
retinoic O
acid O
( O
9-cis O
RA O
) O
to O
differentiate O
towards O
granulocytes O
. O

Accumulation O
of O
C/EBP B
epsilon I
mRNA I
occurred O
as O
early O
as O
1 O
hour O
after O
exposure O
of O
NB4 O
cells O
to O
9-cis O
RA O
( O
5 O
x O
10 O
( O
-7 O
) O
mol/L O
) O
; O
and O
at O
48 O
hours O
, O
levels O
were O
increased O
by O
5.1-fold O
. O

Dose-response O
studies O
showed O
that O
10 O
( O
-7 O
) O
to O
10 O
( O
-6 O
) O
mol/L O
9-cis O
RA O
( O
12 O
hours O
) O
resulted O
in O
peak O
levels O
of O
C/EBP B
epsilon I
mRNA I
; O
but O
even O
10 O
( O
-10 O
) O
mol/L O
9-cis O
RA O
increased O
levels O
of O
these O
transcripts O
. O

NB4 O
cells O
pulse-exposed O
( O
30 O
minutes O
) O
to O
all-trans O
retinoic O
acid O
( O
ATRA O
) O
, O
washed O
, O
and O
cultured O
( O
3 O
days O
) O
with O
either O
dimethylsulfoxide O
( O
DMSO O
) O
or O
hexamethylene O
bisacetamide O
( O
HMBA O
) O
had O
a O
prominent O
increase O
in O
levels O
of O
C/EBP B
epsilon I
mRNA I
and O
an O
increase O
in O
granulocytic O
differentiation O
, O
but O
exposure O
to O
either O
DMSO O
or O
HMBA O
alone O
had O
no O
effect O
on O
base O
levels O
of O
C/EBP O
epsilon O
and O
did O
not O
induce O
differentiation O
. O

Macrophage-differentiation O
of O
NB4 O
reduced O
levels O
of O
C/EBP B
epsilon I
mRNA I
. O

Nuclear O
run-off O
assays O
and O
half-life O
studies O
showed O
that O
accumulation O
of O
C/EBP B
epsilon I
mRNA I
by O
9-cis O
RA O
was O
due O
to O
enhanced O
transcription O
. O

Furthermore O
, O
this O
C/EBP B
epsilon I
mRNA I
accumulation O
did O
not O
require O
synthesis O
of O
new O
protein O
factors O
because O
9-cis O
RA O
induced O
C/EBP B
epsilon I
mRNA I
accumulation O
in O
the O
absence O
of O
new O
protein O
synthesis O
. O

In O
contrast O
to O
the O
increase O
of O
C/EBP O
epsilon O
in O
9-cis O
RA-mediated O
granulocytic O
differentiation O
, O
the O
DMSO-induced O
differentiation O
of O
HL-60 O
cells O
down O
the O
granulocytic O
pathway O
was O
associated O
with O
an O
initial O
reduction O
of O
C/EBP B
epsilon I
mRNA I
levels O
. O

In O
summary O
, O
we O
have O
discovered O
that O
expression O
of O
C/EBP B
epsilon I
mRNA I
is O
markedly O
enhanced O
as O
the O
NB4 O
promyelocytes O
are O
induced O
by O
retinoids O
to O
differentiate O
towards O
granulocytes O
. O

This O
induction O
of O
C/EBP B
epsilon I
mRNA I
expression O
is O
transcriptionally O
mediated O
and O
occurs O
in O
the O
absence O
of O
synthesis O
of O
additional O
protein O
factors O
. O

Constitutive O
expression O
c-fos B
, I
c-jun I
, I
and I
NF I
kappa I
B I
mRNA I
is O
in O
nucleated O
fetal O
blood O
cells O
and O
up-regulation O
of O
c-fos O
and O
c-jun O
with O
anti-CD3 O
stimulation O
. O

We O
demonstrate O
that O
mRNAs B
for O
all O
three O
of O
these O
regulatory O
factors O
are O
expressed O
in O
fetal O
blood O
cells O
by O
the O
27th O
week O
of O
gestation O
and O
in O
term O
cord O
bloods O
. O

Activation O
of O
term O
infant O
cord O
blood O
mononuclear O
cells O
with O
anti-CD3 O
monoclonal O
antibodies O
resulted O
in O
up-regulation O
of O
both O
c-jun O
and O
c-fos O
mRNAs B
within O
15 O
min O
of O
stimulation O
. O

We O
conclude O
that O
fetal O
nucleated O
blood O
cells O
constitutively O
express O
important O
genes O
for O
cytokine O
regulation O
and O
are O
able O
to O
increase O
intracellular O
accumulation O
of O
the O
mRNAs B
for O
these O
factors O
in O
response O
to O
anti-CD3 O
stimulation O
. O

In O
UCSD-AML1 O
, O
we O
have O
also O
identified O
fusion B
transcripts I
between O
the O
ecotropic O
viral O
insertion O
site O
I O
( O
EVI1 O
) O
gene O
in O
3q26 O
and O
GR6 O
and O
between O
EVI1 O
and O
Ribophorin O
I O
that O
maps O
30 O
kb O
telomeric O
to O
GR6 O
in O
3q21 O
. O

In O
peripheral O
blood O
lymphocytes O
, O
expression O
of O
Trident B
mRNA I
was O
absent O
, O
but O
could O
be O
induced O
upon O
stimulation O
with O
mitogens O
in O
vitro O
. O

By O
Northern O
and O
in O
situ O
hybridization O
, O
mNFATc B
transcript I
was O
detected O
from O
the O
early O
stage O
of O
development O
. O

In O
the O
mouse O
embryo O
, O
mNFATc B
transcript I
was O
strongly O
expressed O
in O
thymus O
, O
lung O
and O
submandibular O
gland O
and O
weakly O
in O
skeletal O
muscle O
and O
heart O
suggesting O
that O
mNFATc O
may O
have O
a O
role O
both O
in O
embryogenesis O
and O
in O
mature O
T O
cells O
. O

Alternative O
splicing O
of O
the O
GC B
receptor I
( I
R I
) I
pre-messenger I
RNA I
generates O
a O
second O
GCR O
, O
termed O
GCR-beta O
, O
which O
does O
not O
bind O
GCs O
but O
antagonizes O
the O
transactivating O
activity O
of O
the O
classic O
GCR O
, O
termed O
GCR-alpha O
. O

Freshly O
isolated O
cells O
contain O
high O
levels O
of O
G0S2 B
mRNA I
which O
rapidly O
decline O
. O

In O
cells O
that O
have O
been O
preincubated O
to O
lower O
mRNA O
levels O
, O
there O
is O
a O
transient O
increase O
in O
G0S2 B
mRNA I
, O
peaking O
between O
1-2 O
h O
, O
in O
response O
to O
Concanavalin-A O
( O
ConA O
) O
, O
or O
to O
the O
combination O
of O
phorbol O
ester O
( O
TPA O
) O
, O
and O
the O
calcium O
ionophore O
, O
ionomycin O
. O

RXR-alpha B
mRNA I
was O
present O
in O
untreated O
U937 O
cells O
, O
and O
levels O
increased O
after O
induction O
of O
differentiation O
with O
phorbol O
ester O
. O

The O
same O
was O
found O
for O
RXR-beta B
mRNA I
. O

MZF-2 B
mRNA I
was O
expressed O
in O
myeloid O
cells O
, O
particularly O
in O
the O
cells O
committed O
to O
the O
neutrophilic O
lineage O
, O
and O
down-regulated O
by O
G-CSF O
. O

CONCLUSIONS O
: O
MZF-1 B
and I
MZF-2 I
mRNAs I
seem O
to O
be O
produced O
by O
the O
alternative O
use O
of O
two O
different O
transcription O
initiation O
sites O
. O

Intragenic O
TSG101 O
deletions O
in O
RNA B
transcripts I
were O
frequently O
found O
in O
all O
types O
of O
samples O
. O

We O
analysed O
FHIT O
in O
the O
same O
series O
of O
RNA B
samples I
and O
detected O
truncated O
FHIT B
transcripts I
frequently O
in O
both O
tumour O
and O
normal O
tissues O
. O

Our O
findings O
demonstrate O
that O
truncated B
TSG101 I
and I
FHIT I
transcripts I
are O
commonly O
detected O
in O
both O
normal O
and O
malignant O
tissues O
and O
that O
a O
significant O
fraction O
of O
these O
are O
likely O
to O
be O
the O
result O
of O
aberrant O
splicing O
. O

Polyclonal O
and O
clonal O
CTL O
that O
were O
generated O
by O
stimulating O
peripheral O
blood O
mononuclear O
cells O
with O
an O
HLA O
B8+ O
homozygous O
LCL O
lysed O
T O
cell O
blasts O
pulsed O
with O
the O
peptide O
, O
RAKFKQLLQ O
; O
lysis O
of O
certain O
HLA O
B8+ O
LCL O
targets O
was O
associated O
with O
the O
abundance O
of O
BZLF1 B
transcripts I
. O

Messenger B
RNA I
( O
mRNA B
) O
levels O
for O
the O
granulocyte-colony O
stimulating O
factor O
( O
G-CSF O
) O
receptor O
, O
granulocyte-macrophage O
( O
GM O
) O
-CSF O
receptor O
alpha O
subunit O
and O
tumor O
necrosis O
factor O
( O
TNF O
) O
receptors O
I O
( O
p55 O
) O
and O
II O
( O
p75 O
) O
were O
also O
detected O
in O
this O
subset O
in O
addition O
to O
c-kit O
and O
flt-3 O
, O
receptors O
known O
to O
be O
expressed O
on O
progenitor O
cells O
. O

In O
conclusion O
, O
the O
presence O
of O
myeloid-associated B
growth I
factor I
receptor I
transcripts I
in O
CD34+ O
CB O
subsets O
does O
not O
discriminate O
the O
various O
stages O
of O
differentiation O
, O
with O
the O
exception O
of O
the O
M-CSF O
receptor O
. O

Further O
, O
M. O
tuberculosis O
and O
its O
tuberculin O
, O
purified O
protein O
derivative O
, O
induced O
the O
degradation O
of O
I O
kappa O
B-alpha O
and O
the O
expression O
of O
I B
kappa I
B-alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF-kappa O
B O
in O
monocytes O
. O

As O
shown O
by O
reverse O
transcription-polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF-kappaB O
transcription O
factor O
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF O
promotor O
in O
human O
monocytes O
. O

HeLa O
cells O
stably O
or O
transiently O
transfected O
with O
mutant O
CIITA O
constructs O
showed O
up O
to O
99 O
% O
suppression O
of O
MHC O
class O
II O
antigen O
induction O
by O
IFN-gamma O
and O
marked O
suppression O
of O
HLA-DRA B
mRNA I
expression O
. O

Transient O
transfection O
of O
a O
B O
lymphoma O
line O
resulted O
in O
up O
to O
89 O
% O
reduction O
of O
constitutive O
MHC O
class O
II O
expression O
within O
5 O
days O
and O
suppression O
of O
HLA-DRA B
mRNA I
synthesis O
. O

To O
further O
elucidate O
the O
role O
of O
RelB O
in O
DC O
differentiation O
, O
mRNA B
, O
intracellular O
protein O
expression O
, O
and O
DNA O
binding O
activity O
of O
RelB O
were O
examined O
in O
immature O
and O
differentiated O
human O
DC O
, O
as O
well O
as O
other O
PB O
mononuclear O
cell O
populations O
. O

RelB O
protein O
and O
mRNA B
were O
detected O
constitutively O
in O
lymphocytes O
and O
in O
activated O
monocytes O
, O
differentiated O
DC O
, O
and O
monocyte-derived O
DC O
. O

Northern O
blot O
analysis O
of O
SR-BP O
gene O
expression O
revealed O
a O
single O
transcript O
of O
2 B
kilobases I
which O
was O
widely O
expressed O
among O
organs O
, O
with O
the O
highest O
abundance O
in O
liver O
and O
the O
lowest O
abundance O
in O
brain O
. O

Since O
sequence O
variations O
in O
the O
3 O
' O
UTR O
of O
VDR O
have O
been O
linked O
to O
the O
different O
haplotypes O
, O
investigators O
have O
proposed O
that O
the O
stability O
of O
VDR B
mRNA I
is O
influenced O
by O
allelic O
variations O
. O

Interestingly O
, O
we O
consistently O
observed O
30 O
% O
less O
RT-PCR O
product O
derived O
from O
the O
small B
t I
allele I
mRNA I
in O
steady O
state O
, O
a O
finding O
which O
also O
speaks O
against O
a O
higher O
stability O
of O
the O
small B
t I
allele I
mRNA I
. O

Human O
neutrophils O
express O
GH-N B
gene I
transcripts I
and O
the O
pituitary O
transcription O
factor O
Pit-1b O
. O

Reversed O
transcription O
( O
RT O
) O
-PCR O
analysis O
demonstrated O
GH B
mRNA I
in O
neutrophils O
. O

The O
pp52 O
promoter O
contains O
an O
initiator O
specifying O
the O
unique O
5 O
' O
terminus O
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets O
and O
SP1 O
motifs O
, O
and O
a O
lone O
C/EBP O
motif O
. O

No O
RNA-packaging O
defect O
could O
be O
measured O
for O
any O
of O
the O
mutant O
viruses O
as O
determined O
by O
quantification O
of O
their O
HIV B
genomic I
RNA I
. O

Ad2 O
infection O
induced O
transient O
increase O
in O
the O
mRNA B
levels O
for O
TNF-alpha O
and O
IL-1 O
beta O
in O
both O
monocytes O
and O
in O
macrophages O
, O
although O
the O
kinetics O
of O
the O
transcription O
was O
slightly O
different O
. O

Anti-Ehrlichia O
chaffeensis O
antibody O
complexed O
with O
E. O
chaffeensis O
induces O
potent O
proinflammatory B
cytokine I
mRNA I
expression O
in O
human O
monocytes O
through O
sustained O
reduction O
of O
IkappaB-alpha O
and O
activation O
of O
NF-kappaB O
. O

Our O
previous O
studies O
showed O
that O
the O
exposure O
of O
human O
monocytes O
to O
E. O
chaffeensis O
induces O
the O
expression O
of O
interleukin-1beta O
( O
IL-1beta O
) O
, O
IL-8 O
, O
and O
IL-10 O
genes O
in O
vitro O
but O
not O
the O
expression O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF-alpha I
) I
and I
IL-6 I
mRNAs I
. O

Human O
monocytic O
cell O
line O
THP-1 O
was O
treated O
with O
E. O
chaffeensis O
which O
had O
been O
preincubated O
with O
human O
anti-E. O
chaffeensis O
serum O
for O
2 O
h O
, O
and O
the O
levels O
of O
cytokine B
mRNAs I
were O
evaluated O
by O
competitive O
reverse O
transcription-PCR O
. O

The O
expression O
of O
TNF-alpha B
and I
IL-6 I
mRNAs I
was O
also O
induced O
. O

Fab O
fragment O
of O
anti-E. O
chaffeensis O
immunoglobulin O
G O
complexed O
with O
E. O
chaffeensis O
did O
not O
induce O
any O
of O
these O
three O
cytokines O
, O
indicating O
that O
ehrlichial O
binding O
is O
required O
for O
IL-1beta B
mRNA I
expression O
and O
that O
binding O
of O
the O
immune O
complex O
to O
the O
Fc O
gamma O
receptor O
is O
required O
for O
TNF-alpha O
and O
IL-6 B
mRNA I
expression O
and O
enhanced O
IL-1beta B
mRNA I
expression O
. O

Unlike O
published O
studies O
with O
pyrrolidinedithiocarbamate O
, O
which O
specifically O
inhibited O
vascular O
cell O
adhesion O
molecule O
1 O
( O
VCAM-1 O
) O
, O
NAC O
inhibited O
IL-1 B
beta-induced I
mRNA I
and O
cell O
surface O
expression O
of O
both O
E-selectin O
and O
VCAM-1 O
. O

NAC O
had O
no O
effect O
on O
the O
half-life O
of O
E-selectin B
or I
VCAM-1 I
mRNA I
. O

The O
gene O
has O
41 O
small O
exons O
spanning O
45 O
kb O
of O
genomic O
DNA O
and O
encoding O
a O
5.5 B
kb I
mRNA I
. O

Three O
overlapping O
PCR O
products O
, O
covering O
the O
complete O
coding O
sequence O
of O
mRNA B
, O
were O
generated O
from O
lymphoblastoid O
cell O
lines O
, O
translated O
into O
35S-methionine O
labelled O
protein O
, O
and O
analysed O
by O
SDS-PAGE O
. O

Five O
of O
these O
were O
caused O
by O
mutations O
predicted O
to O
produce O
a O
truncated O
protein O
: O
( O
i O
) O
a O
sporadic O
case O
showed O
a O
32 O
bp O
deletion O
in O
exon B
11 I
, O
and O
a O
mutant B
mRNA I
without O
exon B
11 I
was O
produced O
; O
the O
normal O
exon O
10 O
was O
also O
spliced O
out O
; O
( O
ii O
) O
a O
sporadic O
case O
had O
a O
1 O
bp O
deletion O
in O
exon B
12 I
( O
1634delT B
) O
; O
( O
iii O
) O
a O
TSC2-linked B
mother I
and I
daughter I
pair I
had O
a O
G O
-- O
> O
T O
transversion O
in O
exon B
23 I
( O
G2715T B
) O
introducing O
a O
cryptic O
splice O
site O
causing O
a O
29 O
bp O
truncation O
of O
mRNA O
from O
exon B
23 I
; O
( O
iv O
) O
a O
sporadic O
case O
showed O
a O
2 O
bp O
deletion O
in O
exon B
36 I
; O
( O
v O
) O
a O
sporadic O
case O
showed O
a O
1 O
bp O
insertion O
disrupting O
the O
donor O
splice O
site O
of O
exon B
37 I
( O
5007+2insA B
) O
, O
resulting O
in O
the O
use O
of O
an O
upstream B
exonic I
cryptic I
splice I
site I
to O
cause O
a O
29 B
bp I
truncation I
of O
mRNA B
from O
exon B
37 I
. O

In O
one O
case O
, O
the O
PTT O
shift O
was O
explained O
by O
in-frame O
splicing O
out O
of O
exon B
10 I
, O
in O
the O
presence O
of O
a O
normal O
exon O
10 O
genomic O
sequence O
. O

Alternative O
splicing O
of O
exon B
10 I
of O
the O
TSC2 O
gene O
may O
be O
a O
normal O
variant O
. O

A O
combination O
of O
differential O
splicing O
and O
alternative O
use O
of O
promoters O
generates O
four O
mRNA B
isoforms I
, O
of O
2.6 O
kb O
and O
1.3-1.5 O
kb O
in O
size O
. O

These O
transcripts O
can O
encode O
three O
proteins O
of O
calculated O
molecular O
mass O
32.2 B
kDa I
, O
27.8 B
kDa I
, O
and O
14.3 B
kDa I
. O

C/EBPepsilon B
mRNA I
was O
greatly O
induced O
during O
in O
vitro O
granulocytic O
differentiation O
of O
human O
primary O
CD34 O
( O
+ O
) O
cells O
. O

Retinoic O
acid O
treatment O
of O
HL60 O
promyelocytic O
leukemia O
cells O
for O
24 O
hr O
induced O
C/EBPepsilon B
mRNA I
levels O
by O
4-fold O
, O
while O
prolonged O
treatment O
gradually O
reduced O
mRNA O
expression O
to O
pretreatment O
levels O
. O

Compared O
with O
monocytes O
in O
suspension O
or O
adherent O
on O
plastic O
surfaces O
, O
monocytes O
adherent O
to O
fibronectin O
or O
RGD O
exhibited O
a O
greater O
than O
threefold O
increase O
in O
steady O
state O
levels O
of O
IFN-gamma-induced B
mRNA I
for O
the O
high O
affinity O
Fc O
gammaRI O
receptor O
. O

By O
electrophoretic O
mobility O
shift O
assays O
, O
this O
increase O
in O
mRNA B
was O
associated O
with O
a O
5- O
to O
10-fold O
increase O
in O
the O
STAT1-containing O
DNA-binding O
complex O
that O
binds O
to O
Fc O
gammaRI O
promoter O
elements O
. O

Moreover O
, O
the O
NF-kappa O
B O
inhibitors O
blocked O
SP-A O
-dependent O
increases O
in O
tumor B
necrosis I
factor-alpha I
mRNA I
levels O
. O

Northern O
blot O
analysis O
showed O
that O
IL-10 O
reduced O
the O
accumulation O
of O
ICAM-1 B
mRNA I
in O
IFN-gamma-stimulated O
monocytes O
. O

IL-10 O
inhibition O
of O
ICAM-1 B
steady-state I
mRNA I
was O
detected O
at O
3 O
hours O
and O
remained O
at O
24 O
hours O
. O

Nuclear O
run-on O
transcription O
assays O
showed O
that O
IL-10 O
inhibited O
the O
rate O
of O
IFN-gamma O
-induced O
transcription O
of O
the O
ICAM-1 O
gene O
, O
and O
mRNA O
stability O
studies O
showed O
that O
IL-10 O
did O
not O
alter O
the O
half-life O
of O
IFN-gamma-induced B
ICAM-1 I
message I
. O

Homodimerization O
of O
the O
human O
interleukin O
4 O
receptor O
alpha O
chain O
induces O
Cepsilon B
germline I
transcripts I
in O
B O
cells O
in O
the O
absence O
of O
the O
interleukin O
2 O
receptor O
gamma O
chain O
. O

The O
cytokines O
interleukin O
( O
IL O
) O
-4 O
and O
IL-13 O
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE O
isotype O
switching O
in O
human O
B O
cells O
. O

IL-4 O
induces O
Cepsilon B
germline I
transcripts I
and O
IgE O
isotype O
switching O
in O
B O
cells O
from O
patients O
with O
gammac O
chain O
deficiency O
. O

Induction O
of O
Cepsilon B
germline I
transcripts I
by O
IL-4 O
in O
B O
cells O
that O
lack O
the O
gammac O
chain O
may O
involve O
signaling O
via O
the O
IL-13R O
. O

We O
show O
that O
ligand-induced O
homodimerization O
of O
chimeric O
surface O
receptors O
consisting O
of O
the O
extracellular O
and O
transmembrane O
domains O
of O
the O
erythropoietin O
receptor O
and O
of O
the O
intracellular O
domain O
of O
IL-4Ralpha O
induces O
Janus O
kinase O
1 O
( O
Jak1 O
) O
activation O
, O
STAT6 O
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

Furthermore O
, O
B O
cells O
transfected O
with O
a O
chimeric O
CD8alpha/IL-4Ralpha O
receptor O
, O
which O
is O
expressed O
on O
the O
cell O
surface O
as O
a O
homodimer O
, O
constitutively O
expressed O
Cepsilon B
germline I
transcripts I
. O

SCF O
-mediated O
ligation O
of O
kit/IL-4R O
alpha O
is O
sufficient O
to O
elicit O
IL-4 O
-specific O
gene O
expression O
, O
including O
up-regulation O
of O
CD23 O
and O
synthesis O
of O
germ-line B
epsilon I
transcripts I
. O

Dibutyryl O
cAMP O
also O
increased O
c-fos B
mRNA I
and O
protein O
, O
and O
levels O
remained O
elevated O
even O
after O
12 O
hr O
of O
treatment O
. O

TNF-alpha O
release O
peaked O
at O
24 O
h O
and O
decreased O
thereafter O
, O
and O
it O
was O
dose O
dependent O
and O
preceded O
by O
an O
increase O
of O
TNF-alpha B
mRNA I
detectable O
after O
3 O
h O
of O
stimulation O
with O
mAb O
L243 O
. O

The O
ratio O
of O
adult B
beta-globin/alpha-globin I
mRNA I
in O
the O
mutant O
ES O
cells O
was O
1/15 O
of O
that O
in O
wild-type O
ES O
cells O
. O

The O
rapid O
up-regulation O
of O
RP1 B
mRNA I
in O
properly O
activated O
T O
cells O
suggests O
that O
this O
gene O
might O
belong O
to O
the O
immediate/early O
gene O
family O
, O
which O
controls O
the O
signal O
transduction O
cascade O
downstream O
of O
the O
TCR O
. O

Administration O
of O
dexamethasone O
to O
temporal O
artery-SCID O
chimeras O
for O
1 O
wk O
induced O
a O
partial O
suppression O
of O
T O
cell O
and O
macrophage O
function O
as O
indicated O
by O
the O
reduced O
tissue O
concentrations O
of O
IL-2 B
, I
IL-1beta I
, I
and I
IL-6 I
mRNA I
, O
and O
by O
the O
diminished O
expression O
of O
inducible O
NO O
synthase O
. O

In O
contrast O
, O
synthesis O
of O
IFN-gamma B
mRNA I
was O
only O
slightly O
decreased O
, O
and O
expression O
of O
TGF-beta1 O
was O
unaffected O
. O

IL-1beta O
transcription O
was O
abrogated O
; O
in O
contrast O
, O
TGF-beta1 B
mRNA I
synthesis O
was O
steroid O
resistant O
. O

The O
expression O
of O
anti-sense O
RNA O
to O
SRG3 B
mRNA I
in O
a O
thymoma O
cell O
line O
, O
S49.1 O
, O
reduced O
the O
expression O
level O
of O
the O
SRG3 O
protein O
, O
and O
decreased O
the O
apoptotic O
cell O
death O
induced O
by O
glucocorticoids O
. O

Quantification O
of O
vitamin B
D I
receptor I
mRNA I
by O
competitive O
polymerase O
chain O
reaction O
in O
PBMC O
: O
lack O
of O
correspondence O
with O
common O
allelic O
variants O
. O

To O
evaluate O
the O
physiologic O
plausibility O
of O
these O
claims O
, O
we O
compared O
the O
abundance O
of O
the O
VDR B
mRNA I
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
between O
different O
VDR O
genotypes O
using O
a O
quantitative O
reverse O
transcribed O
polymerase O
chain O
reaction-based O
method O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
was O
10 O
( O
-8 O
) O
to O
10 O
( O
-7 O
) O
g/g O
of O
total O
RNA O
in O
cell-sorted O
monocytes O
and O
in O
in O
vitro O
activated O
lymphocytes O
, O
but O
only O
10 O
( O
-12 O
) O
g/g O
of O
total O
mRNA O
in O
resting O
lymphocytes O
, O
establishing O
that O
the O
VDR B
mRNA I
determined O
by O
our O
method O
in O
PBMCs O
is O
due O
to O
constitutive O
expression O
in O
monocytes O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum O
calcitriol O
, O
serum O
osteocalcin O
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

We O
conclude O
that O
VDR O
polymorphism O
does O
not O
affect O
the O
abundance O
of O
the O
VDR B
mRNA I
. O

Significance O
of O
quantitative O
analysis O
of O
AML1/ETO B
transcripts I
in O
peripheral O
blood O
stem O
cells O
from O
t O
( O
8 O
; O
21 O
) O
acute O
myelogenous O
leukemia O
. O

Recently O
, O
we O
have O
developed O
a O
quantitative O
assay O
using O
competitive O
reverse O
transcriptase O
polymerase O
chain O
reaction O
that O
estimates O
the O
number O
of O
AML1/ETO B
transcripts I
in O
t O
( O
8 O
; O
21 O
) O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
in O
order O
to O
determine O
the O
degree O
of O
leukemic O
cell O
contamination O
in O
PBSC O
harvests O
, O
and O
to O
monitor O
minimal O
residual O
disease O
( O
MRD O
) O
quantitatively O
in O
patients O
with O
t O
( O
8 O
; O
21 O
) O
AML O
. O

There O
appears O
to O
be O
no O
relationship O
between O
the O
number O
of O
AML1/ETO B
transcripts I
found O
in O
the O
infused O
PBSC O
harvests O
and O
the O
incidence O
of O
leukemic O
relapse O
following O
autologous O
PBSCT O
in O
our O
study O
. O

However O
, O
a O
substantial O
decrease O
of O
AML1/ETO B
transcripts I
was O
seen O
following O
autologous O
PBSCT O
. O

Thus O
, O
the O
quantitative O
analysis O
of O
AML1/ETO B
transcripts I
may O
be O
clinically O
useful O
in O
patients O
with O
t O
( O
8 O
; O
21 O
) O
AML O
. O

Exogenous O
recombinant O
Tat O
protein O
was O
also O
able O
to O
upregulate O
c-fos O
promoter O
activity O
in O
serum-activated O
Jurkat O
and O
U937 O
cells O
, O
as O
well O
as O
endogenous O
c-fos B
mRNA I
expression O
and O
c-Fos O
protein O
synthesis O
in O
both O
serum-activated O
cell O
lines O
and O
primary O
PBMC O
. O

Previously O
, O
we O
showed O
that O
fibroblast O
conditioned O
medium O
( O
FCM O
) O
is O
able O
to O
inhibit O
both O
TNF B
mRNA I
accumulation O
and O
protein O
release O
in O
peripheral O
blood-derived O
human O
monocytes O
( O
PBM O
) O
stimulated O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

In O
addition O
, O
RNase O
protection O
assays O
revealed O
that O
anti-CD3/ O
PMA-stimulated O
T O
cells O
from O
a O
substantial O
proportion O
of O
elderly O
subjects O
exhibited O
decreased O
levels O
of O
c-fos B
and/or I
c-jun I
mRNA I
compared O
to O
T O
cells O
from O
young O
subjects O
. O

Retinoic O
acid-induced O
modulation O
of O
IL-2 B
mRNA I
production O
and O
IL-2 O
receptor O
expression O
on O
T O
cells O
. O

In O
the O
present O
study O
we O
have O
examined O
the O
immune O
modulating O
effects O
of O
RA O
on O
IL-2 B
mRNA I
, O
another O
important O
cytokine O
for O
B O
cell O
immunoglobulin O
production O
, O
the O
expression O
of O
IL-2 O
receptors O
on O
T O
cells O
, O
and O
the O
RA O
nuclear O
receptors O
. O

Total O
mRNA B
was O
extracted O
from O
T O
cells O
, O
and O
using O
RT-PCR O
, O
changes O
in O
the O
production O
of O
IL-2 O
and O
RA O
receptors O
( O
RAR O
) O
- O
alpha B
, O
beta B
, O
gamma B
mRNA I
were O
determined O
. O

CONCLUSION O
: O
These O
studies O
suggest O
that O
RA O
can O
augment O
IL-2 B
mRNA I
production O
by O
T O
cells O
with O
a O
possible O
paracrine O
effect O
on O
IL-2R-alpha O
expression O
. O

Interleukin-6 O
protein O
and O
IL-6 B
mRNA I
were O
measured O
in O
control O
and O
CMV O
immediate O
early O
transfected O
cells O
. O

Analysis O
of O
RelA B
( I
p65 I
) I
mRNA I
revealed O
that O
the O
stability O
of O
RelA B
( I
p65 I
) I
mRNA I
was O
significantly O
higher O
in O
MDMs O
, O
compared O
with O
monocytes O
. O

In O
parallel O
with O
the O
decreased O
cytokine O
generation O
, O
each O
cytokine B
mRNA I
was O
less O
expressed O
in O
the O
presence O
of O
10 O
( O
-5 O
) O
M O
Azeptin O
. O

GATA-1 O
protein O
and O
mRNA B
vary O
in O
a O
similar O
manner O
through O
the O
cell O
cycle O
, O
suggesting O
that O
the O
expression O
of O
the O
gene O
or O
the O
stability O
of O
its O
message O
is O
regulated O
. O

Proinflammatory O
neutrophil O
stimuli O
also O
promoted O
the O
accumulation O
of O
IkappaB-alpha B
mRNA I
transcripts I
, O
resulting O
in O
the O
reexpression O
of O
the O
IkappaB-alpha O
protein O
. O

Induction O
of O
IL-5 B
mRNA I
upon O
TCR O
and O
IL-2R O
stimulation O
was O
totally O
inhibited O
by O
dexamethasone O
. O

The O
LAZ3/BCL6 B
transcript I
was O
found O
in O
a O
variety O
of O
tissues O
, O
including O
skeletal O
muscle O
, O
peripheral O
blood O
leukocytes O
, O
and O
weakly O
in O
normal O
lymph O
nodes O
. O

Nucleolin O
is O
an O
abundant O
nucleolar O
protein O
which O
is O
believed O
to O
play O
a O
role O
in O
rDNA O
transcription O
or O
organization O
, O
or O
rRNA B
processing O
. O

Here O
, O
we O
demonstrate O
a O
novel O
role O
for O
IK O
in O
MHC O
class O
II O
expression O
since O
over-expression O
of O
this O
protein O
by O
stable O
transfection O
into O
human O
B O
cells O
led O
to O
a O
total O
disappearance O
of O
constitutive O
MHC B
class I
II I
mRNA I
expression O
. O

Examination O
of O
CIITA B
mRNA I
in O
IK O
stably O
transfected O
clones O
revealed O
a O
marked O
reduction O
of O
CIITA B
mRNA I
transcription O
. O

Among O
genes O
that O
respond O
to O
these O
transcription O
factors O
, O
IL-2 B
mRNA I
induction O
was O
suppressed O
by O
PF O
, O
whereas O
IL-2R B
( I
alpha I
) I
chain I
mRNA I
induction O
was O
not O
affected O
. O

However O
, O
V3-BH10 O
enhanced O
IL-2 O
-induced B
mRNA I
expression O
of O
c-fos O
but O
not O
c-myc O
or O
junB O
. O

The O
existence O
of O
alternative O
Pax-5 B
transcripts I
was O
confirmed O
using O
RNase O
protection O
assays O
. O

We O
demonstrate O
that O
upon O
stimulation O
by O
lipopolysaccharide O
, O
Taxol O
, O
phorbol O
myristate O
acetate O
, O
interleukin-1 O
, O
or O
double-stranded B
RNA I
, O
I O
kappaB O
alpha O
is O
not O
degraded O
, O
as O
a O
result O
of O
an O
absence O
of O
induced O
phosphorylation O
on O
serines O
32 O
and O
36 O
. O

In O
this O
manuscript O
we O
have O
investigated O
the O
molecular O
mechanisms O
by O
which O
T O
cell O
lines O
stimulated O
with O
phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
and O
phytohemagglutin O
( O
PHA O
) O
display O
significantly O
higher O
levels O
of O
NF-kappa O
B1 O
encoding O
transcripts B
than O
cells O
stimulated O
with O
tumor O
necrosis O
factor-alpha O
, O
despite O
the O
fact O
that O
both O
stimuli O
activate O
NF-kappa O
B O
. O

Furthermore O
, O
Egr-1 O
induction O
was O
required O
for O
endogenous O
NF-kappa O
B1 O
gene O
expression O
, O
since O
PMA/ O
PHA-stimulated O
T O
cell O
lines O
expressing O
antisense O
Egr-1 B
RNA I
were O
inhibited O
in O
their O
ability O
to O
upregulate O
NF-kappa O
B1 O
transcription O
. O

In O
addition O
, O
translation O
of O
NFATc B
mRNA I
apparently O
initiates O
at O
two O
different O
AUG O
codons O
, O
giving O
rise O
to O
proteins O
that O
differ O
in O
size O
by O
36 O
amino O
acids O
. O

Using O
ATL-16T O
cells O
which O
express O
IL-5 B
mRNA I
, O
we O
have O
identified O
a O
region O
, O
within O
the O
human O
IL-5 O
gene O
promoter O
, O
that O
regulates O
IL-5 O
gene O
transcription O
. O

ATL-16T O
cells O
express O
mRNA B
of O
three O
GATA-binding O
proteins O
, O
hGATA-2 O
, O
hGATA-3 O
and O
hGATA-4 O
, O
and O
each O
of O
them O
has O
a O
potential O
to O
bind O
to O
the O
consensus O
( O
A/T O
) O
GATA O
( O
G/ O
A O
) O
motif O
. O

Primer O
extension O
analysis O
of O
C/EBP-epsilon B
mRNA I
detected O
a O
single O
major O
transcription O
start O
site O
approximately O
200 O
bp O
upstream O
of O
the O
start O
codon O
. O

Northern O
analyses O
showed O
similar O
levels O
of O
two O
elf-2 B
transcripts I
( O
3.5 O
kb O
and O
3.8 O
kb O
) O
in O
all O
tissues O
except O
thymus O
. O

Thymocytes O
expressed O
four- O
to O
10-fold O
greater O
amounts O
of O
the O
3.5 B
kb I
transcript I
than O
other O
tissues O
. O

The O
transfected O
cell O
lines O
expressed O
elevated O
levels O
of O
spi-1 B
mRNA I
and O
protein O
and O
high O
Spi-1 O
-DNA O
binding O
activity O
. O

In O
PMA-treated O
THP-1 O
cells O
we O
could O
detect O
three O
major O
transcription O
initiation O
sites O
as O
revealed O
by O
Nuclease O
Protection O
Assay O
carried O
out O
with O
two O
overlapping B
antisense I
RNA I
probes I
. O

In O
situ O
RT-PCR O
detection O
of O
Epstein-Barr B
virus I
immediate-early I
transcripts I
in O
CD4+ O
and O
CD8+ O
T O
lymphocytes O
. O

EBV B
immediate-early I
gene I
transcripts I
( O
BZLF1 B
, O
BRLF1 B
, O
and O
BMLF1 B
) O
encoded O
in O
the O
BamHI O
Z O
, O
R O
, O
and O
M O
fragments O
could O
be O
detected O
by O
in O
situ O
RT-PCR O
in O
the O
EBV O
producer O
cell O
line O
B95.8 O
. O

Both O
BZLF1 B
and I
BRLF1 I
immediate-early I
transcripts I
, O
but O
not O
BMLF1 B
transcript I
, O
could O
be O
detected O
in O
individual O
CD4+ O
and O
CD8+ O
T O
cells O
infected O
with O
EBV O
. O

Demonstration O
of O
EBV B
mRNA I
transcripts I
encoding O
immediate-early O
transcriptional O
transactivators O
in O
EBV-infected O
T O
cells O
provides O
the O
first O
evidence O
for O
a O
possible O
mechanism O
whereby O
EBV O
could O
contribute O
to O
T O
cell O
proliferation O
and O
EBV-associated O
T O
cell O
malignancies O
. O

Quantitative O
reverse O
transcriptase O
-polymerase O
chain O
reaction O
( O
RT-PCR O
) O
showed O
an O
increase O
in O
steady-state O
TNF-alpha B
mRNA I
after O
3 O
to O
4 O
hours O
of O
cross-linking O
. O

CD15 O
cross-linking O
also O
concomitantly O
increased O
interleukin-1 B
beta I
( I
IL-1 I
beta I
) I
mRNA I
, O
while O
no O
apparent O
change O
was O
observed O
in O
the O
levels O
of O
beta-actin B
mRNA I
, O
indicating O
specificity O
. O

IL-4 O
and O
IL-13 O
up-regulated O
the O
expression O
of O
both O
genomic O
and O
spliced O
HIV B
mRNA I
in O
monocytes O
cultured O
on O
Teflon O
, O
as O
determined O
by O
Northern O
analysis O
and O
p24 O
Ag O
assay O
. O

IL-4 O
stimulated O
nuclear O
factor-kappaB O
nuclear O
translocation O
and O
binding O
before O
enhancement O
of O
HIV B
RNA I
expression O
. O

Dexamethasone O
, O
a O
glucocorticoid O
that O
is O
widely O
used O
as O
an O
immunomodulatory O
and O
anti-inflammatory O
agent O
, O
inhibits O
granzyme B
B I
mRNA I
transcript I
in O
phytohemagglutinin-activated O
peripheral O
blood O
mononuclear O
cells O
. O

In O
order O
to O
investigate O
the O
factors O
that O
influence O
the O
induction O
of O
ICAM-1 O
molecules O
, O
Northern O
blot O
analysis O
to O
measure O
the O
expression O
level O
of O
ICAM-1 B
mRNAs I
and O
Southern O
blot O
hybridization O
to O
analyze O
the O
integration O
of O
human O
T-cell-leukemia O
virus O
type O
1 O
( O
HTLV-1 O
) O
provirus O
were O
done O
. O

The O
levels O
of O
ICAM-1 B
mRNA I
expression O
of O
ATL O
cells O
were O
generally O
higher O
than O
those O
of O
T-lymphoid O
cells O
. O

However O
, O
ILT-mat O
cells O
and O
ATL16T O
( O
- O
) O
cells O
, O
although O
they O
were O
ATL O
cells O
, O
showed O
rather O
low O
surface O
ICAM-1 O
expression O
and O
ICAM-1 B
mRNA I
expression O
. O

The O
amount O
of O
vimentin B
mRNA I
was O
also O
increased O
during O
recovery O
from O
stress O
, O
indicating O
that O
vimentin O
expression O
was O
not O
exclusively O
regulated O
at O
the O
protein O
level O
. O

Finally O
, O
it O
was O
observed O
that O
the O
rate O
of O
decay O
of O
vimentin B
mRNA I
upon O
actinomycin O
D O
administration O
was O
decreased O
in O
heat- O
and O
cadmium-pretreated O
cells O
in O
comparison O
to O
untreated O
cells O
. O

Representational O
difference O
analysis O
has O
been O
used O
to O
isolate O
cDNA O
clones O
corresponding O
to O
mRNA B
species I
activated O
following O
stable O
expression O
of O
HOX11 O
in O
NIH O
3T3 O
cells O
. O

Study O
of O
Aldh1 O
gene O
expression O
during O
spleen O
development O
showed O
that O
the O
presence O
of O
Aldh1 B
mRNA I
inversely O
correlated O
with O
Hox11 O
. O

Hox11 O
null O
mouse O
embryos O
have O
elevated O
Aldh1 B
mRNA I
in O
spleen O
primordia O
prior O
to O
atrophy O
, O
while O
Aldh1 O
seems O
to O
be O
repressed O
by O
Hox11 O
during O
organogenesis O
of O
the O
spleens O
of O
wild-type O
mice O
. O

The O
RALDH2 B
transcripts I
in O
T-ALL O
were O
, O
however O
, O
mostly O
initiated O
within O
the O
second B
intron I
. O

In O
agreement O
with O
this O
, O
decrease O
in O
the O
insulin B
mRNA I
and O
insulin O
content O
was O
observed O
in O
the O
glycation-induced O
cells O
. O

We O
cloned O
and O
characterized O
a O
fork O
head O
cDNA O
from O
human B
T I
helper I
cell I
mRNA I
using O
differential O
display O
RT-PCR O
. O

A O
procedure O
suitable O
for O
cloning B
labile I
mRNAs I
that O
contain O
AU O
motifs O
is O
presented O
( O
AU-DD O
) O
. O

During O
15 O
days O
of O
treatment O
of O
K562 O
cells O
with O
sodium O
phenylacetate O
, O
we O
observed O
an O
increase O
in O
the O
cellular O
hemoglobin O
concentration O
with O
a O
similar O
increase O
in O
the O
expression O
of O
gamma-globin B
mRNA I
. O

We O
conclude O
that O
sodium O
phenylacetate O
treatment O
of O
K562 O
cells O
increases O
gamma-globin B
mRNA I
and O
induces O
cell O
maturation O
as O
judged O
by O
morphology O
without O
affecting O
the O
expression O
of O
the O
erythroid O
transcription O
factors O
, O
some O
of O
which O
are O
known O
to O
be O
involved O
in O
the O
regulation O
of O
beta-like O
globin O
genes O
. O

The O
tissular O
patterns O
of O
CIITA O
and O
MHC O
class O
II O
gene O
expression O
are O
tightly O
correlated O
: O
CIITA B
mRNA I
is O
highly O
expressed O
in O
B O
cells O
, O
and O
is O
induced O
by O
interferon O
gamma O
( O
IFN-gamma O
) O
in O
macrophage O
and O
epithelial O
cell O
lines O
. O

The O
helper O
activity O
for O
IgE O
synthesis O
by O
the O
CD27 O
/CD70 O
interaction O
did O
not O
contribute O
to O
the O
enhancement O
of O
germline B
epsilon I
transcripts I
. O

These O
B O
cells O
expressed O
p40 B
and I
p35 I
mRNA I
, O
and O
phorbol O
myristate O
acetate O
( O
PMA O
) O
stimulation O
strongly O
enhanced O
p40 O
and O
p70 O
production O
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c-fos B
( O
99+/-15 O
and O
126+/-11 O
% O
, O
p O
= O
0.0126 O
) O
and O
c-jun B
( I
123+/-9 I
and I
185+/-38 I
% I
, I
p I
= I
0.0291 I
) I
mRNA I
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post- O
alphaCD3 O
stimulation O
. O

In O
this O
study O
we O
demonstrated O
that O
a O
mutant O
Escherichia O
coli O
endotoxin O
lacking O
myristoyl O
fatty O
acid O
at O
the O
3 O
' O
R-3-hydroxymyristate O
position O
of O
the O
lipid O
A O
moiety O
retained O
its O
full O
capacity O
to O
coagulate O
Limulus O
amoebocyte O
lysate O
compared O
with O
the O
wild-type O
E. O
coli O
endotoxin O
and O
markedly O
stimulated O
the O
activation O
of O
human O
monocyte O
nuclear O
factor-kappaB O
and O
the O
induction O
of O
Mn B
SOD I
mRNA I
and O
enzyme O
activity O
. O

Initial O
experiments O
indicated O
that O
a O
50 O
% O
decrease O
in O
VDR O
levels O
was O
associated O
with O
a O
2-fold O
increase O
in O
cell O
proliferation O
and O
a O
similar O
rise O
in O
c-myc B
mRNA I
expression O
. O

Northern O
analysis O
confirmed O
that O
expression O
of O
both O
mRNAs B
was O
reduced O
in O
cells O
with O
decreased O
numbers O
of O
VDR O
. O

Further O
Northern O
analyses O
indicated O
that O
there O
was O
no O
significant O
change O
in O
17beta-HSD O
IV O
or O
DNA-PK B
( I
CS I
) I
mRNA I
levels O
following O
treatment O
with O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
although O
expression O
of O
both O
genes O
varied O
with O
changes O
in O
cell O
proliferation O
. O

It O
is O
shown O
here O
that O
during O
monocyte O
to O
macrophage O
differentiation O
, O
the O
expression O
of O
LAL-mRNA B
is O
induced O
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast-Green/Neutral-Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil-associated O
granule O
proteins O
, O
eosinophil O
cationic O
protein O
( O
ECP O
) O
, O
eosinophil-derived O
neurotoxin O
( O
EDN O
) O
, O
eosinophil O
peroxidase O
( O
EPO O
) O
, O
and O
major O
basic O
protein O
( O
MBP O
) O
, O
and O
for O
the O
Charcot-Leyden O
crystal O
( O
CLC O
) O
protein O
. O

The O
monocytic O
characteristics O
of O
YJ O
cells O
treated O
with O
PMA O
were O
confirmed O
by O
morphological O
analysis O
with O
alpha-naphthyl O
butyrate O
esterase O
staining O
, O
by O
CD14 O
expression O
, O
and O
by O
increased O
expression O
of O
Egr-1 B
mRNA I
. O

YJ O
cells O
treated O
in O
vitro O
with O
2 O
microM O
RA O
differentiated O
into O
metamyelocytes O
and O
band O
neutrophils O
, O
and O
increased O
the O
number O
of O
nitroblue O
tetrazolium O
( O
NBT O
) O
-positive O
cells O
and O
increased O
gp91phox B
mRNA I
expression O
. O

In O
contrast O
, O
increased O
expressions O
of O
C/EBPbeta O
and O
MZF-1 B
mRNA I
occurred O
with O
neutrophilic O
differentiation O
. O

Using O
semiquantitative O
RT-PCR O
, O
we O
found O
a O
striking O
increase O
in O
IL-6 B
mRNA I
levels O
only O
in O
resuscitated O
HS O
, O
with O
peak O
levels O
observed O
1 O
h O
after O
initiation O
of O
resuscitation O
. O

Electrophoretic O
mobility O
shift O
assay O
of O
protein O
extracts O
from O
shock O
lungs O
exhibited O
an O
increase O
in O
Stat3 O
activation O
with O
kinetics O
similar O
to O
IL-6 B
mRNA I
. O

However O
, O
this O
region O
directed O
extremely O
low O
reporter O
mRNA O
levels O
relative O
to O
endogenous O
IL-4 B
mRNA I
, O
suggesting O
that O
full O
gene O
activity O
requires O
additional O
enhancer O
elements O
. O

When O
peripheral O
murine O
monocytes O
that O
do O
not O
express O
the O
lipoxygenase O
were O
treated O
with O
IL-4 O
expression O
of O
12/15-lipoxygenase B
mRNA I
was O
induced O
, O
suggesting O
pretranslational O
control O
mechanisms O
. O

Interferon-gamma-induced O
factor O
binding O
to O
the O
interleukin-4-responsive O
element O
of O
CD23b O
promoter O
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up-regulation O
of O
the O
interleukin-4-induced B
CD23b I
mRNA I
. O

Although O
IFN-gamma O
alone O
did O
not O
induce O
CD23 B
mRNA I
transcription O
, O
Northern O
blot O
analysis O
revealed O
a O
transient O
up-regulation O
of O
the O
IL-4-induced B
CD23 I
mRNA I
by O
IFN-gamma O
within O
2 O
h O
of O
IFN-gamma O
treatment O
in O
these O
tonsillar O
cells O
. O

This O
was O
associated O
with O
the O
down-regulation O
of O
IL-12p40 B
mRNA I
expression O
. O

We O
show O
that O
increased O
transcription O
of O
the O
NF-IL6 O
gene O
is O
responsible O
, O
at O
least O
in O
part O
, O
for O
induction O
of O
NF-IL6 B
mRNA I
following O
activation O
of O
U937 O
promonocytic O
cells O
. O

Moreover O
, O
our O
data O
provide O
evidence O
that O
the O
expression O
pattern O
of O
MHC B
class I
II I
mRNA I
is O
correlated O
with O
that O
of O
the O
class O
II O
transactivator O
( O
CIITA O
) O
, O
suggesting O
that O
CIITA O
is O
the O
actual O
target O
of O
the O
silencing O
. O

RNA O
analysis O
in O
these O
cells O
and O
in O
a O
cell O
line O
that O
is O
defective O
in O
class O
II O
transactivator O
( O
CIITA O
) O
demonstrates O
that O
NK O
cell-induced O
HLA-DR B
alpha I
mRNA I
expression O
is O
also O
CIITA O
-independent O
. O

The O
Janus O
kinase-1-deficient O
cell O
line O
U4A O
expresses O
HLA-DR B
alpha I
mRNA I
in O
response O
to O
NK O
cell O
activation O
, O
and O
HLA-DR O
alpha O
promoter O
constructs O
transfected O
into O
these O
cells O
are O
induced O
by O
NK O
cells O
but O
not O
IFN-gamma O
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte B
colony-stimulating I
factor I
( I
G-CSF I
) I
receptor I
mRNA I
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT O
enhancer O
binding O
protein O
alpha O
( O
C/EBPalpha O
) O
-deficient O
mice O
. O

Transfection O
experiments O
showed O
that O
both O
Stat1alpha O
and O
Stat3 O
inhibited O
the O
induction O
by O
EPO O
of O
gamma-globin B
and I
erythroid-specific I
5-aminolevulinate I
synthetase I
transcripts I
, O
resulting O
in O
a O
reduction O
of O
the O
percentage O
of O
hemoglobin-positive O
cells O
. O

Northern O
blot O
analysis O
failed O
to O
detect O
IL-2 B
mRNA I
, O
suggesting O
that O
IL-2 O
may O
act O
in O
a O
paracrine O
manner O
in O
vivo O
. O

PIEC O
clones O
stably O
transfected O
with O
one O
of O
these O
constructs O
showed O
up O
to O
99 O
% O
suppression O
of O
SLA-DR O
and O
SLA-DQ O
antigen O
induction O
and O
marked O
suppression O
of O
SLA-DRA B
mRNA I
induction O
. O

Human O
monocytes O
and O
monocyte-derived O
macrophages O
cultured O
for O
6 O
days O
in O
5 O
% O
human O
serum O
expressed O
PPARgamma B
mRNA I
and O
protein O
by O
reverse O
transcription-polymerase O
chain O
reaction O
and O
Western O
blotting O
, O
respectively O
. O

In O
addition O
, O
PPARgamma B
mRNA I
expression O
in O
U937 O
cells O
increased O
during O
phorbol O
12-myristate O
13 O
acetate-induced O
differentiation O
. O

IL-3 O
, O
IL-4 O
, O
and O
IL-5 O
independently O
up-regulated O
TGF-beta1 B
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

The O
concentration O
of O
c-fos B
, I
c-jun I
, I
c-myc I
, I
junB I
, I
and I
fra-1 I
mRNAs I
was O
increased O
in O
activated O
peripheral O
blood O
lymphocytes O
incubated O
with O
ciprofloxacin O
compared O
to O
that O
in O
untreated O
controls O
. O

Taken O
together O
, O
ciprofloxacin O
increased O
the O
levels O
of O
immediate-early B
transcripts I
, O
enhanced O
IL-2 O
and O
metallothionein O
promoter O
induction O
, O
and O
upregulated O
AP-1 O
concentrations O
in O
primary O
lymphocytes O
, O
reflecting O
a O
program O
commonly O
observed O
in O
mammalian O
stress O
responses O
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

These O
cells O
were O
examined O
for O
ER B
mRNA I
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O

RESULTS O
: O
In O
all O
cells O
tested O
, O
ER B
mRNA I
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O

Partial O
sequences O
from O
exons O
1-8 O
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B
ER I
mRNA I
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

In O
vitro O
stimulation O
did O
not O
affect O
ER B
mRNA I
expression O
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML/RAR B
alpha I
or I
AML1/ETO I
mRNA I
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Using O
the O
reverse O
transcription-polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
-5 O
) O
to O
10 O
( O
-6 O
) O
for O
PML/RAR B
alpha I
transcript I
and O
10 O
( O
-4 O
) O
to O
10 O
( O
-5 O
) O
for O
the O
AML1/ETO B
transcript I
. O

Two O
unrearranged O
TcR O
delta O
transcripts O
had O
a O
size O
similar O
to O
that O
of O
the O
functional O
TcR B
delta I
mRNA I
( O
2.3 O
and O
1.3 O
kb O
) O
found O
in O
TcR O
gamma/delta+ O
T O
lymphocytes O
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA-3-specific B
mRNA I
, O
suggesting O
that O
hGATA-3 O
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR O
delta O
gene O
expression O
in O
NK O
cells O
. O

Here O
we O
report O
that O
binding O
of O
human O
IL-2 O
to O
its O
binding O
site O
leads O
to O
transcriptional O
activation O
of O
the O
macrophage O
CSF O
( O
M-CSF O
) O
gene O
in O
Mo O
resulting O
in O
accumulation O
of O
M-CSF B
mRNA I
and O
subsequent O
release O
of O
bioactive O
M-CSF O
protein O
as O
demonstrated O
by O
ELISA O
and O
inhibition O
of O
IL-2 O
induced O
release O
of O
an O
activity-stimulating O
growth O
of O
monocyte-type O
colonies O
by O
a O
neutralizing O
anti-M-CSF O
antibody O
. O

Expression O
of O
mRNA B
for O
the O
GATA-binding O
proteins O
in O
human O
eosinophils O
and O
basophils O
: O
potential O
role O
in O
gene O
transcription O
. O

Eosinophils O
express O
mRNA B
for O
GATA-1 O
, O
GATA-2 O
, O
and O
GATA-3 O
. O

Treatment O
of O
HL-60 O
eosinophilic O
sublines O
with O
either O
interleukin-5 O
or O
butyric O
acid O
increased O
the O
expression O
of O
GATA-1 B
mRNA I
concomitant O
with O
the O
expression O
of O
eosinophil-specific O
genes O
, O
whereas O
levels O
of O
GATA-2 B
mRNA I
remained O
relatively O
constant O
. O

The O
presence O
of O
mRNA B
for O
these O
proteins O
in O
eosinophils O
and O
basophils O
suggests O
that O
gene O
transcription O
in O
these O
lineages O
may O
be O
regulated O
by O
GATA-binding O
proteins O
. O

The O
results O
demonstrate O
that O
multidrug-resistant O
HL-60 O
cells O
, O
designated O
HL-60/vinc O
, O
fail O
to O
respond O
to O
TPA O
with O
an O
increase O
in O
c-jun B
transcripts I
or O
other O
phenotypic O
characteristics O
of O
monocytic O
differentiation O
. O

Overexpression O
of O
p65 O
increases O
endogenous O
I O
kappa O
B O
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

The O
increased O
levels O
of O
these O
proteins O
correlated O
with O
increases O
in O
the O
amounts O
of O
their O
mRNAs B
during O
LPS O
activation O
of O
THP-1 O
cells O
. O

LPS O
activation O
of O
THP-1 O
cells O
resulted O
in O
phosphorylation O
of O
MAD3 O
( O
an O
I O
kappa O
B O
-like O
protein O
) O
, O
a O
rapid O
increase O
in O
MAD3 B
mRNA I
, O
and O
an O
increase O
in O
MAD3 O
protein O
by O
2 O
h O
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM-9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16-18 O
h O
, O
treatment O
of O
6TG1.1 O
cells O
resulted O
in O
an O
8-fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase O
protection O
analysis O
, O
with O
a O
corresponding O
3- O
to O
4-fold O
increase O
in O
GR O
protein O
. O

Half-maximal O
induction O
of O
GR B
mRNA I
and O
protein O
in O
6TG1.1 O
cells O
was O
observed O
between O
10-100 O
nM O
dexamethasone O
, O
and O
inclusion O
of O
1 O
microM O
RU O
38486 O
completely O
blocked O
the O
effects O
of O
100 O
nM O
dexamethasone O
, O
demonstrating O
that O
positive O
autoregulation O
of O
GR O
expression O
in O
6TG1.1 O
cells O
is O
a O
receptor-mediated O
response O
. O

Measurement O
of O
GR B
mRNA I
turnover O
in O
6TG1.1 O
cells O
treated O
with O
actinomycin-D O
revealed O
a O
half-life O
of O
2.5 O
h O
, O
which O
was O
unaffected O
by O
dexamethasone O
treatment O
. O

It O
is O
demonstrated O
here O
with O
human O
T O
lymphocytes O
and O
monocytes O
that O
different O
stimuli O
, O
including O
tumor O
necrosis O
factor O
alpha O
and O
phorbol O
12-myristate O
13-acetate O
, O
cause O
rapid O
degradation O
of O
I O
kappa O
B-alpha O
, O
with O
concomitant O
activation O
of O
NF-kappa O
B O
, O
followed O
by O
a O
dramatic O
increase O
in O
I B
kappa I
B-alpha I
mRNA I
and O
protein O
synthesis O
. O

Transfection O
studies O
reveal O
that O
the O
I B
kappa I
B-alpha I
mRNA I
and O
the O
encoded O
protein O
are O
potently O
induced O
by O
NF-kappa O
B O
and O
by O
homodimers O
of O
p65 O
and O
of O
c-Rel O
. O

Subsequently O
, O
I B
kappa I
B-alpha I
mRNA I
and O
protein O
levels O
are O
quickly O
induced O
by O
the O
activated O
NF-kappa O
B O
. O

We O
now O
report O
that O
EC O
costimulation O
causes O
increased O
levels O
of O
IL-2 B
mRNA I
as O
a O
result O
of O
increased O
IL-2 O
transcription O
in O
PBL O
. O

PBL O
constitutively O
express O
c-jun O
transcripts O
, O
and O
the O
level O
of O
c-jun B
mRNA I
is O
not O
altered O
by O
PHA O
activation O
in O
the O
absence O
or O
presence O
of O
EC O
. O

In O
contrast O
, O
c-fos B
mRNA I
is O
absent O
from O
resting O
T O
cells O
and O
is O
induced O
on O
PHA O
activation O
. O

EC O
alone O
do O
not O
induce O
c-fos B
mRNA I
but O
augment O
the O
level O
of O
c-fos B
mRNA I
in O
PHA-activated O
T O
cells O
by O
3- O
to O
10-fold O
. O

UT-7 O
Epo O
and O
UT-7 O
expressed O
similar O
levels O
of O
GATA-1 B
mRNA I
and O
binding O
activity O
. O

The O
two O
lines O
also O
expressed O
comparable O
levels O
of O
Epo-R B
mRNA I
while O
the O
number O
of O
Epo O
-binding O
sites O
on O
UT-7 O
Epo O
cells O
was O
one-sixth O
the O
number O
of O
UT-7 O
cells O
( O
2400 O
+/- O
3 O
vs. O
13 O
, O
800 O
+/- O
300 O
) O
. O

The O
number O
of O
gamma-positive O
cells O
and O
their O
fluorescence O
intensity O
were O
higher O
in O
UT-7 O
Epo O
than O
in O
UT-7 O
cells O
( O
0 O
to O
17 O
% O
barely O
positive O
cells O
and O
23 O
to O
40 O
% O
clearly O
positive O
cells O
, O
respectively O
) O
, O
indicating O
that O
the O
increase O
in O
globin B
mRNA I
observed O
in O
UT-7 O
Epo O
is O
due O
to O
both O
an O
increase O
of O
gene O
expression O
per O
cell O
and O
an O
increase O
in O
numbers O
of O
cells O
containing O
gamma-globin O
. O

The O
levels O
of O
GATA-1 O
, O
Epo-R O
and O
globin B
mRNA I
expressed O
were O
not O
affected O
by O
a O
24-hour O
incubation O
of O
either O
cell O
line O
with O
Epo O
, O
GM-CSF O
or O
interleukin-3 O
( O
IL-3 O
) O
. O

The O
increased O
mRNA B
accumulation O
was O
found O
to O
be O
primarily O
because O
of O
the O
increase O
in O
the O
transcription O
rate O
of O
the O
interleukin-1 O
genes O
. O

This O
increased O
processing O
and O
secretion O
correlated O
with O
the O
stimulation O
of O
IL-1 B
beta I
convertase I
mRNA I
accumulation O
. O

PMA O
induced O
the O
expression O
of O
both O
CD14 O
and O
CD23 B
mRNA I
and O
protein O
. O

Exposure O
to O
VitD3 O
rapidly O
induced O
the O
de O
novo O
expression O
of O
CD14 B
mRNA I
and O
protein O
. O

The O
addition O
of O
cycloheximide O
completely O
blocked O
the O
VitD3 O
induction O
of O
CD14 B
mRNA I
expression O
, O
indicating O
that O
the O
induction O
was O
dependent O
on O
ongoing O
protein O
synthesis O
. O

In O
contrast O
, O
U-937 O
cells O
induced O
by O
RA O
strongly O
increased O
their O
expression O
of O
CD23 B
mRNA I
and O
protein O
, O
whereas O
they O
completely O
lacked O
detectable O
CD14 O
cell O
surface O
or O
mRNA O
expression O
. O

The O
induction O
of O
CD20 B
mRNA I
was O
temporally O
associated O
with O
induction O
of O
Oct-2 B
mRNA I
and O
a O
BAT O
box-deleted O
CD20-CAT O
construct O
, O
in O
contrast O
to O
the O
wild O
type O
, O
was O
poorly O
induced O
by O
phorbol O
esters O
. O

Although O
endothelial B
leukocyte I
adhesion I
molecule I
( I
ELAM I
) I
mRNA I
synthesis O
can O
be O
regulated O
by O
NF O
kappa O
B O
, O
ELAM O
was O
not O
expressed O
and O
ELAM B
mRNA I
was O
only O
slightly O
elevated O
in O
response O
to O
MM-LDL O
. O

Interleukin-4 O
inhibits O
the O
lipopolysaccharide-induced O
expression O
of O
c-jun B
and I
c-fos I
messenger I
RNA I
and O
activator O
protein-1 O
binding O
activity O
in O
human O
monocytes O
. O

Maximal O
accumulation O
of O
either O
c-fos B
and I
c-jun I
messenger I
RNA I
( O
mRNA O
) O
occurred O
30 O
minutes O
after O
LPS O
addition O
. O

Specific O
mRNAs B
for O
c-fos O
and O
c-jun O
were O
detectable O
within O
30 O
min O
after O
cell O
activation O
and O
reached O
maximal O
levels O
within O
2 O
h O
. O

Both O
c-fos B
and I
jun I
B I
mRNAs I
decreased O
to O
pre-activation O
levels O
within O
6 O
h O
, O
while O
c-jun B
mRNA I
remained O
elevated O
. O

However O
, O
c-jun B
mRNA I
levels O
decreased O
significantly O
( O
1.73 O
+/- O
0.08 O
vs. O
1.16 O
+/- O
0.09 O
arbitrary O
units O
, O
P O
< O
0.01 O
, O
young O
vs. O
old O
) O
in O
PBL O
from O
elderly O
individuals O
activated O
with O
PHA O
. O

These O
results O
suggest O
that O
the O
decreased O
IL-2 O
production O
and O
proliferative O
response O
displayed O
by O
PHA-activated O
PBL O
from O
elderly O
adults O
may O
be O
related O
to O
age-related O
changes O
in O
c-jun B
mRNA I
expression O
and O
in O
the O
ratio O
of O
c-fos O
to O
c-jun B
mRNA I
. O

To O
address O
the O
role O
of O
Oct-2 O
in O
the O
T-cell O
lineage O
, O
we O
studied O
the O
expression O
of O
Oct-2 B
mRNA I
and O
protein O
in O
nontransformed O
human O
and O
mouse O
T O
cells O
. O

Oct-2 B
mRNA I
induction O
during O
antigen-driven O
T-cell O
activation O
was O
blocked O
by O
cyclosporin O
A O
, O
as O
well O
as O
by O
protein O
synthesis O
inhibitors O
. O

Since O
both O
AP-1 O
and O
NF-kappa O
B O
have O
been O
reported O
to O
be O
important O
in O
the O
induction O
of O
the O
tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
gene O
we O
examined O
the O
effects O
of O
okadaic O
acid O
on O
TNF-alpha B
mRNA I
levels O
. O

Treatment O
with O
okadaic O
acid O
resulted O
in O
a O
striking O
increase O
in O
TNF-alpha B
mRNA I
transcripts O
within O
1 O
h O
of O
stimulation O
and O
large O
amounts O
of O
TNF-alpha O
were O
released O
into O
the O
culture O
media O
. O

c-myc B
mRNA I
expression O
in O
minor O
salivary O
glands O
of O
patients O
with O
Sjogren O
's O
syndrome O
. O

c-myc O
protooncogene O
is O
implicated O
in O
the O
pathogenesis O
of O
B O
cell O
lymphoid O
malignancies O
and O
high O
levels O
of O
c-myc B
mRNA I
expression O
are O
observed O
in O
activated O
blood O
mononuclear O
cells O
. O

In O
this O
study O
, O
c-myc B
protooncogene I
mRNA I
expression O
in O
29 O
labial O
minor O
salivary O
gland O
biopsies O
from O
patients O
with O
primary O
SS O
and O
15 O
controls O
was O
examined O
using O
in O
situ O
hybridization O
histochemistry O
. O

High O
c-myc B
mRNA I
expression O
was O
detected O
on O
acinar O
epithelial O
cells O
. O

Stronger O
c-myc B
mRNA I
expression O
was O
detected O
in O
labial O
salivary O
glands O
of O
patients O
with O
longer O
disease O
duration O
( O
p O
less O
than O
or O
equal O
to O
0.002 O
) O
and O
more O
intense O
T O
lymphocyte O
infiltrates O
( O
p O
less O
than O
0.05 O
) O
although O
these O
patients O
revealed O
no O
hypergammaglobulinemia O
. O

No O
correlation O
was O
observed O
between O
c-myc B
mRNA I
and O
B O
lymphocyte O
monoclonicity O
or O
lymphoma O
. O

In O
conclusion O
, O
strong O
c-myc B
mRNA I
expression O
was O
observed O
on O
epithelial O
cells O
of O
labial O
salivary O
glands O
from O
patients O
with O
primary O
SS O
. O

Treatment O
of O
SKW O
6.4 O
cells O
with O
IL O
6 O
induced O
a O
transient O
and O
early O
stimulation O
of O
c-fos B
sense I
mRNA I
expression O
. O

Gangliosides O
appear O
to O
act O
at O
an O
early O
step O
of O
activation O
in O
that O
TNF B
transcripts I
were O
reduced O
and O
the O
mobilization O
of O
the O
nuclear O
factor O
kappa O
B O
was O
blocked O
. O

This O
induction O
of O
monocytic O
differentiation O
was O
associated O
with O
transient O
increases O
in O
c-jun B
mRNA I
levels O
, O
which O
were O
maximal O
at O
6 O
h O
. O

c-jun B
mRNA I
levels O
were O
superinduced O
in O
cells O
treated O
with O
both O
okadaic O
acid O
and O
cycloheximide O
, O
whereas O
inhibition O
of O
protein O
synthesis O
had O
little O
, O
if O
any O
, O
effect O
on O
okadaic O
acid-induced O
c-jun O
transcription O
. O

The O
half-life O
of O
c-jun B
mRNA I
was O
similar O
( O
45-50 O
min O
) O
in O
both O
untreated O
and O
okadaic O
acid-induced O
cells O
. O

The O
c-jun B
mRNA I
, O
which O
is O
constitutively O
expressed O
in O
human O
peripheral-blood O
monocytes O
at O
relatively O
high O
levels O
, O
was O
also O
slightly O
augmented O
by O
LTB4 O
, O
although O
to O
a O
much O
lower O
extent O
than O
c-fos O
. O

The O
kinetics O
of O
expression O
of O
the O
two O
genes O
were O
also O
slightly O
different O
, O
with O
c-fos B
mRNA I
reaching O
a O
peak O
at O
15 O
min O
after O
stimulation O
and O
c-jun O
at O
30 O
min O
. O

Stability O
of O
the O
c-fos O
and O
c-jun B
mRNA I
was O
not O
affected O
by O
LTB4 O
, O
as O
assessed O
after O
actinomycin O
D O
treatment O
. O

We O
have O
previously O
shown O
that O
prolonged O
treatment O
of O
the O
untransformed O
T O
cell O
clone O
Ar-5 O
with O
phorbol O
esters O
results O
in O
downmodulation O
of O
the O
alpha O
and O
beta O
isozymes O
of O
PKC O
, O
and O
abrogates O
induction O
of O
IL-2 B
mRNA I
and O
protein O
. O

Inducibility O
of O
endogenous O
IFN-beta B
and I
IFN-alpha I
RNA I
was O
also O
increased O
in O
PLB-IIIB O
cells O
. O

These O
findings O
suggest O
that O
the O
combination O
of O
p49 O
( O
100 O
) O
and O
p65 O
NF-kappa O
B O
can O
act O
in O
concert O
with O
the O
tat-I O
gene O
product O
to O
stimulate O
the O
synthesis O
of O
HIV B
RNA I
. O

Stable O
transfectants O
of O
HB24 O
were O
established O
that O
expressed O
high O
levels O
of O
HB24 B
mRNA I
and O
possessed O
an O
altered O
phenotype O
suggestive O
of O
activated O
T O
cells O
. O

Furthermore O
, O
as O
a O
consequence O
of O
the O
increased O
HB24 B
mRNA I
levels O
, O
the O
Jurkat O
HB24 O
transfectants O
proliferated O
more O
rapidly O
than O
control O
cell O
lines O
. O

In O
nonerythroid O
HL-60 O
cells O
in O
which O
the O
HS2 O
enhancer O
is O
inactive O
, O
long B
enhancer I
transcripts I
are O
not O
detectable O
. O

Splitting O
the O
HS2 O
enhancer O
between O
two O
tandem O
Ap1 O
sites O
abolishes O
the O
synthesis O
of O
a O
group O
of O
long B
enhancer I
transcripts I
and O
results O
in O
loss O
of O
enhancer O
function O
and O
transcriptional O
silencing O
of O
the O
cis-linked O
CAT O
gene O
. O

In O
directing O
the O
synthesis O
of O
RNA B
through O
the O
intervening O
DNA O
and O
the O
gene O
by O
a O
tracking O
and O
transcription O
mechanism O
, O
the O
HS2 O
enhancer O
may O
( O
i O
) O
open O
up O
the O
chromatin O
structure O
of O
a O
gene O
domain O
and O
( O
ii O
) O
deliver O
enhancer O
binding O
proteins O
to O
the O
promoter O
sequence O
where O
they O
may O
stimulate O
the O
transcription O
of O
the O
gene O
at O
the O
cap O
site O
. O

Much O
attention O
has O
been O
focused O
on O
the O
interaction O
of O
Tat O
with O
a O
specific O
RNA B
target I
termed O
TAR B
( O
transactivation B
responsive I
) O
which O
is O
present O
in O
the O
leader O
sequence O
of O
all O
HIV-1 B
mRNAs I
. O

A O
Tat-responsive O
element O
is O
found O
upstream O
within O
the O
viral O
promoter O
that O
in O
glial-derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR B
. O

We O
demonstrated O
that O
AP-2 B
mRNA I
was O
present O
in O
T-lymphocytes O
and O
that O
cellular O
factors O
from O
both O
non-transformed O
and O
transformed O
T-lymphocytes O
specifically O
bound O
to O
the O
consensus O
motif O
for O
AP-2 O
in O
each O
21 O
bp O
. O

ISG15 B
mRNA I
accumulation O
in O
U937 O
cells O
is O
not O
detectable O
before O
6 O
h O
of O
IFN-alpha O
treatment O
, O
peaks O
at O
24 O
h O
, O
and O
requires O
protein O
synthesis O
. O

Glucocorticoids O
are O
known O
to O
downregulate O
interleukin-1 O
beta O
production O
in O
monocytic O
cells O
by O
two O
different O
mechanims O
: O
direct O
inhibition O
of O
the O
gene O
transcription O
and O
destabilization O
of O
the O
preformed O
interleukin-1 B
beta I
mRNA I
. O

When O
dexamethasone O
was O
added O
to O
the O
cultures O
3 O
hours O
after O
the O
stimulators O
, O
it O
clearly O
decreased O
the O
interleukin-1 B
beta I
mRNA I
levels O
regardless O
of O
the O
stimulator O
used O
( O
although O
the O
effect O
was O
clearly O
weaker O
on O
the O
PMA-induced B
mRNA I
) O
. O

Thus O
these O
data O
suggest O
that O
the O
phorbol O
myristate-induced O
signal O
( O
prolonged O
protein O
kinase O
C O
activation O
? O
) O
can O
not O
be O
inhibited O
by O
prior O
incubation O
with O
dexamethasone O
and O
it O
also O
protects O
the O
induced B
mRNA I
for O
the O
degradative O
action O
of O
dexamethasone O
. O

We O
have O
cloned O
a O
group O
of O
cDNAs O
representing O
mRNAs B
that O
are O
rapidly O
induced O
following O
adherence O
of O
human O
monocytes O
. O

One O
of O
the O
induced O
transcripts O
( O
MAD-3 B
) O
encodes O
a O
protein O
of O
317 O
amino O
acids O
with O
one O
domain O
containing O
five O
tandem O
repeats O
of O
the O
cdc10/ankyrin O
motif O
, O
which O
is O
60 O
% O
similar O
( O
46 O
% O
identical O
) O
to O
the O
ankyrin O
repeat O
region O
of O
the O
precursor O
of O
NF-kappa O
B/KBF1 O
p50 O
. O

Cortivazol O
mediated O
induction O
of O
glucocorticoid B
receptor I
messenger I
ribonucleic I
acid I
in O
wild-type O
and O
dexamethasone-resistant O
human O
leukemic O
( O
CEM O
) O
cells O
. O

It O
has O
been O
shown O
recently O
that O
in O
wild-type O
CEM O
cells O
but O
not O
in O
a O
dex-resistant O
, O
glucocorticoid O
receptor O
( O
GR O
) O
-defective O
clone O
ICR-27 O
TK-3 O
, O
dex O
induces O
GR B
mRNA I
. O

To O
test O
the O
hypothesis O
that O
cortivazol O
acts O
in O
dex-resistant O
cells O
by O
making O
use O
of O
the O
residual O
GR O
found O
there O
, O
wild-type O
and O
dex-resistant O
clones O
were O
treated O
with O
various O
concentrations O
of O
cortivazol O
and O
induction O
of O
GR B
mRNA I
was O
studied O
. O

Cortivazol O
significantly O
induced O
GR B
mRNA I
in O
the O
normal O
CEM-C7 O
as O
well O
as O
in O
two O
classes O
of O
dex-resistant O
clones O
, O
although O
the O
dex-resistant O
clones O
needed O
at O
least O
10 O
times O
more O
cortivazol O
than O
the O
normal O
cells O
for O
significant O
GR B
mRNA I
induction O
. O

Increased O
levels O
of O
GR B
mRNA I
were O
noticed O
as O
early O
as O
3 O
h O
after O
treatment O
. O

A O
general O
correlation O
between O
induction O
of O
GR B
mRNA I
and O
lysis O
of O
the O
normal O
and O
dex-resistant O
cells O
was O
found O
. O

Positive O
induction O
of O
GR B
mRNA I
might O
be O
one O
of O
the O
earliest O
crucial O
steps O
in O
the O
lysis O
of O
normal O
and O
dex-resistant O
CEM O
cells O
, O
or O
might O
serve O
as O
a O
marker O
for O
the O
process O
. O

This O
probe O
was O
used O
to O
identify O
a O
rel-related O
complementary O
DNA O
that O
hybridized O
to O
a O
2.6-kilobase B
messenger I
RNA I
present O
in O
human O
T O
and O
B O
lymphocytes O
. O

The O
human O
myelomonocytic O
cell O
line O
U-937 O
as O
a O
model O
for O
studying O
alterations O
in O
steroid-induced O
monokine O
gene O
expression O
: O
marked O
enhancement O
of O
lipopolysaccharide-stimulated B
interleukin-1 I
beta I
messenger I
RNA I
levels O
by O
1 O
, O
25-dihydroxyvitamin O
D3 O
. O

To O
establish O
a O
model O
for O
1 O
, O
25- O
( O
OH O
) O
2D3 O
regulation O
of O
human O
monocyte O
monokine O
synthesis O
, O
three O
human O
cell O
lines O
( O
U-937 O
, O
THP-1 O
, O
and O
HL-60 O
) O
were O
examined O
for O
: O
1 O
) O
the O
presence O
of O
functional O
1 O
, O
25- O
( O
OH O
) O
2D3 O
receptors O
; O
2 O
) O
the O
accumulation O
of O
interleukin-1 B
beta I
( I
IL-1 I
beta I
) I
mRNA I
and O
IL-1 O
beta O
protein O
in O
response O
to O
lipopolysaccharide O
( O
LPS O
) O
; O
and O
3 O
) O
the O
regulation O
of O
this O
response O
by O
1 O
, O
25- O
( O
OH O
) O
2D3 O
. O

All O
three O
cell O
lines O
expressed O
vitamin O
D O
receptor O
and O
had O
increased O
levels O
of O
IL-1 B
beta I
mRNA I
in O
response O
to O
LPS O
. O

Preincubation O
of O
cells O
with O
1 O
, O
25- O
( O
OH O
) O
2D3 O
augmented O
IL-1 B
beta I
mRNA I
levels O
only O
in O
U-937 O
and O
HL-60 O
cells O
. O

Preincubation O
of O
cells O
with O
1 O
, O
25- O
( O
OH O
) O
2D3 O
had O
no O
effect O
on O
the O
time O
course O
of O
IL-1 B
beta I
mRNA I
appearance O
in O
response O
to O
LPS O
. O

However O
, O
exposure O
of O
U-937 O
cells O
to O
1 O
, O
25- O
( O
OH O
) O
2D3 O
increased O
by O
200 O
% O
the O
level O
of O
IL-1 B
beta I
mRNA I
detected O
and O
decreased O
by O
three O
orders O
of O
magnitude O
the O
concentration O
of O
LPS O
required O
to O
achieve O
steady O
state O
mRNA O
levels O
equivalent O
to O
those O
observed O
in O
U-937 O
cells O
not O
preincubated O
with O
the O
hormone.2+o O

In O
human B
histiocytic I
U937 I
cells I
mRNA I
of O
clone O
pAT O
133 O
was O
constitutively O
expressed O
, O
whereas O
mRNA B
of O
pAT O
225/EGR1 O
was O
induced O
upon O
induction O
of O
terminal O
differentiation O
. O

NAC O
and O
other O
thiol O
compounds O
also O
blocked O
the O
activation O
of O
NF-kappa O
B O
by O
cycloheximide O
, O
double-stranded B
RNA I
, O
calcium O
ionophore O
, O
TNF-alpha O
, O
active O
phorbol O
ester O
, O
interleukin-1 O
, O
lipopolysaccharide O
and O
lectin O
. O

Transcription O
factor O
requirements O
for O
U2 B
snRNA I
-encoding O
gene O
activation O
in O
B O
lymphoid O
cells O
. O

Enhancers O
containing O
a O
single O
Oct O
have O
, O
nevertheless O
, O
the O
capacity O
to O
partially O
activate O
U2 B
snRNA I
transcription O
in O
both O
HeLa O
cells O
, O
in O
which O
only O
OTF-1 O
is O
expressed O
, O
and O
in O
BJA-B O
cells O
in O
which O
OTF-2 O
is O
the O
predominantly O
expressed O
octamer-binding O
factor O
. O

The O
most O
likely O
interpretation O
of O
our O
results O
is O
that O
both O
the O
ubiquitous O
transcription O
factor O
, O
OTF-1 O
, O
and O
the O
B-cell-specific O
transcription O
factor O
, O
OTF-2 O
, O
can O
activate O
U2 B
snRNA I
transcription O
. O

The O
results O
also O
revealed O
a O
similar O
functional O
cooperation O
between O
the O
transcription O
factors O
which O
bind O
to O
the O
Oct O
and O
the O
adjacent O
Sp O
1-binding O
site O
in O
BJA-B O
cells O
, O
as O
has O
been O
observed O
in O
HeLa O
cells O
, O
since O
a O
template O
which O
contains O
a O
weak O
binding O
site O
for O
OTFs O
expresses O
wild-type O
levels O
of O
U2 B
snRNA I
in O
both O
cell O
types O
when O
the O
weak O
octamer-binding O
site O
is O
combined O
with O
a O
Sp O
1-binding O
site O
. O

Consistent O
with O
this O
result O
, O
these O
cell O
lines O
expressed O
increased O
levels O
of O
mRNAs B
encoding O
the O
AP-1 O
proteins O
, O
c-Fos O
, O
Fra-1 O
, O
c-Jun O
, O
JunB O
, O
and O
JunD O
. O

By O
using O
the O
human O
T-cell O
line O
( O
JPX-9 O
) O
, O
in O
which O
expression O
of O
the O
Tax1 O
is O
inducible O
, O
we O
showed O
that O
expression O
of O
mRNAs B
for O
Fra-1 O
, O
c-Jun O
, O
and O
JunD O
was O
also O
transactivated O
by O
Tax1 O
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 O
, O
25- O
( O
OH O
) O
2D3 O
receptor O
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical O
vitamin O
D O
receptor O
. O

These O
findings O
were O
associated O
with O
a O
block O
in O
appearance O
of O
the O
monocytic O
phenotype O
, O
including O
inhibition O
of O
TPA-induced O
increases O
in O
lamin B
A I
, I
lamin I
C I
, I
and I
vimentin I
transcripts I
. O

Tumor B
necrosis I
factor-alpha I
mRNA I
accumulation O
in O
human O
myelomonocytic O
cell O
lines O
. O

The O
cell O
lines O
exhibit O
a O
low O
level O
of O
constitutive O
TNF B
mRNA I
expression O
. O

Within O
2 O
to O
4 O
h O
of O
PMA O
exposure O
, O
steady O
state O
levels O
of O
TNF B
mRNA I
are O
markedly O
elevated O
in O
all O
myelomonocytic O
cell O
lines O
studied O
. O

The O
PMA O
induction O
of O
c-fos B
mRNA I
correlated O
well O
with O
TNF O
gene O
induction O
; O
expression O
of O
genes O
encoding O
other O
proteins O
in O
the O
AP-1 O
complex O
( O
junB O
and O
junD O
) O
were O
also O
induced O
by O
PMA O
. O

Transforming O
growth O
factor-beta O
suppresses O
human O
B O
lymphocyte O
Ig O
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

Furthermore O
, O
a O
significant O
decrease O
in O
the O
switch O
from O
the O
membrane B
forms I
of O
mu B
and O
gamma B
to O
their O
respective O
secreted B
forms I
was O
noted O
in O
the O
presence O
of O
TGF-beta O
. O

Oct-2 B
mRNA I
levels O
and O
both O
Oct-2 O
and O
NF-kappa O
B O
proteins O
in O
nuclear O
extracts O
were O
not O
altered O
by O
treatment O
with O
TGF-beta O
. O

These O
findings O
demonstrate O
that O
TGF-beta O
decreases O
B O
lymphocyte O
Ig O
secretion O
by O
inhibiting O
the O
synthesis O
of O
Ig B
mRNA I
and O
inhibiting O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
forms I
of O
mu B
and I
gamma I
mRNA I
. O

1 B
, I
25-Dihydroxyvitamin I
D3 I
receptor I
RNA I
: O
expression O
in O
hematopoietic O
cells O
. O

Little O
is O
known O
of O
expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
in O
hematopoietic O
cells O
. O

We O
examined O
the O
expression O
and O
modulation O
of O
expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
in O
various O
proliferating O
and O
nonproliferating O
hematopoietic O
cells O
. O

Constitutive O
expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
was O
detected O
in O
various O
kinds O
of O
hematopoietic O
cells O
, O
including O
macrophages O
and O
activated O
T O
lymphocytes O
, O
as O
well O
as O
in O
cell O
lines O
KG-1 O
( O
myeloblasts O
) O
, O
HL-60 O
( O
promyelocytes O
) O
, O
ML-3 O
( O
myelomonoblasts O
) O
, O
U937 O
, O
THP-1 O
( O
monoblasts O
) O
, O
K562 O
( O
erythroblasts O
) O
, O
and O
S-LB1 O
( O
HTLV-1-transfected O
T O
lymphocytes O
) O
. O

Receptor B
transcripts I
were O
4.6 O
kilobases O
( O
kb O
) O
, O
and O
no O
variant O
sizes O
were O
observed O
. O

Most O
B O
lymphocyte O
lines O
expressed O
negligible O
levels O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
and O
protein O
; O
however O
; O
analysis O
of O
a O
lymphoid/myeloid O
somatic O
hybrid O
suggested O
that O
suppression O
of O
expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
in O
B O
lymphocytes O
may O
be O
a O
dominant O
characteristic O
. O

Steady-state O
levels O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
were O
not O
affected O
by O
terminal O
differentiation O
of O
HL-60 O
toward O
either O
granulocytes O
or O
macrophages O
. O

Nondividing O
macrophages O
from O
normal O
individuals O
also O
expressed O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
. O

In O
contrast O
, O
nondividing O
peripheral O
blood O
lymphocytes O
from O
normal O
individuals O
did O
not O
express O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
; O
with O
stimulation O
of O
proliferation O
of O
these O
cells O
, O
accumulation O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
increased O
markedly O
. O

Half-life O
( O
t1/2 O
) O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
in O
T O
lymphocytes O
was O
short O
( O
1 O
hour O
) O
as O
determined O
by O
measuring O
decay O
of O
the O
message O
after O
addition O
of O
actinomycin O
D O
. O

Consistent O
with O
this O
short O
t1/2 O
, O
accumulation O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
RNA I
increased O
in O
cells O
as O
their O
protein O
synthesis O
was O
inhibited O
. O

We O
have O
found O
that O
purified O
human O
peripheral-blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto-oncogenes O
c-jun B
, I
jun I
B I
and I
jun I
D I
mRNA I
. O

Upon O
functional O
activation O
of O
granulocytes O
by O
4 O
beta-phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
, O
the O
levels O
of O
c-jun B
, I
jun I
B I
and I
jun I
D I
transcripts I
were O
increased O
. O

Genes O
actively O
involved O
in O
the O
G0/G1 O
switch O
( O
G0S B
genes I
) O
may O
be O
differentially O
expressed O
during O
the O
lectin O
-induced O
switch O
of O
lymphocytes O
from O
the O
G0 O
to O
the O
G1 O
phases O
of O
the O
cell O
cycle O
. O

This O
paper O
presents O
studies O
of O
G0S2 O
, O
a O
member O
of O
a O
set O
of O
putative O
G0S B
genes I
, O
for O
which O
cDNAs O
were O
cloned O
and O
selected O
on O
the O
basis O
of O
differential O
cDNA O
hybridization O
. O

G0S2 B
mRNA I
increases O
transiently O
within O
1-2 O
hr O
of O
the O
addition O
of O
lectin O
or O
cycloheximide O
to O
cultured O
blood O
mononuclear O
cells O
. O

Northern O
blot O
experiments O
demonstrate O
further O
that O
TCF-1 B
alpha I
mRNA I
is O
highly O
tissue O
specific O
, O
found O
primarily O
in O
the O
thymus O
or O
T O
cell O
lines O
. O

The O
immature O
CEM O
T O
cell O
line O
expresses O
relatively O
low O
levels O
of O
TCF-1 B
alpha I
mRNA I
, O
which O
are O
increased O
upon O
activation O
of O
these O
cells O
by O
phorbol O
esters O
. O

In O
THP-1 O
cells O
with O
restricted O
HIV O
expression O
, O
there O
is O
an O
absence O
of O
DNA-protein O
binding O
complex O
formation O
with O
the O
HIV-1 O
promoter-enhancer O
associated O
with O
markedly O
less O
viral B
RNA I
production O
. O

Although O
three O
sites O
in O
the O
TNF-alpha O
promoter O
( O
kappa O
1 O
, O
kappa O
2 O
, O
and O
kappa O
3 O
) O
specifically O
bind O
the O
transcription O
factor O
NF-kappa O
B O
in O
lymphoid O
nuclear O
extracts O
, O
TNF-alpha B
mRNA I
induction O
by O
PMA O
does O
not O
correlate O
with O
NF-kappa O
B O
binding O
activities O
displayed O
by O
different O
T O
and O
B O
cell O
lines O
. O

Therefore O
, O
TNF-alpha B
mRNA I
induction O
by O
PMA O
, O
like O
its O
induction O
by O
virus O
and O
LPS O
, O
is O
not O
primarily O
mediated O
by O
NF-kappa O
B O
, O
but O
rather O
is O
mediated O
through O
other O
sequences O
and O
protein O
factors O
. O

Human O
erythroid O
5-aminolevulinate O
synthase O
: O
promoter O
analysis O
and O
identification O
of O
an O
iron-responsive O
element O
in O
the O
mRNA B
. O

An O
iron-responsive B
element I
( I
IRE I
) I
motif I
has O
been O
identified O
in O
the O
5'-untranslated O
region O
of O
the O
human B
erythroid I
ALAS I
mRNA I
, O
but O
is O
not O
present O
in O
the O
housekeeping B
ALAS I
mRNA I
. O

Gel O
retardation O
experiments O
established O
that O
this O
IRE B
motif I
formed O
a O
protein O
- O
RNA O
complex O
with O
cytosolic O
extracts O
from O
human O
K562 O
cells O
and O
this O
binding O
was O
strongly O
competed O
with O
IRE B
transcripts I
from O
ferritin B
or I
transferrin I
receptor I
mRNAs I
. O

These O
results O
suggest O
that O
the O
IRE B
motif I
in O
the O
ALAS B
mRNA I
is O
functional O
and O
imply O
that O
translation O
of O
the O
mRNA B
is O
controlled O
by O
cellular O
iron O
availability O
during O
erythropoiesis O
. O

Treatment O
of O
these O
cells O
with O
10 O
( O
3 O
) O
units/ml O
human O
recombinant O
M-CSF O
was O
associated O
with O
rapid O
and O
transient O
increases O
in O
c-jun B
mRNA I
levels O
. O

Nuclear O
run-on O
assays O
and O
mRNA O
stability O
studies O
demonstrated O
that O
M-CSF O
regulates O
c-jun O
expression O
by O
both O
an O
increase O
in O
transcription O
rate O
and O
a O
prolongation O
in O
the O
half-life O
of O
c-jun B
transcripts I
. O

We O
further O
demonstrate O
that O
M-CSF O
increases O
c-fos B
mRNA I
levels O
in O
human O
monocytes O
through O
control O
at O
both O
the O
transcriptional O
and O
posttranscriptional O
levels O
. O

TCF-1 B
mRNA I
was O
expressed O
uniquely O
in O
T O
lymphocytes O
. O

Levels O
of O
c-fos B
and I
c-jun I
transcripts I
remained O
elevated O
during O
periods O
of O
PKC O
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30-36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

During O
latent O
Epstein-Barr O
virus O
( O
EBV O
) O
infection O
of O
human O
B O
lymphocytes O
, O
six O
viral O
nuclear O
antigen O
( O
EBNAs O
) O
are O
expressed O
from O
long B
primary I
transcripts I
by O
means O
of O
alternative B
splicing I
and O
alternative B
polyadenylylation I
sites I
. O

Okadaic O
acid O
treatment O
was O
found O
to O
dramatically O
increase O
mRNA B
transcripts I
of O
the O
jun O
family O
of O
proto-oncogenes O
including O
c-jun O
, O
junD O
, O
and O
junB O
and O
to O
a O
lesser O
extent O
the O
fos O
family O
including O
c-fos O
and O
fra-1 O
. O

Similar O
to O
its O
effect O
on O
the O
induction O
of O
AP1 O
by O
okadaic O
acid O
, O
PMA O
inhibits O
the O
induction O
of O
c-jun B
mRNA I
by O
okadaic O
acid O
. O

Northern O
blot O
analysis O
of O
polyadenylated B
RNA I
purified O
from O
activated O
human O
B O
cells O
revealed O
a O
single B
mRNA I
transcript I
of O
approximately O
2.3 O
kb O
. O

The O
HB24 B
mRNA I
was O
absent O
or O
present O
at O
low O
levels O
in O
normal O
B O
and O
T O
lymphocytes O
; O
however O
, O
with O
the O
appropriate O
activation O
signal O
HB24 B
mRNA I
was O
induced O
within O
several O
hours O
even O
in O
the O
presence O
of O
cycloheximide O
. O

Rhom-2 B
mRNA I
is O
expressed O
in O
early O
mouse O
development O
in O
central O
nervous O
system O
, O
lung O
, O
kidney O
, O
liver O
, O
and O
spleen O
but O
only O
very O
low O
levels O
occur O
in O
thymus O
. O

The O
Thy-1 O
gene O
promoter O
resembles O
a O
`` O
housekeeping O
'' O
promoter O
in O
that O
it O
is O
located O
within O
a O
methylation-free O
island O
, O
lacks O
a O
canonical O
TATA O
box O
, O
and O
displays O
heterogeneity O
in O
the O
5'-end B
termini I
of O
the O
mRNA B
. O

Upon O
activation O
, O
T O
lymphocytes O
accumulate O
high O
levels O
of O
the O
neuropeptide O
enkephalin O
which O
correlate O
with O
high O
levels O
of O
proenkephalin B
mRNA I
in O
the O
cells O
. O

